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Abstract 
Viral infections regularly pose detrimental health risks to humans. Preventing 
viral infections through global immunization requires the production of large doses of 
vaccines. The increasing demand for vaccines, especially during pandemics such as 
COVID-19, has challenged current manufacturing strategy to develop advanced unit 
operations with high throughput capability. Over the decade, the upstream processing 
responsible for synthesizing viral products in cell cultures has shown significant success 
in yielding high titers of viruses and virus-like particles. The progress in the upstream 
stage has now shifted the bottleneck to the downstream processing (DSP). Overlooked 
for decades, the DSP responsible for viral product purification from the cell culture 
contaminants requires a makeover with the development of new purification strategies 
and an upgrade in the traditional unit operations. The current DSP train employing 
chromatography and filtration methods have been suboptimal in efficiently processing 
comparatively complex and fragile viral particles. Thus, the lack of platform technology 
for viral vaccine and biotherapeutic DSP has led to a search for alternative and innovative 
methods that have not only high-throughput capabilities but also have potential for 
continuous operation.    
In the pool of potential technologies, aqueous two-phase system (ATPS) has shown 
to be a promising candidate with the numerous advantages over conventional methods. 
However, an unambiguous and complex biomolecule partitioning mechanism has 
required a large experimental setup for optimizing virus purification. This work focused 
on a framework utilizing a phase diagram of a rationalized polyethylene glycol-citrate 
system to optimize virus purification. The partitioning behavior of two non-enveloped 
viruses, porcine parvovirus (PPV) and human rhinovirus-14 (HRV), were studied in 
various system compositions. A tie-line length framework was utilized to define the 







1.1 Viruses, infectious disease, and immunity 
Pathogens have been disrupting the functioning of living beings for ages. Viruses 
are among the five classes of pathogens responsible for causing mild to severe infectious 
diseases in animals and humans. These pathogens are essentially small parasites made of 
protein cage housing nucleic acids (Figure 1-1) [1]. In some types of viruses, the protein 
cage is enclosed in an external lipid bilayer (Figure 1-1) [1]. Viruses are designed by 
nature to obligatorily invade a cell utilizing the host cell’s metabolic machinery for their 
replication [2]. The shedding of progeny viruses leads to an infection of adjacent cells 
that spreads throughout the tissue or organ. During the replication process, viruses seize  
 
 
Figure 1-1. The structural basis of viruses: non-enveloped virus and enveloped virus. 
Virus images were created in BioRender. 
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the functioning of the host cells, thereby inhibiting the vital operation of a tissue or an 
organ. A human body encounters numerous types of viruses via different routes of 
transmission, such as air, water, food, or bodily fluids. 
 
Table 1-1. Human virus species and disease [3] 
Virus Species Structure Host cell Disease 
Influenza A 
Enveloped 





Hepatitis B Liver cells Hepatitis 
Herpes simplex virus  Cold sores and genital herpes 




Intestinal cells poliomyelitis 
Hepatitis A Liver cells hepatitis 
Human papilloma virus Skin and mucosal cells 
Genital/skin warts, 
cervical cancer 
Human rhinovirus Respiratory cells Flu 
Rotavirus Gastrointestinal cells Gastroenteritis 
 
Viruses are one of the integral parts of every ecosystem and have played an 
essential role in the human evolutionary scheme [4, 5]. However, wild-type viruses are 
prominently known for causing diseases (common examples of viruses in Table 1-1). 
Woolhouse and coworkers (2012) have listed over 200 viral species known to infect 
humans, as of 2005 [6], and the list is expected to expand at a rate of 2 viral species/year 
[7]. With the identification of yellow fever virus in 1901 to severe acute respiratory 
syndrome virus-coronavirus-2 (SARS-COV-2) in 2019, numerous viruses have been and 
are causing life-threatening infections in humans. Some viruses such as influenza or 
rotavirus cause acute diseases, which are sudden and severe infections. Other viruses, 
such as human immunodeficiency virus (HIV) or human papillomavirus (HPV), tend to 
persist in causing long-term or chronic diseases. Viral infections of different virus species 
are linked with a characteristic behavior in terms of etiology, pathology, and 
epidemiology. Although these areas are a wide field of focus, it is crucial to understand 
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the viral infections. Each virus species is addressed to infect a specific type of host cells 
which are present in different parts of the body. It is also established in the previous 
studies that viral infection vulnerability varies with season [8]. Commonly known 
seasonal viruses include influenza and common coronavirus, while some of the viruses 
that spread through direct contact such herpes virus, HIV, hepatitis A virus do not have 
any seasonal constraints to cause infections.   
One of the vital lines of defense is an immune system that is equipped to protect a 
body against any foreign antigens. If a virus enters a body, the immune system detects the 
structural composition of the virus or the virus-infected cell and responds to inhibit the 
viral activity [9]. The immune system operates with two types of responses, i.e., A) 
innate immune response and B) adaptive (or acquired) immune response [10, 11]. 
Initially, the innate immune response is triggered when a foreign body or non-self 
molecules are identified by a family of proteins called pattern recognition receptors 
(PRR). PRR recognizes a pathogen-associated molecular pattern, such as 
lipopolysaccharides of gram-negative bacteria, ds-RNA of viruses, or mannan of yeast, 
which are commonly displayed by a group of germlines [9]. The action by the innate 
immunity is fast (hours to days). However, the response is generic towards a group of 
germlines. Simultaneously, the adaptive immune response is triggered that recognizes 
each pathogen family and species, precisely and in detail. The response action to seize the 
antigen’s activity and proliferation is highly specific. The virus-infected cells and a 
particular type of professional cells display the antigenic information in the form of 
epitopes, a small antigenic peptide, on the cell surface. T-cells, a type of immune cell, 
detect the antigenic peptide through a complex interaction and undergo functional 
transformation known as maturation to eliminate the virus-infected cells. 
 In addition to the cell-mediated immune response by T-cells, another group of 
cells called B-cells, are equipped to synthesize antigen-specific small proteins known as 
antibodies [12]. The antibodies are designed to attach to a specific region on the virus 
surface to either neutralize the pathogen or disrupt the virus replication cycle [13]. Both 
the cell-mediated response by T-cells and antibody-mediated response by B-cells develop 
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a prolonged memory to detect and neutralize the re-exposure of the same virus. The 
adaptive immune response is highly efficient and robust as compared to the innate 
immunity to defend against most viral infections. The response kinetics of the adapted 
immunity is as fast as the innate response, reaching the peak within hours to days only if 
the acquired immunity is developed prior to the viral infection. The primary response 
time is much slower (days to weeks) for the first exposure [10]. The spread of disease due 
to the exposure of viruses could be averted or mitigated by inducing a stimulated immune 
response through the safe medical intervention of vaccination.     
1.2 Overview 
Public health can be protected by designing safe and highly immunogenic 
vaccines and ensuring a global outreach of the vaccines. A literature review is presented 
in chapter 2 on the traditional vaccine designs and the current development in designing 
modular vaccines to improve the immunogenicity and safety for strong long-term 
protection. Further, the outreach of vaccines depends on the capacity and portfolio 
flexibility of a production plant. The chapter reviews the vaccine manufacturing stages 
with a focus on the conventional upstream and downstream processing strategies along 
with the progress made in each stage to identify and resolve the bottlenecks. As the focus 
of the dissertation is the downstream purification of the viruses and virus-like particles, 
mechanisms used in the unit operations of the downstream processing stage have been 
thoroughly discussed, and the bottlenecks of the conventional unit operations have been 
identified. Moreover, a potential and unconventional method, aqueous two-phase system 
(ATPS), a liquid-liquid extraction operation, has been reviewed. In the end, gaps in the 
understand driving forces of ATPS and optimization framework for preferential 
biomolecule recovery in ATPS have been identified. 
In chapter 3, a framework is proposed to optimize virus recovery and purity in 
aqueous PEG-citrate system. The system is based on a rational selection of processing 
parameters and using the phase diagrams consisting of binodal curves and tie lines of 
aqueous two-phase systems. The recent evidence of unique virus surface characteristics 
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such as hydrophobicity and charge, combined with the phase forming component 
characteristics such as polymer amphiphilicity and salting-out ability of ions, were 
considered in the system selection. Two non-enveloped virus models – porcine 
parvovirus (PPV) and human rhinovirus-14 (HRV) were included in the study. Further, 
viral partitioning behavior was studied in the PEG 12kDa-citrate system using a tie line 
framework to develop an optimization method. A high PPV recovery (~80%) and purity 
were achieved in the PEG-rich phase at the highest tie-line length studied, owing to a 
relatively high surface hydrophobicity and net negative surface charge of the virus. The 
proposed setup significantly reduced the experimental space required for optimizing the 
virus purification, which is one of the hindrances in commercial implementation. Low 
recovery of uncharged HRV (~35%), due to the system operated at the isoelectric point 
of the virus, indicated the necessity of charge in partitioning. The virus models used 
demonstrated not only the dominance of viral surface hydrophobicity but also indicated 
the importance of viral surface charge in driving the viral particles to the contaminant-
poor phase.  
In chapter 4, additives were included in the PEG 12kDa-citrate system to enhance 
the driving forces for viral partitioning. Water structure modulator molecules, known as 
osmolytes, were used as additives to achieve high virus recoveries and alleviate the 
processing conditions such as high system composition and viscosity. Osmolytes glycine, 
betaine, TMAO, mannitol, and urea were used in the study. Initially, the influence of 
osmolytes on the phase diagrams was studied to elucidate amendments in the phase 
characteristics. Further, the efficiency of the osmolyte class on viral partitioning was 
screened to identify the influential osmolyte. Two virus models, a non-enveloped PPV 
and an enveloped human immunodeficiency virus-group specific antigen virus-like 
particles (HIV-gag-VLP), were used to demonstrate the enhanced recovery. The osmolyte 
efficiency for improving virus recoveries followed the order glycine > betaine > TMAO 
> urea > osmolyte-free control. Overall, >90% virus recoveries could be achieved in 
glycine or betaine-containing systems. However, none of the osmolytes affected the 
contaminant protein partitioning yielding a pure PEG-rich phase with viruses. Further, 
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the tie line framework was employed for each osmolyte-containing system to 
demonstrate that high partitioning can be achieved irrespective of the volume ratios of the 
PEG-rich phase to the citrate-rich phase. Overall, the study demonstrated a strategy to 
enhance virus purification in ATPS and alleviate high concentration processing 
conditions that pose challenges in manufacturing. 
In chapter 5, the use of a novel affinity ATPS was postulated to improve virus 
partitioning by enhancing the affinity of the PEG-rich. The specific binding affinity of a 
trimeric peptide WRW towards PPV was harnessed to enhance the virus recovery in the 
PEG-rich phase at lower volume ratios, where there are lower PEG-rich phase volumes. 
90-100% PPV recovery was obtained in the PEG-rich phase of the systems 
complemented with the affinity-peptide ligand, without affecting the contaminant 
partitioning. Further, the affinity peptide-PEG conjugate was characterized by acrylamide 
quenching that demonstrated the accessibility of the peptide. The accessibility of the 
peptide was a significant success as PEG chains have shown to shield smaller affinity 
tags in past experiments. Overall, the use of multimodal affinity peptides achieved high 
virus recovery in the systems where the PEG-rich phases are the dispersed phase, thereby 
alleviating the processing challenges of ATPS.   
In the concluding chapter (chapter 6), the impact of the current research on the 
biomanufacturing is expressed by discussing the novel findings. In the end, a course of 
future work is proposed to gain additional insights into the mechanism of viral 
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2 Literature Review 
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2.1 Vaccines and biotherapeutics 
One of the ways to protect an individual or public health is to develop an 
individual or herd immunity against viral infection through vaccination. As stated earlier, 
the immune system generates a robust defense mechanism if it recognizes a generic or 
specific component of a virus. This is what the vaccines are intended to do. The main 
constituent of a vaccine is a virus component immunogen presented to the body to induce 
an immune response against the injected agent. The injected immunogen stimulates an 
immune response in the same way as the virus exposure. The adaptive immune system 
generates a memorized pathway to inactivate the virus which is undertaken by the innate 
immune system in the event of reoccurrence of a similar antigen [1]. The memory of the 
immune system results in a short or long-term immunity against the virus exposure.   
There are numerous ways to present an immunogen to the immune system. 
Conventional vaccines are composed of live attenuated viruses (LAV) and inactivated 
viruses. The two types of vaccines are prepared using a whole wild-type virus. The 
attenuation of virus is done by passaging the wild-type virus in a novel growth condition 
or reassorting the genotypes of virus species [2, 3]. The unfamiliar growth condition 
involves a repeated propagation of a wild-type virus in a non-human cell line or an 
abnormal growth media and temperature. which renders the virus less virulent or non-
pathogenic to the original host [3-5]. The later found reassortment method could be 
accomplished by coinfecting multiple viruses of similar family but different serotypes or 
subspecies [6-8]. The coinfection results in a mismatch of the interspecies virus genes 
producing viruses with structural components of the co-infected viruses. A specific virus 
isolate with immunologically relevant segment and attenuating segment is chosen as a 
vaccine strain [5]. The second type of whole-virus immunogen is an inactivated vaccine. 
The inactivated vaccine type comprises of viruses that have been treated chemically by 
formaldehyde, formalin, and β-propiolactone, or physically by gamma irradiation to 
disable the infection process [9]. The other types of vaccine designs include presenting a 
virus structural fragment such as spike protein and nucleic acid, which are called as 
subunit vaccines. The subunit vaccines are the safest of all the types of vaccines, 
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however, they provide lowest immunogenicity [10]. Monovalent hepatitis B is one of the 
well-established viral subunit vaccines available in the market and approved by the WHO 
[11]. A lower immune response by the subunit vaccines require higher amounts of 
immune-adjuvants or carriers to optimize the antigen presentation and enhance 
immunogenicity [12, 13]. Recent developments in the antigen presentation have used 
VLP as a modular vaccine. VLPs are either viruses void of genomes or antigenic proteins 
self-assembled to mimic the authenticity of virus structure [14]. Hepatitis B and HPV 
vaccines are some of the widely accepted and commercially available vaccines [15, 16]. 
As the VLP-based vaccines have recently gained attention, there are fewer approved 
vaccines than the whole virus vaccines. However, a substantial progress is being done 
with more than 20 vaccines approved or in clinical trials [17].  
 
2.2 Viral-based Biotherapeutic Manufacturing 
Extensive progress has been made to identify various virus forms as 
biotherapeutic modalities to induce immunity and treat pre-existing diseases. However, 
the outreach of biotherapeutics across the world is possible only if they can be produced 
in sufficient quantities to meet the demand of the ever-growing population and strict 
regulatory norms. Manufacturing effective biotherapeutics in large quantities has been a 
challenging question for decades due to their complex nature and behavior. Production of 
biotherapeutics is majorly divided into three stages (Figure 2-2). The upstream stage that 
deals with the synthesis of active biological ingredients through high-level expressing 
cell lines, followed by the downstream processing (DSP) to recover and purify the active 
ingredient from a complex biological broth, containing contaminants such as host cell 
proteins (HCP), nucleic acids, and growth media components. The final stage of 
formulation ensures the targeted biologic is suspended in a specifically composed 
solution to provide prolonged biotherapeutic stabilization during transportation and 
storage. Although the manufacturing stages remain broadly the same, the process design 
of the individual stage differs for different viral products due to a high diversity in the 
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tropism and physicochemical properties. The current focus of the discussion will be the 
upstream and downstream processing of viral- and viral-like particle-based 
biotherapeutics and vaccines. The challenges and advances of each stage are explored in 
the following sub-sections.  
 
 
Figure 2-1. General Viral vaccine and biotherapeutic manufacturing scheme 
 
Before understanding the manufacturing strategies of the viral biotherapeutics, it 
is essential to grasp the research efforts made in the pre-upstream stage to determine the 
feasibility of an appropriate cell platform for viral vaccine production. Various cell lines 
are susceptible and permissive for a virus infection. The production of whole virus 
vaccines has been mainly focused on mammalian, insect, and chicken embryonic (eggs) 
cell lines (Table 2-1). The traditional methods to produce vaccines have utilized chicken 
embryonic fibroblast (eggs) cell line [2]. However, the vaccines produced in egg-based 
cell line had shortcomings due to lack of egg supply, possible virus strain mutations, 
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difficulty in quick adaptation to produce circulating virus strains, possibility of allergies 
and anaphylactic reactions [18-20]. Thus, the newer generation of vaccines are majorly 
produced in the primary or diploid cell lines [21]. However, not every cell line has the 
potential to produce high titers of virus. Different virus species have different sites of 
replication, mechanisms of virus-host interaction, and growth kinetics [22]. Some viruses 
require cell nucleus for replication such as influenza virus, herpes simplex virus-1, and 
adenovirus [23, 24]. Other viruses replicate in the cytoplasm, such as poliovirus, severe 
acute respiratory syndrome coronavirus (SARS-CoV) [24, 25]. Moreover, most viruses 
replicate in mitotically functional cells with a few exceptions that can replicate in non-
dividing cells such as human immunodeficiency virus (HIV) [26, 27]. Progeny viruses 
utilize different modes of cell-to-cell transmission, such as extracellular space or cell-cell 
direct contact sites [28, 29].  Overall, the factors associated with the host cell 
susceptibility and viral life cycle are considered while choosing an appropriate cell 
substrate, and even the susceptible cell lines are genetically modified to yield a clone that 
increases the viral titer [22].  
The current motivation is to design a platform cell substrate for a wide range of 
viral vaccines. However, a potential cell line is screened for multiple characteristics such 
as the ability to produce high titers of potent viruses, maintain the cell culture stability for 
longer passages, and meet the safety guidelines of identity, stability, and purity of master 
cell banks [30, 31]. Most manufacturers are currently inclined towards the approved host 
cells for a faster commercialization of vaccines due to the strict safety regulations by the 
FDA and WHO [32]. In this interest, Vero cell line has been widely accepted in the 








Table 2-1. Established cell lines currently used in vaccine production and the virus 
susceptibility [22]. 
Cell line Origin Virus susceptibility 
Vero Green monkey kidney  






Dog Kidney Influenza A, influenza B 
MRC5 Human embryonic lung 
Varicella zoster virus, 
rabies, hepatitis A 
WI-38 Human embryonic lung Rubella, adenovirus 
 
A VLP may be a type of subunit vaccines self-assembled to resemble a virus 
structure or an empty capsid of wild-type virus void of genetic material, making it a non-
infectious antigen. VLP expressions have been successfully demonstrated in a wide range 
of cell platforms such as bacteria, yeast, insect cells, mammalian cells, and plant cells 
(Table 2-2). However, each of the cell platforms has advantages and disadvantages, 
which are mentioned in Table 2-3. The main factors that differentiate between the cell 
platforms are feasibility of expression by gene recombination or delivery, expression 
levels for higher antigen concentrations, and post-translational modifications for a close 
resemblance of a wild-type antigen [17, 35, 36]. Recently licensed VLP vaccines for 
HepB virus [37] and Gardasil for HPV [38] have utilized yeast-based cell substrates for 






Table 2-2.Commonly used cell platforms for producing virus-like particles 
Commonly used cell platforms for producing virus-like particles 
 *HBsAg: Hepatitis B surface antigen  
 
Table 2-3. Advantages and disadvantages of cell platforms for VLP production [35] 
 
Some of the schemes for viruses and VLP manufacturing are similar in the 
upstream and downstream stages if a similar cell platform is used to produce VLP as 
Virus-like particle Expression system Cell line References 
HBsAg* Yeast Saccharomyces cerevisiae [37] 




HPV 16 and 18 Baculovirus - Insect Trichoplusia ni Rix4446 [39] 
Ebola Mammalian HEK-293T [40] 
Zika Mammalian Expi293F [41] 
Cell 
platform Advantages Disadvantages 
Yeast 
• Ease expression 
• Scale-up potential 
• Low production cost 
• Improper protein 
glycosylation 
• Inconsistent folding & 
assembly 
Bacteria  
 (E. coli) 
• Easy expression 
• Scale-up potential 
• Low production cost 
• Forbid glycosylation 
• Presence of endotoxins 
Mammalian 
Cell 
• Closely related to natural 
host 
• Appropriate post 
translational modifications 
• High production cost 
• Lower titers 
Insect Cell 
• Scale-up potential 
• High titers of correctly 
folded VLP 
• Minimum risk of other 
pathogens as compared to 
mammalian cell lines 
• Limited post translational 
modification 
• Difficult baculovirus 
contaminant removal 
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traditional virus vaccine. The current discussion will focus on the infectious virus 
production from the mammalian cell platform.  
 
2.2.1 Upstream Processing 
The advancements in the host cell screening, and media composition have 
contributed significantly towards increasing the throughput of the biotherapeutics and 
vaccines at a lab-scale. However, scale-up of biotherapeutic manufacturing is very 
challenging as the dynamics of the culture environment changes significantly at larger 
scales. The following focus to improve the production capacity of viral vaccines was 
shifted to optimize the bioreactor designing and operation to yield highly potent antigens. 
Currently, the adherent cell lines, that proliferate when attached to a surface, are 
predominantly used in the biotherapeutic manufacturing [42]. Moreover, cells maintain 
their productivity in the exponential growth phase and incur a productivity loss when the 
growth kinetics reaches equilibrium with the death kinetics due to apoptosis and 
autophagy [43, 44]. However, some viruses are produced with a single harvest with 
higher cell densities of metabolically active cells with a low multiplicity of infection 
(MOI) [45, 46]. The common strategy to scale-up the cultivation is a stepwise increment 
in the bioreactor size, which is performed in different formats of bioreactor systems [47]. 
There are two major types of cultivation methods used for cell proliferation and 
virus propagation- static and dynamic systems [48]. The static bioreactors such as T-
flasks, cell stacks, and roller bottles are vessels with unagitated culture media. The 
dynamic systems such as stirred tank, and wave bioreactors have mechanical agitators to 
induce mixing for uniform distribution of the media components. Roller bottles are 
preferably employed for small scale cell culturing, seed cells and inoculate viruses. For a 
large-scale production, the dynamic systems are used. The systems that achieve higher 
cell densities (~106 cell/mL) are of great interest [49]. In this interest, stirred tank 
bioreactor is preferentially used in the industries for its expertise in operation and 
hydrodynamic modelling [42]. Most cells are adherent cell lines that is they require a 
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surface to proliferate except some newly adapted suspension cell lines such as Vero [50, 
51] and MDCK [52]. Current operation of stirred tank bioreactors utilizes microcarriers 
made of polymers as a substrate for the cells to grow [43, 46]. Trabelsi et. Al. (2012) 
were able to achieve 4x106 cells/mL of MRC5 cell lines and produce 106.5 infectious 
measles virus/day using a non-porous cytodex 1 microcarrier in 7 L stirred tank 
bioreactor. Fixed bed bioreactor is another option being explored for to achieve a high 
cell density and higher titer of viruses. A study demonstrated that the iCeLLis Nano, a 
packed bed bioreactor with medical grade polyester microfibers by Pall Corporation, 
achieved a high cell density of 4x106 cells/mL of Vero cells [53]. Moreover, there was a 
significant increase in the hepatitis A and chikungunya viral vaccine doses as compared 
to the roller bottle and other undisclosed commercial packed bed bioreactors.  
The efforts made to increase the virus production capacity in the upstream sector 
are impressive. However, the increased virus titer and higher cell densities increases the 
complexity of the culture broth that has pushed downstream sector to purify and recover 
high amounts of viruses from a complex HCP profile. Thus, the current bottleneck in the 
vaccine manufacturing has been recognized to be the downstream processing and efforts 
are being geared towards the recovering viruses from crude stock [54].  
 
2.2.2 Unit Operation Mechanisms in Downstream Processing 
A high vaccine production throughput relies on the yield of unit operations 
employed to recover viral agents from the contaminants. The purification of viral 
particles is crucial as the contaminants from the culture broth are unwanted agents in the 
vaccines and biotherapeutics. The regulatory bodies such as the FDA, CDC, and WHO 
have imposed stringent guidelines for the industries to evaluate and demonstrate that the 
final product has minimal traces of the contaminants. For example, the limitations 
suggested on the residual HC-DNA originating from non-tumorigenic continuous cell 
lines, e,g, Vero, is less than 10 ng/dose for parental inoculation and 100 µg/dose for oral 
vaccines [55]. A robust process design must be implemented to ensure the final products 
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are nearly free of contaminants. The purification process exploits the differences in the 
surface characteristics of the viral particles and contaminants (proteins and nuclei acids) 
to gently separate them without disturbing the structural and functional integrity of the 
antigens. However, the virus surface and behavior are very complex, and they share some 
physicochemical properties with the contaminants. This makes the purification process 
very complicated and thus utilizes a train of unit operations each harnessing a unique 
intermolecular interaction to differentially interact with the biomolecules. The 
methodology, advantages, and disadvantages of these separation technologies are 
discussed below. 
2.2.2.1       Conventional Methods and their upgrades 
2.2.2.1.1 Size-based separation 
One of the characteristic differences between a virus and contaminants is the size. 
A typical hydrodynamic diameter of viruses (20-300 nm) is much larger than the 
contaminants’ size (< 20 nm). Obviously, the separation of these biomolecules based on 
the size differences was the first choice in developing the unit operation. Three types of 
methods – filtration, ultracentrifugation, and size exclusion chromatography, have been 
developed which use size as the driving parameter. The membrane-based filtration is 
used at multiple stages of the downstream processing. The filtration at the clarification 
step is used to remove larger contaminant particles such as cell debris and microcarriers, 
if used, from the culture broth [56]. Commonly used filtration-based technique utilize a 
microfiltration mode with pore sizes ranging from 0.45 µm to 10 µm [57]. This pore size 
range retains the larger contaminants on the filter and allows the smaller particles, 
viruses, proteins, and nucleic acids, to flow through the filter. This method is widely used 
in most of the biotherapeutic manufacturing strategy. The other filtration technique - 
diafiltration is used post-purification step as a buffer exchanger to resuspend the viruses 
in the desired solution for the formulation of the vaccines and biotherapeutics. 
Diafiltration is a type of ultrafiltration which exchanges the pre-suspended buffer with a 
new buffer by mixing the retentate with the desired buffer and repeating the filtration 
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again until the pre-suspended buffer dilutes down to an acceptable concentration [58]. 
The ultrafiltration membranes are rated as the molecular weight cutoff (MWCO), which 
retain any particulate with a larger molecular weight than the rated MWCO. A typical 
filter used in this step has a MWCO range of 100 kDa (~10 nm) to 1000 kDa (~100 nm). 
Appropriately selected membranes yield a high step recovery and high flowrate, 
however, are prone to viral losses due to virus-filter non-specific interactions and high 
shear rates [57, 59].  
The membrane chemistry is an important aspect while selecting a filter, as the 
polymers used to prepare the filters affect the separation efficiency. Polypropylene, 
regenerated cellulose, cellulose acetate, and polyether sulfone are some of the prevalent 
membrane filters used in the biomanufacturing. Viruses adsorb on the filter due to 
specific and non-specific interactions with the filter material. Most viruses are negatively 
charged at the physiological pH (~7), as the pI of the viruses are generally between pH 
3.5-7 [60]. Negatively charged viruses have been shown to adsorb on the positively 
charged membranes [61]. Therefore, such membranes might be useful in the antibody 
manufacturing where and antibodies are the target product and viruses are contaminants. 
Moreover, the hydrophobic membranes, such as polyether sulfone, cause biofouling due 
to the virus adsorption by hydrophobic interaction [62]. If the viruses are the target 
biomolecules, more hydrophilic membranes with low zeta potentials might be used to 
avoid any electrostatic and hydrophobic interactions [63]. Such intermolecular 
interactions are easily mitigated by selecting the appropriate buffer compositions and 
surface modifications to membrane or inert materials such as polypropylene [64]. 
However, these interactions are not significant as compared to the fouling and shearing 
phenomena that hinders the yield of viruses [65]. 
Filtration is operated in two modes – dead-end/depth mode and tangential/cross 
flow (TFF) mode. The feed flow is parallel to the permeate stream in the depth filtration 
mode and tangential in the crossflow filtration (See Figure 2-2). The depth filtration 
generally achieves a high purity in the retentate with a decreasing permeate flux. A 
higher feed volume leads to membrane fouling due to particulate accumulation at the 
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membrane interface causing a high degree of concentration polarization. The plugged 
pores cause a high transmembrane pressure that affects the potency of the viral products 
due to structural damage, especially enveloped viruses, and aggregation [54, 66]. A TFF 
mode is used to alleviate the flux issues and structural damage to viruses. This mode of 
operation reduces the concentration polarization along a membrane by sweeping the viral 
particles off from the membrane [63]. The flux reduces until an equilibrium concentration 
polarization is reached and attains a saturation. However, shear sensitive viruses are still 
susceptible for structural damage. Moreover, TFF are more suitable for low cell density 
cultures, as TFF is operated at much lower pressures (~0.7 bar) [54, 67].   Among the two 
modes of filtration, the tangential flow filtration is commonly used to optimize the 
processing capacity and time. Overall, the microfiltration and ultrafiltration techniques 
are still highly preferred method for clarification and post-polishing steps due to its ease 
of operation, scale-up ability, and versatility.  
 
Figure 2-2. Operating modes of filtration – A) Depth filtration and B) Tangential flow 
filtration. This image was created in BioRender. 
 
 Another method using size-based separation of biomolecules is the 
ultracentrifugation. This centrifugation technique utilizes density gradient mechanism to 
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separate viruses from the contaminants (see Figure 2-3). The solutions such as sucrose, 
caesium chloride (CsCl) [68], and iodixanol [69] are prepared in graduated 
concentrations and layered in a tube with the decreasing concentration from the bottom. 
A crude stock applied at the top comprising of the minimum density layer and 
centrifuged at high speeds in the range of 30000-300000 x g [68, 69]. Viruses being 
denser than contaminant proteins and DNA settle in the heavier layer as compared to the 
contaminants (see Figure 2-3). Two types of approaches used to develop a density 
gradient are - rate-zonal centrifugation and isopycnic centrifugation. The rate-zonal 
separation is a method in which the crude is added to the top layer of the density gradient 
and centrifuged for an optimized time. In this method, the density of the media should be 
lower than the density of target biomolecule [70]. The biomolecules settle at a different 
density layer depending on the characteristic sedimentation rate which is a function of the 
size, density, centrifugal force, and the physicochemical profile (density and viscosity) of 
the gradient [71]. Segura et. Al. (2006) demonstrated a 36.5% retroviral recovery in 10-
30% continuous iodixanol gradient [72]. Such a low recovery of the virus in a single step 
is not feasible to produce a high throughput of the viral biotherapeutics. On the other 
hand, isopycnic centrifugation operated by pre-formed gradients in a tube separate the 
biomolecules solely based on the density difference [71]. Gias et. Al. (2008) 
demonstrated a 71% recovery of human respiratory syncytial virus in an iodixanol 
gradient centrifugation [73]. This recovery is acceptable for a large-scale manufacturing. 
The density gradient centrifugation has the capacity to both purify and concentrate the 
viral particles in a single step [54]. This is one of the oldest techniques used at a 
laboratory scale. However, this method is not feasible to be used at industrial scale 
because of the disadvantages of labor-intensive and non-scalable [65]. 
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The third method of purification that uses differences in the size of biomolecules 
is a size exclusion chromatography (SEC). This column chromatographic method is one 
of the four modes of chromatography-based separation. A column is packed with beads 
having crevices or pores with some rated MWCO as the filters. The separation of 
biomolecules depends on the residence time in the column before eluting out of the 
column (See Figure 2-4). Viruses are larger than the pore size of the bead crevices and 
are thus excluded from the pores. Viruses follow a path of inter-bead void volume to 
elute from the column. On the other hand, smaller contaminants diffuse in the pores 
which increases their residence time in the column. The viral particles with the lower 
residence time elute earlier than the contaminants thereby separating from the 
contaminants. However, it has been shown that viruses and other biomolecules might 
interact with the packing materials [74, 75], generally composed of agarose gel-based 
complexes or synthetic polymers like methacrylate-based copolymers [75]. The 
Figure 2-3. Principle of virus purification in density gradient centrifugation. 
This image was created in BioRender. 
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interaction between the virus and the packing material increases the residence thereby 
decreasing the resolution of separation. However, the main disadvantages of SEC are 
dilution of the product, low processing capability, and poor distribution of media flow at 
larger scales [54]. For the larger scale operations, SEC is possibly replaced by the 
ultrafiltration method [54]. 
 
 
Figure 2-4. Principle of size exclusion chromatography for virus purification. A) Column 
pores allow diffusion of small contaminant proteins and exclude viruses. B) A typical 
chromatogram showing increased residence time of proteins, which elute later than 
viruses. 
 
2.2.2.1.2 Charge-based separation 
 The charge on amino acids determines the net charge of a protein. An amino acid 
is negatively charged in a solution with pH higher than the pKa and positively charged if 
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the pH is lower than the pKa. However, if the solution pH is identical to the isoelectric 
point (pI) of a protein, the net surface charge is zero. Most viruses have a 
 
pI in the pH range of 2.1 – 8.3 with a mean of 5.0 (see Figure 2-5, [60]), while HCP 
impurities can range from 2-11 [76]. The change in the pH away from the pI also changes 
the net and relative surface charge of the biomolecules, which is commonly measured 
using a bulk characterizing measurements - zeta potential, isoelectric focusing, and 
electrophoretic titration curves [65]. The charge distribution on the surface is regulated 
by the complex and long sequences of amino acids with varying pIs and electrostatic 
interactions with the ions in a solution [77]. The difference in the net charge and the 
charge densities between viruses and impurities are utilized to purify viruses.  
 Ion exchange chromatography (IEC), one of the four modes of chromatography, 
is one of the prominently used methods in biotherapeutic manufacturing during the 
purification step [78]. The IEX column is packed with resins (stationary phase) carrying 
ionic charges, either positive (anion exchanger, AEX) or negative (cation exchanger, 
CEX) charges. The electrostatic interaction between the virus and resin is promoted by 
Figure 2-5. Frequency of isoelectric points of viruses reported in literature. Reprinted 
with permission from [71]. 
25 
the mobile phase using a pH at which the viruses are oppositely charged. AEX with 
quaternary amine or primary amine-functionalized resins are commonly used, as most of 
the viruses with pI ≤ 7.4 bind to the positively charged resins. The binding conditions 
may allow the majority of the contaminant proteins to elute in the flow-through without 
binding to the resin. The differential elution of viruses and some bound protein impurities 
can be achieved by varying the pH or increasing the salt concentration [79]. However, the 
stability of monodispersed viruses, especially enveloped viruses, persists in a narrow pH 
range [65, 80]. Thus, salt gradient, in the range of 100 – 1500 mM, is commonly used in 
the virus purification, where the contaminant proteins elute at lower concentrations as 
compared to viruses [81, 82]. A careful selection of salt gradient combined with a pH 
change can achieve high resolution in the elution profiles, even for closely related 
physicochemical properties of virus and protein impurity. However, some of the 
challenges faced in this purification method are pore inaccessibility for viruses, low 
dynamic binding capacities, mass transfer properties, and limited flow rates [54].  
The commercial resins have pore sizes ranging from 30-300 nm, and smaller 
proteins with higher diffusion rates occupy these pores, excluding the larger sized, low 
diffusive viral particles [83]. The inaccessibility of the surface area for virus-resin 
interaction lowers the dynamic binding capacities of the resins [83]. Recent studies 
suggest the use of membranes to improve the binding capacities and mass transfer 
properties [84]. Mass transport in these setups is regulated by the convection, thereby 
overcoming the diffusion limitation in the resin pores [85]. One of the studies explored 
the impact of increasing DAAE (diethylaminoethyl) ligand densities to enhance the 
recombinant baculovirus yield [86]. However, a lower ligand density demonstrated a 
20% increase in the yield as compared to the commercial membrane [86], suggesting that 
the optimum ligand density depends on the virus species. One common challenge faced is 
that the multiple binding sites with different binding strengths hinder a smooth elution 
through the column and add to the shearing of viruses. Moreover, it has been shown that 
unwanted interactions, such as hydrophobic interaction of viruses with the resins, also 
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makes the choice of elution conditions difficult [87]. Thus, more control over the elution 
media and condition needs to be explored to improve the purification efficiency. 
 
2.2.2.1.3      Hydrophobicity-based separation 
One of the surface characteristics that differentiate biomolecules is surface 
hydrophobicity. A molecular composition with a lower solvent-exposed hydrophilic to 
hydrophobic ratio increases the hydrophobicity of a biomolecule. In proteins and virus 
capsids, amino acids with aliphatic and aromatic side chains contribute to the 
hydrophobicity of the structure. Enveloped viruses have some solvent side glycoproteins 
that contribute towards the surface hydrophobicity, while the solvent-exposed lipid 
bilayer is extremely hydrophilic due to the polar head group. The detailed surface 
characteristics of viruses are not well understood, as this is still a growing area of interest. 
However, the differential hydrophobic interactions between viruses or proteins with a 
hydrophobic functional group of a third molecule have been studied. 
Hydrophobic interaction chromatography (HIC) is a mode of chromatography that 
utilizes the differences in the hydrophobic interaction strength of viruses and proteins 
with the hydrophobic ligands immobilized on resins. The interaction with the ligands is 
induced by loading the crude at high salt concentration [88]. The kosmotropic ions and 
biomolecules compete to maintain the hydration shell. The excess ions, beyond the 
thermodynamic equilibrium, result in the weakening of the hydration shell of 
biomolecules, thereby exposing hydrophobic patches on the surface. The exposure of 
hydrophobic components decreases the system entropy and increases the biomolecule 
free energy, which promotes the interaction between the hydrophobic patch and 
immobilized ligand to reconfigure the hydration shell of the complex. The biomolecule-
ligand complex strength varies depending on the type and number of hydrophobic 
components involved, which is regulated by the ionic strength of the mobile phase. 
Lowering the salt concentration of the mobile phase disrupts the hydrophobic interaction, 
which allows the biomolecule to elute from the column. Larger viruses contain more 
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hydrophobic patches than proteins, the virus complexes are disrupted at much lower salt 
concentrations than proteins. Thus, the salt gradient applied in the mobile phase separates 
the viruses from the protein impurities.   
Various hydrophobic ligands are commercially available, displaying alkyl (butyl, 
octyl, ether, and isopropyl) and aryl (phenyl) functional groups [89]. Longer alkyl chains 
provide stronger hydrophobic interactions and phenyl groups supplement the 
hydrophobic interactions with the π- π interaction [90]. One of the studies showed a 92% 
recovery of inactivated foot-mouth-disease virus (FMDV) using butyl Sepharose resin 
and 26% recovery with phenyl Sepharose [88]. It demonstrated that the viruses were 
bound too strongly at 0.8 M (NH)2SO4 to enrich the product in the elution step using 
phenyl Sepharose resin. If the interaction is too strong the recovery and purity both 
decreases, on the other hand, if the interaction is too weak viral loss might incur in the 
flow-through [91]. Moreover, this study also demonstrated that the HIC (60%) achieved 
much higher recovery than IEX (17%) for Mumps and Measles viruses. However, HIC is 
seldomly used in industry for vaccine manufacturing. The virus elution from the 
stationary phase require high salt concentrations and the column chromatography induces 
shear stress, both disrupting the structural integrity of viruses [54].   
 Recent interest has geared towards the use of ligands utilizing multiple 
physiochemical properties (charge, hydrophobicity, and hydrogen bonding) of the 
biomolecules to increase the specificity of binding and elution in the chromatographic 
methods [92]. The conventional multimodal ligands comprise of small functional 
molecules such as octyl amine (CaptoTM Core 700, GE Healthcare), N-benzyl methyl 
ethanolamine (CaptoTM adhere, GE Healthcare), and N-benzoyl-homocysteine (CaptoTM 
MMC, GE Healthcare). The binding and elution conditions are unique to a given 
biomolecule that not only improves the recovery but also enriches the purity of the 
vaccine product. However, the binding mechanisms of each virus has to be studied in 
detail to understand the optimal processing conditions. The binding studies of phages 
PR772, PP7, and ΦX-174 with the Capto adhere showed that the comparatively 
hydrophobic phages PR772 and PP7 bound to the resin via synergistic electrostatic and 
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hydrophobic interactions as compared, while the less hydrophobic ΦX-174 bound to the 
resin only through the electrostatic interaction [93]. This suggests that the process 
development of every virus product with Capto adhere resin would need extensive 
research. Thus, Capto 700 resin is more frequently being studied as this resin is 
developed based on the flow-through mode as compared to the bind-and-elute mode of 
other resins. The flow-through mode is when the target viruses are collected in the flow-
through during the loading step, while the impurities bind to the resin [94]. The Capto 
Core 700 uses a functionalized core and an unfunctionalized shell that allows smaller 
proteins to diffuse into the pores to strongly interact with the ligands [95]. Viruses, 
unable to diffuse into the pores due to size exclusion, elute without interacting with any 
ligands [95]. Some recent studies showing the efficiency of multimodal chromatography 
are shown in Table 2-5.   
Table 2-4. Virus and VLP purification in Capto Core 700 multimodal resin 
Virus Recovery (%) Purity (%) Reference 
Influenza A VLP 89 60 [95] 
Influenza A virus 79 66 [96] 
Zika VLP 90 112 [97] 
Yellow fever VLP 89 98 [97] 
Yellow fever virus 65 99 [98] 
Respiratory syncytial virus 100 87 [99] 
Rabies virus 87 94 [100] 
    
2.2.2.1.4 Affinity-based separation        
The multimodal resins, such as Capto Core 700, have shown promise in the 
polishing step but may need additional chromatography steps beforehand to achieve the 
desired purity of vaccines [98, 100]. With more steps, higher losses are incurred in the 
virus yield [101]. A novel approach to mitigate the footprint of the process equipment has 
been the affinity ligand development to increase the specificity in the bind-and-elute 
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mode for viral particles. The affinity ligands explored to date include virus-specific 
antibodies [102, 103], protein-based lectin [104, 105], metal ions [106, 107], and 
polysaccharide-based heparin and heparan sulfate [108, 109]. The mechanism and 
advantages of these ligands are described in Table 2-6. 
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Among the above-mentioned ligands, an antigen-specific antibody shows the 
highest binding specificity towards viruses, which can yield a high purity of the viral 
particles. Due to the antibody production cost and stability issues, the approach has been 
directed towards developing short peptides with 3-12 amino acid residues that mimic the 
specific interaction mechanism of antibodies [101, 110]. The high affinity peptides can be 
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either a closed ring cyclic structure or an open chain linear structure. Ho et al. (2017) 
identified cyclic peptides C-WSFFSNI-C and C-WPFWGPW-C that bind tightly to 
HBcAg as the previously screened linear peptide LLGRMK [111]. The binding 
mechanism of peptides with viruses can vary. The high affinity of cyclic peptide C-
WSFFSNI-C towards HBcAg was suggested as the hydrogen bonding mechanism while 
the other cyclic peptide C-WPFWGPW-C was anticipated to interact with the 
hydrophobic regions on the surface [111]. An octamer, DWDLRLLY, identified was 
found to bind to the hydrophobic residues of the major coat protein VP1 of murine 
polyomavirus like particles [112]. In another study, YKLKYY hexamer binding to the 
VP2 capsid protein of porcine parvovirus was suggested to be constrained to the 
secondary structure of the hexamer, docking in the capsomere pocket [113]. The large 
library of screened affinity peptides has the potential to be included in the purification 
step. However, more studies are needed to identify optimal conditions for the processing 
of viral particles. Overall, there is still a gap in the comparison studies between the novel 
chromatographic modes with traditional methods, and economic feasibility analysis needs 
to be evaluated [110].  
2.2.2.2 The conventional downstream processing train 
The yields obtained in a single unit operation, using any separation mechanism, is 
generally not enough to meet the regulatory criteria of purity. Thus, multiple unit 
operations functioning with different mechanisms are employed in a series to achieve the 
desired purity, final buffer solution, and dose concentration (Figure 2-6). Unlike 
antibody production, vaccine manufacturing lacks a platform downstream processing 
strategy. Every virus has a unique behavior with a wide range of characteristics. The 
virus surface topologies are complex, and studies have employed different mechanisms to 
separate viral particles from the different classes of contaminants at each DSP stage 
(Figure 2-6). Bandeira et al. (2012) utilized depth filtration for clarification, DEAE AEX 
in the purification step, 100 kDa vivaflow ultrafiltration for concentration, and SEC for 
the polishing step to develop a DSP train for lentivirus production [114]. The 
chromatographic steps were the least yielding unit operations (80% in AEX, and 68% in 
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SEC), which achieved a cumulative virus recovery of 36%. In another study of 
inactivated HAV vaccine (VAQTA®) production, a long series of the traditional methods 
were utilized in the DSP [115]. The clarification was performed using ultrafiltration, 
which was followed by Benzonase® treatment. The clarified product was processed 
through AEX, followed by PEG precipitation and solvent extraction in the purification 
step. The polishing step included AEX followed by SEC. The viral product was then 
inactivated using formaldehyde for the vaccine formulation. The use of three 
chromatography modes, and a time-consuming laborious PEG precipitation yielded a 
final virus recovery of 20% and 99% purity [115].  
The strategy to include novel modes of chromatography for increasing the 
selectivity and recovery of viral particles has been shown in some studies. One of the 
steps where this reform was explored is the polishing step by using a multimodal-based 
Capto Core 700 resin in the negative mode chromatography. For example, the proposed 
DSP train of inactivated yellow fever virus vaccine included clarification by 
microfiltration followed by AEX in the purification step with a final polishing step using 
Capto Core 700 [98]. This two-step purification process (regarded clarification as a 
midstream stage) yielded an overall 53% virus recovery with ~99% purity. Overall, the 








2.2.2.3 Continuous Integrated Processing: Vision for Biotherapeutic 
Manufacturing 
The rapid growth in the demand for the vaccines and biotherapeutics, along with 
the need to reduce the production cost and increase product quality, has motivated 
scientists and engineers to explore next-gen strategies [116]. One of the strategies 
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currently being considered to enhance productivity and economic benefits is the 
continuous manufacturing capability with integrated processes [117]. Most of the existing 
biomanufacturing facilities operate in the batch mode, for which the way to enhance the 
productivity is by improving the yield of individual unit operations combined with 
scaling up the size of the unit operations. However, an increase in the scale-up not only 
increases the facility footprint but might also hinder the flexibility of the product 
portfolio [118]. Some studies have evaluated the economic benefits of shifting to 
continuous processing and have shown to reduce the costs substantially [119, 120]. The 
idea of continuous manufacturing is to integrate the upstream processing and downstream 
processing with minimum or no hold up in between each of the unit operations. One 
study suggested a hybrid model where some unit operations function in the batch mode 
and others in the continuous mode [121]. The combination evaluated for a fed-batch 
culture integrated with a continuous capture step and a batch polishing step for 
monoclonal antibodies was found to be more economically feasible and flexible for the 
companies of all sizes with multiple product portfolios [121]. However, such feasibility 
studies have rarely been performed for viral manufacturing. The general vision with the 
integrated continuous viral manufacturing is to develop a downsized ballroom like 
facility which would still produce the required number of high-quality doses [122, 123].   
 Focusing on downstream processing, one of the major bottlenecks in continuous 
operation is the chromatographic method of separation [124]. Advances are being made 
to address this issue. Some strategies recommended to operate a continuous 
chromatography included the use of multiple columns to keep a constant output flow 
[124]. The concept of using multiple columns is to keep the process steady by utilizing 
the columns alternatively in the active and passive state. This is achieved by simulated 
moving bed (SMB), which indicates a periodical use of columns for loading and eluting 
the biomolecules [125]. However, the use of multiple chromatography columns might 
only increase the facility size and is counter-intuitive to the future paradigm of ballroom-
sized biomanufacturing. Moreover, it has also been shown that an increase in the 
chromatography steps increases the process mass index, which is the amount of raw 
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materials used per unit mass of active pharmaceutical ingredients [126]. The impact of 
increased process mass index was suggested to harm the sustainable and green 
biomanufacturing initiative [126, 127]. Some studies have shown that the use of SMB 
reduces the processing cost, buffer, and water usage but increases the resin cost, which is 
one of the major expenses of the DSP [128]. Thus, some of the groups have been 
exploring unconventional methods to potentially substitute for the current challenges of 
productivity, cost, time and energy consumption, facility architecture, and environmental 
factors in the biomanufacturing. 
There is a motivation to improve the DSP by reducing the number of unit 
operations and equipment used in the unit operations while increasing the production 
capacity. One such method being explored is a liquid-liquid extraction (LLE)-based unit 
operation.    
2.2.3 Liquid-Liquid Phase Separation 
The conventional use of LLE in the petroleum refineries employ organic-organic 
or organic-water phases to extract a solute from the mixture into either organic phase or 
aqueous phase. However, most organic solvents such as benzene, toluene, and 
acetonitrile, etc. are denaturants for biological materials. The discovery of two-phase 
systems (ATPS) composing of aqueous solutions, by Beijerinck (1896), opened 
opportunities for various applications for the bio micro and macromolecules [129]. The 
formation of two incompatible phases was observed after a certain critical concentration 
of phase forming components, while the lower compositions yielded a homogeneous 
solution. In contrast to the completely immiscible organic-water systems, the aqueous 
two-phase systems (ATPS) are partially miscible systems that generate two incompatible 
phases. The partially miscible phases signify that a fraction of both the aqueous solutions 
is distributed between the two incompatible phases. The component distribution in the 
phases leads to one phase being rich in one of the components, and the other phase rich in 
the counter component used to form two-phases. The partially miscible aqueous solutions 
form two incompatible micro (precipitate and complex coacervate) or macro-phases 
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[129]. Two such microphase separation methods are polyethylene glycol (PEG) 
precipitation in high ionic strength aqueous solution and colloidal complex coacervation 
of oppositely charged polymers in low ionic strength aqueous solution (see Figure 2-7). 
The immiscibility of the incompatible aqueous phases is an excellent means to separate 
biological materials by preferentially partitioning the target biomolecule in one phase 
(preferentially in the microphase) and the contaminants in the other phase. However, due 
to their time consuming and labor-intensive operation, they might not be feasible for 
large-scale bioprocessing. The use of aqueous solutions that form two macro-phases upon 
separating is notable for the downstream processing of biomolecules (see Figure 2-7). 
 
Figure 2-7. Different types of two-phase systems used for biomolecule partitioning. The 
image was created in BioRender. 
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The macro aqueous t/wo-phase systems (ATPS) were traditionally generated 
using aqueous polymer-polymer or polymer-salt pairs (Table 2-7). Polyethylene glycol-
dextran/dextran sulfate is a commonly used polymer-polymer system. The separation of 
two phases yields a PEG-rich phase and a dextran-rich phase with a fraction of the 
complementary component in each of the polymer-rich phases. Similarly, a PEG-salt 
system yields a PEG-rich phase and a salt-rich phase. The equilibrated two immiscible 
phases have been suggested to prevail as hydrophobic-hydrophilic pairs [129]. For 
example, the hydrophobic PEG-rich phase is complemented with a hydrophilic dextran-
rich phase or salt-rich phase. A combination of these phase property differences and 
biomolecule surface properties drive the biomolecules either to the top phase (polymer-
rich phase), the bottom phase (polymer/salt-rich phase), or the interface between the top 
and the bottom phase. The variation in the physicochemical characteristics of different 
biomolecules decides the target partitioning phase for a given system, which is used to 
segregate biomolecules between the two-phases. The partitioning of biomolecules 





         (2-1) 
where, C is the concentration of biomolecule in the top phase (T) or bottom phase (B). 
The systems are designed to achieve a distinct partition coefficient for the target 
biomolecule and contaminants to achieve separation. Novel phase forming component 
pairs such as ionic liquid-salts (Table 2-6) are being investigated for their added relative 






Table 2-6. Phase forming components for ATPS [130] 
ATPS type Phase forming components 
Polymer - polymer 
PEG - dextran 
UCON - dextran 
PEG - sodium polyacrylate 
Polymer - salt 
PEG - phosphate 
PEG - sulfate 
PEG - citrate  
Ionic liquid - salt 
[N2,2,2,2] Br - citrate 
[Bmim] BF4 - phosphate 
[C4MIM] Br - sulfate 
Micellar 
Triton X-100 - citrate 
PEG - Triton X-100  
 
ATPS has been explored as a potential alternative to conventional unit operations, 
mainly chromatography. ATPS consists of water as a major component (>70%), which is 
essential for the stability of biological materials. Moreover, the two-phase systems 
provide processing advantages such as low-cost raw materials, gentle environments for 
biologics, easy scalability, and continuous operation [131, 132]. The phase forming 
components such as PEG, dextran, salts are less expensive than the chromatography 
resins. A direct comparison of IEX and ATPS for penicillin acylase demonstrated a lower 
operational cost and higher recovery of the enzyme in the PEG-phosphate system [133]. 
Rosa et al. (2011) assessed the operating cost of ATPS and concluded that ATPS would 
alleviate the operating cost by 1.5 fold as compared to the protein A chromatography 
used for antibody purification [134].  However, such process economic analysis has not 
been performed for the viral vaccine manufacturing scenario. Another benefit of ATPS is 
easy scalability. The scale-up of ATPS has been shown to yield similar partitioning 
behavior of proteins with high recovery [132]. Conventional LLE equipment, such as 
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mixer-settler and counter-current partitioning, which are commonly utilized in chemical 
industries, can be easily adapted to the bioprocessing [135, 136]. Moreover, ATPS has 
been demonstrated to easily adapt to continuous operation and integrate into the 
downstream processing at the laboratory scale [137, 138]. Common process design for 
continuous operation may include an inline or online static mixer with a tubular separator 
or a conventional mixer tank with a separator [138, 139]. These advantages have 
motivated the exploration of the potential of ATPS as a purification method for numerous 
biological materials. 
ATPS has been applied in the purification of numerous biomolecules. However, 
many studies have focused on antibody and enzyme purification. Purification of 
biotherapeutics using ATPS has been focused on cells, antibodies, nucleic acids, and 
viruses. The biotherapeutic applications have targeted the primary clarification and 
purification steps of the DSP train [132]. Cell-based regenerative therapeutics have 
gained interest in treating diseases such as osteoarthritis, Parkinson’s disease, ALS, and 
heart failure [140]. Stem cell therapy involves a differentiated form of the pluripotent cell 
and demands the separation of differentiated and undifferentiated cells in the DSP [141]. 
The antibody therapy, such as monoclonal IgG, targeted to bind an antigen-presenting 
cell, are predominantly expressed in mammalian cell lines, such as Chinese hamster 
ovary (CHO) [142]. The DSP is intended to purify antibodies from cell culture 
contaminants. The novel DNA vaccines produced in various cell platforms have host cell 
DNA and RNA contaminants, and studies have explored ATPS as the potential method 
for the separation of the therapeutic DNA from HC-nucleic acids [143]. Some examples 





Table 2-7. Examples of ATPS for purification of different biomolecules 
$Recovery in the top phase; *purification factor 
The inclusion of ATPS for viral-based biotherapeutic and vaccine DSP has 
recently gained interest. However, the complex viral tropism and fragile structure had 
challenged the method optimization for infectious virus recovery. Some studies have 
shown higher recoveries of VLPs (up to 80%) as compared to viruses (Table 2-8). The 
VLPs, void of genetic material and replication deficient, are assessed with the major 
quality attributes pertaining to the structural integrity and immunogenic glycoprotein 
conformation retention [149]. On the other hand, whole virus vaccines and 
biotherapeutics such as LAV and gene therapy vectors have comparatively complex 
quality attributes. One of the unique critical attributes for LAVs is the potency of the viral 
product, which is measured by the infectivity assays (cell-based assay to quantify 
infectious dose) and quantitative PCR (counts the number of gene copies) [3]. The viral 
infectivity losses incurred during DSP reduces the product yield. This is generally 




Ficoll T400 - Dex T70 CD133+ stem cells 59 60 [144] 
PEG 8000 - Dex T500 CD11b+ HL-60 cells 93 99 [145] 
Proteins 
PEG 3350 – citrate IgG 97 76 [146] 
PEG 600 – phosphate Xylose reductase 117 1.2* [147] 
Nucleic acids 
PEG 8000 – 
polyacrylate T240 - 
sulfate 
Plasmid DNA 55 - [143] 
PEG 8000 – 
polyacrylate T240 - 
sulfate 
DNA fragments  
(< 6000 bp) 60 ~100 [148] 
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observed with the lower virus recoveries measured using the infectivity assays. 
Moreover, traditional ATPSs have been utilizing polymer-polymer systems [129, 150, 
151]. Recently, PEG-salt systems have been in demand due to lower interfacial tensions, 
viscosities, and cost as compared to the polymer-polymer systems [152, 153]. 
 
Table 2-8. Virus and VLP recovery in PEG-rich phases of ATPS 
System Virus / VLP Recovery (%) Reference 
PEG 400 - phosphate Rotavirus-like particle 60 [154] 
PEG 6000 - Dex T500 HIV-1 60 [155] 
PEG 1000 - MgSO4 B19 VLP 58 - VP2 [156] 
PEG 400 - phosphate B19 VLP 98 [157] 
PEG 400 – phosphate M13 bacteriophage 83 [158] 
 
2.2.4 ATPS phase diagrams 
The experimental design for a given pair of phase-forming components is 
governed by a graphical representation of the concentration of the components. The two-
phase systems formed above certain concentrations of the phase forming solutions are 
represented by a binodal curve. The system compositions above a binodal curve form 
two-phases upon mixing, and the systems below form homogenous solutions with a 
single phase (Figure 2-8). The position of the binodal curve and system compositions 
within the two-phase region govern the driving forces for the partitioning of biomolecules 
(see Section 2.2.5 for details). The area of the two-phase region is dictated by the type 
and characteristics of the phase-forming components such as polymer and salt type, 
polymer molecular weight, pH, and temperature [153]. The binodal curves for a given 
system, pH, and temperature are generated using a turbidity method [153]. High system 
compositions are chosen that form two phases, which is indicated by turbid mixture, and 
titrated with water to dilute the systems until the turbidity disappears. The system 




Figure 2-8. Phase diagram demonstrating binodal curve and tie lines for ATPS 
 
The closer the curve is to the origin or axes, the higher the driving forces involved 
in the phase formation are. This means that the lower system compositions that can form 
two-phases have better immiscibility. In PEG-salt systems, the immiscibility of the 
phases is suggested to be the effect of salting-out nonelectrolyte polymer (PEG) from the 
salt-rich phase [159]. The salting-out effect of PEG was determined to be in the order of 
the Hoffmeister series for anions as phosphate > citrate > carbonate > sulfate > hydroxide 
[159, 160]. The salts of anions in the higher order of the Hoffmeister series cause 
depression in the binodal curve, resulting in the immiscibility at lower compositions 
[160]. The multivalent cations (Mg2+ and Zn2+) have been indicated to favorably interact 
with the ether oxygens to form a complex causing a higher salting-in of PEG chains as 
compared to the monovalent cations (Na+ and (NH4)+) [159]. However, the depression of 
binodal curve has been shown in the order of Na+ > (NH4)+ > Zn2+ >Mg2+ [160]. The 
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counter-intuitive effect of the multivalent and monovalent cations was supported with the 
complexation ability of the multivalent cations. On the other hand, binodal curve has also 
been shown to be affected by the PEG molecular weight. Longer PEG chains have added 
hydrophobic character to the polymer due to the increased hydrophobic methyl to 
hydrophilic oxide groups. The increased hydrophobicity has been shown to aid in the 
salting-out PEG leading to immiscibility at lower concentrations of salt and depression in 
the binodal curve [161]. The physicochemical factors affecting the binodal curve changes 
the experimental workspace to choose an appropriate system for the partitioning of the 
biomolecules.        
The other characteristics of the systems are the phase compositions. A set of 
systems within the two-phase region separate into two phases with identical equilibrium 
phase compositions, which are represented by tie lines (Figure 2-9). While the 
equilibrium phase compositions remain the same, the phase volume ratio decreases as the 
systems compositions approach the bottom node [153]. The volume ratio is defined by 
the ratio of PEG-rich phase volume to salt-rich-phase volume. A tie line is defined by the 
length of the tie line (TLL) joining the two nodes on the binodal curve and is expressed 
as shown in the equation 2-2 [153] 
𝑇𝑇𝑇𝑇𝑇𝑇 =  �∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃2 +  ∆𝑥𝑥𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠2       (2-2) 
Δx represents the concentration difference of the component (PEG or salt) in the PEG-
rich phase and salt-rich phase. An increase in the TLL increases the phase concentrations. 
The difference in the phase composition is characterized by a tie line slope, which is 
expressed as equation 2-3 [153] 
  𝑇𝑇𝑇𝑇 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 =  ∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃
 ∆𝑥𝑥𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠
                   (2-3) 
The TL slope is unique for a given system PEG molecular weight, salt type, and pH. For 
a given system composition, the TL slope dictates the final composition of the PEG-rich 
phase and salt-rich phase. Further, the phase compositions aid in the separation of 
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biomolecules (see Section 2.6.6 for details). The phase diagrams are the blueprint of a 
given pair of the phase forming components to study the partitioning behavior of 
biomolecules. However, the phase diagrams being unique to each pair, the optimization 
of the biomolecule purification using ATPS generates an extensive experimental space. 
The previous works have used a lab-specific or wide range of phase forming components 
varying in PEG molecular weight, salt type, and pH to optimize virus recovery in the 
PEG-salt system [154, 156-158]. The goal of current biotherapeutic manufacturing is to 
develop a standard method of purification with a minimum variation in the processing 
conditions for faster FDA approval. The lack of a standard system or optimization 
method for optimization of virus recovery is the bottleneck of ATPS for biotherapeutic 
processing applications.     
2.3 Biomolecule Partitioning Theories in ATPS 
2.3.1 Excluded volume and intermolecular interactions 
The commercial implementation of ATPS is lacking due to an ambiguity in 
understanding the partitioning mechanism of the biomolecules and lack of expertise in 
the process development for large-scale production [162, 163]. There have been 
numerous studies to elucidate the partitioning mechanisms of biomolecules in the ATPS. 
The two major theories argue the role of excluded-volume effect [154, 158, 164] and 
intermolecular interactions [129, 164, 165]. The excluded volume theory states that the 
volume occupied by a polymer chain in the polymer-rich phase is saturated with the 
polymer chains and hydration molecules [164]. The unavailability of the free volume 
leads to a steric hindrance for comparatively larger sized globular biomolecules (proteins, 
cells, and viruses), resulting in the exclusion of the biomolecules from the phase [156, 
166]. Benavides et al. (2006) demonstrated that the majority of double layer rotavirus-
like particle partitioned in the PEG-rich phase when PEG 400 Da was used, and the 
partitioning shifted to the interface when the molecular weight was >1000 Da [154]. The 
partitioning shift from the PEG-rich phase to the interface was suggested due to the 
reduced free volume of the PEG-rich phase with the increased PEG MW supporting 
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previous observations of protein partitioning [167, 168]. A similar argument was made by 
Gonzalez-Mora et al. (2017) when the partitioning of M13 bacteriophage shifted from the 
PEG-rich phase to the interface when the cation type of phosphate salt was changed from 
Na+ to K+ in the PEG-salt system [158]. It was proposed that Na+ with more water 
molecules in the hydration shell, as compared to the larger sized K+ ion, reduces the 
availability of free water molecules for bacteriophage hydration in the PEG-rich phase, 
resulting in the interface partitioning [158]. However, the interpretation of the ion effects 
on biomolecule partitioning is at the edge of the excluded volume theory and 
intermolecular interactions. 
 Another partitioning mechanism proposed was the net effect of intermolecular 
interactions. The driving forces governing the partitioning was proposed to include 
hydrophobic interactions, electrostatic interactions, and phase-specific affinity [129, 165]. 
Over the years, studies have suggested that the hydrophobic interactions of biomolecules 
with the PEG-rich phase and electrostatic interactions with the salt-rich phase majorly 
influence the partitioning [169, 170]. It has been shown that the hydrophobic patches of 
proteins interact with the ethyl groups of PEG [171, 172]. The attractive forces between 
some proteins and PEG aids in the preferential partitioning of the proteins in the PEG-
rich phase. On the other hand, the electrostatic interaction of charged biomolecules with 
the ions in the salt-rich phase either helps in salting-out or salting-in proteins [146, 165]. 
In a way, the principle of hydrophobic interaction of combined salting-out effect and 
induced hydrophobic interaction has been suggested to govern the biomolecule 
partitioning. The specific affinity of the biomolecules towards the PEG-rich phase in a 
PEG-salt system can be interpreted as the interaction of biomolecules, especially 
proteins, with the higher molecular weight of PEG (>10 kDa) [172]. However, this effect 
may be negligible in the studies that utilized lower molecular weight PEG (< 10 kDa). 
The specific affinity has also been shown to supplement the driving force if an affinity 
functionalized PEG or affinity ligands are used in the systems to enhance the specificity 
of a target biomolecule [173]. Moreover, intermolecular interactions have been shown to 
be determinant of the biomolecule size and conformation [129, 165]. The overall 
45 
partitioning coefficient (K) of a biomolecule is the net effect of these intermolecular 
interactions, which was proposed as equation 2-4 [129, 174] 
𝐾𝐾 = 𝐾𝐾𝑂𝑂  ∙ 𝐾𝐾𝐻𝐻 ∙  𝐾𝐾𝑃𝑃 ∙  𝐾𝐾𝐴𝐴 ∙  𝐾𝐾𝑆𝑆 ∙  𝐾𝐾𝐶𝐶      (2-4) 
where the subscripts H, E, A, S, and C are the contributions of hydrophobicity, 
electrostatics, affinity, size, and conformation to the partitioning coefficients, 
respectively. The subscript O represents the miscellaneous contributions affecting the 
partitioning of biomolecules as there are other factors that influence the partitioning 
[165]. Overall, Grilo et al. (2016) suggested that the influence of excluded-volume 
effects, hydrophobicity, and electrostatics depends on the chosen system and target 
biomolecule [163]. 
The biomolecule transport from one phase to another is also governed by the 
interfacial characteristics. The characteristics that affect the partitioning are interfacial 
tension and electrostatic potential difference [163, 175]. The initial step in phase 
partitioning of a biomolecule is the adsorption at the interface. The interfacial tension 
governs the free energy profile of biomolecule [176]. If the free energy of a biomolecule 
reaches equilibrium at the interface, the biomolecule diffusion across the barrier is seized 
[176, 177]. A previous study demonstrated that the partitioning of skin cancer cells was 
shifted from the dextran-rich phase to the interface and PEG-rich phase when the 
interfacial tension was increased beyond a certain limit [176]. However, the embryonic 
stem cells partitioned majorly at the interface without diffusing to the PEG-rich phase, 
which was suggested due to the free energy minimization at the interface of stem cells as 
compared to the cancer cells [176]. On the other hand, the biomolecule partitioning has 
been shown to increase in the PEG-rich phase as the system compositions increase [178, 
179]. An increase in the system composition also elevates the interfacial tension [180, 
181]. This indicates that interfacial tension aids in the biomolecule partitioning between 
the phases until a certain limit, after which it hinders the transport leading to the 
interfacial partitioning of biomolecules. 
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The other physicochemical characteristics that drive the partitioning behavior of 
biomolecules is the electrostatic potential difference between the phases [175]. The 
differences in the partitioning of cations and anions in the PEG-dextran system have been 
shown to generate a potential difference across the interface [175, 182]. It has been 
reported that the PEG-salt systems generate a positive potential difference, typically in 
the range of -30 to 30 mV for PEG-phosphate or sulfate systems, measured as the 
difference between the top (PEG-rich) and bottom phase (salt-rich) [183]. Sufficient 
charge on a biomolecule results in the partitioning behavior that yields a net 
electroneutrality of the phases [183, 184]. 
2.4 Parameters and their effect on driving forces in ATPS 
The optimization of a target biomolecule’s recovery in a PEG-salt system 
includes designing a system to yield an optimal balance of the driving forces. Previous 
studies reported a list of characteristics of the phase forming components that have a 
direct effect on the driving forces. The parameters influencing hydrophobic interaction, 
electrostatic interaction, and interfacial mass transport properties depend on the PEG and 
salt characteristics [183]. These phase forming components directly affect the phase 
diagrams yielding different driving forces. The effects of these parameters on the phase 
diagrams and driving forces are discussed below. 
2.4.1 Phase forming component parameters 
2.4.1.1 Polymer molecular weight and concentration 
PEG is the most common polymer utilized in ATPS of both polymer-polymer and 
polymer-salt system (Tables 2-7 and 2-8). PEG MW significantly affects the phase 
characteristics by changing the phase diagrams. An increase in MW has been shown to 
reduce the system compositions that form two phases, resulting in depression of the 
binodal curve (see Figure 2-9) [161]. It has also been shown that the tie line slope 
decreases with an increase in MW [185]. This signifies that for a given system 
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composition with a higher PEG MW, the equilibrium salt-rich phase has a lower 
composition, and the PEG-rich phase has a higher composition (see Figure 2-10).  
 
 
Figure 2-9. The binodal curve shift with an increasing PEG molecular weight. Wp and 
Ws represents the PEG and salt concentrations. Reprinted with permission from [186]. 
Copyright (2018) Elsevier. 
 
An increase in the PEG MW has been shown to decrease the partitioning of 
proteins to the PEG-rich phase [187, 188]. The reduced partitioning has been argued with 
both steric exclusion [154, 187] and hydrophobicity [163] mechanisms. The steric 
exclusion was suggested based on the reduced free volume of the PEG-rich phase. An 
increase in the PEG MW for a constant PEG concentration reduces the number of 
ethylene oxide in the PEG-rich phase, thereby reducing the hydrophobicity of the PEG-
rich phase [163]. On the other hand, Asenjo et al. (2011) states that for a given polymer, 
an increase in the PEG MW increases the hydrophobicity of the polymer due to an 
increase in the ethyl to oxygen group ratio [165]. An elevated hydrophobicity of the 
higher MW PEG has been shown to favorably interact with the hydrophobic patches of 
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the proteins [172]. Moreover, the PEG-rich phase yields a higher phase composition with 
a higher PEG MW for a given system composition that has shown to increase the 
partitioning of relatively hydrophobic proteins [165]. The discrepancy in the arguments 
of the effect of PEG MW causing steric exclusion and changing hydrophobicity of the 
PEG-rich phase needs more characterization of the phases to elucidate the exact 
mechanism. 
The proposed theory of hydrophobicity as one of the dominant driving forces has 
also been studied by increasing the PEG concentration. The increased PEG concentration 
increases the number of PEG chains in the PEG-rich phase, thereby dehydrating the 
phase and increasing the phase hydrophobicity [165]. However, a study demonstrated 
that the PEG concentration does not affect the partitioning of IgG in the PEG-phosphate 
system, and the antibodies preferentially partitioned to the PEG-rich phase irrespective of 
the PEG and phosphate concentration [189]. In the other study, the α-Lactalbumin 
partition coefficient increased up to a certain PEG concentration and then decreased 
[190]. While others reviewed that increasing the PEG concentration decreases protein 
partitioning in the PEG-rich phase due to steric hindrance exhibited by the increased PEG 
chains in the PEG-rich phase [163]. The different partitioning behavior of proteins 
demonstrates that the biomolecule characteristics play important role that interact with 
PEG-rich phase uniquely.  
2.4.1.2 Salt type and concentration 
Salts play a significant role as the drivers of electrostatic interactions for 
biomolecule partitioning. One of the primary roles of salts is to induce a preferential 
salting-out for a target biomolecule. The salting-out ability of different ions studied was 
by Hofmeister postulated a kosmotropic series for ions. The anion kosmotropic series for 
the salting-out ability was given as PO43- > citrate3- > CO32- > SO42- > Cl- [191]. On the 
other hand, the kosmotropic series for cations was given as Na+ > K+ > NH4+ [191]. The 
salt type has been shown to modulate the binodal curve and tie line slope. A higher 
kosmotropic salt in the series increases the two-phase region by pulling the binodal curve 
49 
closer to the axes, similar to binodal curve behavior shown in Figure 2-9 [192, 193]. 
However, it was observed that the anion effect on the binodal curve was more influential 
and shifted the curve more prominently towards the axes as compared to the cations 
[193]. Moreover, the tie line slopes get steeper for higher kosmotropic anions, indicating 
that lower salt-rich phase compositions have higher salting-out ability to yield a more 
concentrated PEG-rich phase [194]. However, one study demonstrated that sulfate ion 
was better at salting-out HIV-GFP-VLP as compared to the phosphate and citrate ions 
[195]. There have been some studies indicating that the salting-out effect by anions does 
follow the Hofmeister series due to other non-specific interactions of salts with 
biomolecules [196]. On the other hand, it has been shown that Na+ salts increase the 
relative hydrophobicity of the PEG-rich phase as compared to Mg2+ [197]. Moreover, a 
salt of highly kosmotropic ion generates a high electrostatic potential difference, which is 
postulated to highly influence biomolecule partitioning to the PEG-rich phase [183].  
The kosmotropic anions, such as citrate and phosphate, have been shown to 
induce the salting-out effect of biomolecules at much lower concentrations as compared 
to the other salts [198]. It has been shown that the preferential hydration ability of 
kosmotropes causes an increase in the surface tension near a biomolecule surface that 
leads to aggregation and interfacial interactions of biomolecules [146, 199, 200]. In the 
ATPS, a kosmotropic salt aids in the interfacial interaction of biomolecules with the 
PEG-rich phase caused by the salting-out effect. A previous study showed that, for a 
constant PEG molecular weight, porcine parvovirus partition more towards the interface 
or PEG-rich phase [178]. In another study, M13 bacteriophage recovery in systems 
containing sodium phosphate decreased when crude stock with contaminants was fed as 
compared to the pre-purified bacteriophage feedstock [158]. However, the system 
containing potassium phosphate demonstrated a similar bacteriophage recovery 
irrespective of the feedstock [158]. The authors proposed that as Na+ ions are highly 
hydrated as compared to K+ ions, the PEG-rich phase where cations partition is easily 
saturated when Na+ ions are used. Overall, the literature demonstrates the effect of 
different ion-biomolecule pair for a given system composition and limited studies have 
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focused on showing the effect of selecting systems of different salts which yield similar 
salt-rich phase composition.  
The salting-out ability for a given salt type depends on the ionic strength of the 
solution. An increase in the ionic strength by increasing the salt concentration has been 
shown to induce the salting-out effect [158]. The salting-out of dlrotavirus-like particles 
were shown to recover at the interface but not in the PEG-rich phase [154]. It might be 
due to an insufficient hydrophobic driving force that the VLPs did not partition to the 
PEG-rich phase at all the PEG MW studied.   
2.4.1.3  pH  
Ion charge on is one of the influential parameters in governing the driving forces 
for biomolecule partitioning, as discussed above. The ionic charge depends on the pH of 
the solution, and modulating the pH affects the phase characteristics and biomolecule 
partitioning. An increase in the pH causes depression in the binodal curve towards the 
axes for a given PEG-salt system [185]. The slope of tie lines increases with an increase 
in system pH, indicating lower equilibrium salt-rich phase composition and higher PEG-
rich phase composition for a given system composition [201].  
 The change in the phase characteristics due to pH affects the biomolecule 
partitioning. An increase in the system pH increases the biomolecule partitioning to the 
PEG-rich phase [167, 170]. The partitioning behavior of biomolecules has been 
associated with the free volumes of the phases [183, 202]. Oxygen atoms of PEG interact 
with metal ions and exclude divalent and trivalent anions, thereby causing the phase 
formations. A lower pH decreases the free volume of the PEG-rich phase by reducing the 
metal ion availability causing a lower partitioning of the biomolecules in the PEG-rich 
phase [167]. Moreover, pH modulates the charge on biomolecules by changing the 
protonated to deprotonated sites that supplements the change in the partition behavior of 
biomolecules (see Section 2.4.2). 
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2.4.1.4 Summary of phase parameters and effects 
The driving forces involved in phase formation and biomolecule partitioning have 
been discussed as a complex synergy of free volume and intermolecular interactions. 
These driving forces are influenced by multiple characteristics of the phase forming 
components, and a net effect is provided to allow for biomolecule partitioning in either 
phase. In summary, the studies have indicated different theories for which the phase 
forming components affect the driving forces which are maintained. Moreover, most of 
the studies have been focused on proteins, enzymes. Very few studies were performed to 
understand viral behavior in the ATPS, and the studies that were completed focused on 
the polymer-polymer systems [150, 151, 203]. Recently, studies are showing interest for 
the viral behavior in the PEG-salt systems, but the effects of phase parameters were 
correlated with the protein partitioning behavior [154, 156, 158, 195]. Most studies have 
reported an experimental design by changing one parameter at a time, such as PEG MW, 
PEG concentration, salt type, and concentration by keeping the other factors constant. 
However, the conventional setup might not be appropriate to study viral partitioning 
behavior in ATPS as the physical characteristics of the phases such as volume ratio, tie 
line length, and equilibrium phase compositions, change thereby deviating from the 
expected partitioning behavior. While the conventional setup is very crucial for an initial 
understanding of viral behavior in the ATPS, this setup is not optimal to develop a clear 
picture of the phase parameters as the empirical models have not been validated for 
complex structures such as viruses. A systematic approach by understanding the 
differences in viral and protein behavior is needed to achieve similar success as 
comparatively smaller proteins. 
2.4.2 Biomolecule characteristics and the effect on partitioning behavior  
2.4.2.1 Surface hydrophobicity  
The hydrophobic and electrostatic interactions were shown to be the dominating 
driving forces for the biomolecule partitioning. The proteins composed of amino acids 
display some amino groups on the solvent accessible side while the rest being solvent 
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inaccessible due to secondary and tertiary structures. The solvent accessible amino acids 
have a mixture of hydrophobic and hydrophilic side chains, and the ratio of these side 
chains determine a net hydrophobicity of proteins. Studies performed with small peptides 
with a different number of hydrophobic amino acids have demonstrated, that for a given 
PEG-salt system, relatively more hydrophobic peptides readily partition to the PEG-rich 
phase [204, 205].  A similar study performed on an array of proteins characterized by the 
surface hydrophobicity demonstrated a linear correlation in the partition coefficient with 
the surface hydrophobicity in a PEG-citrate system [206]. Thus, the partitioning behavior 
indicates a strong relation to the surface hydrophobicity of biomolecules.  
 
 
Figure 2-10. Comparison of surface hydrophobicity of protein and viruses determined by 
the elution salt concentration in hydrophobic interaction chromatography. Reprinted with 
permission from [207].  
 
There is growing evidence that viruses are relatively more hydrophobic than 
proteins. A study characterized the hydrophobicity of a range of proteins and viruses by a 
HIC framework and showed that proteins such as RNase, ovalbumin, and lysozyme 
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eluted from the hydrophobic resins at higher salt concentrations as compared to the 
bacteriophages such as ΦΧ174, PP7, and PR72 [207]. The mammalian viruses, such as 
minute virus of mice, xenotropic murine leukemia virus, reovirus, and pseudorabies 
virus, retained on the resin until much lower salt concentrations than bacteriophages, 
indicating the higher hydrophobic character of mammalian viruses (see Figure 2-10) 
[208]. Most studies have indicated that viral particles are often excluded from the 
relatively PEG-rich phase due to the steric exclusion when either PEG concentration or 
PEG MW are increased [154, 158]. However, a recent study demonstrated that high 
recoveries can be obtained with a higher PEG MW and concentration [178].  
2.4.2.2 Surface charge 
The other physicochemical characteristic of biomolecules that affect partitioning 
behavior is the surface charge. The electrostatic interaction induced by the salt-rich phase 
on a biomolecule depends on the pH of the solution. The presence of amine and carboxyl 
groups on amino acids have different pKa that are protonated or deprotonated depending 
on the solution pH. Thus, a change in solution pH changes the surface charge of the 
biomolecule. The pH at which the net surface charge nears zero is determined as the 
isoelectric point (pI) of a biomolecule. The surface becomes negatively charged if the 
solution pH is above the pI of the biomolecule and carries a positive charge if pH < pI. 
Negatively charged viruses effectively partition to the interface or PEG-rich and 
positively charged viruses partition to the salt-rich phase [178, 209]. 
 The virus purification has not been studied systematically by relating the phase 
characteristics and viral surface characteristics. The viruses are much larger particles as 
compared to proteins and their behavior cannot be easily predicted in the two-phase 
systems. Maintaining the infectivity of viruses and surface tropism during processing 
adds to the challenge and unambiguity in predicting the behavior. Thus, a more studies 
need to be conducted to understand the viral behavior in ATPS. 
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2.5 Osmolytes  
2.5.1 Osmoregulators under environmental stress 
Osmolytes are naturally occurring compounds synthesized in most of the cell 
types in response to environmental stress [210]. Osmolytes change the water structure in 
the environment that allow living creatures to regulate the osmotic pressure and water 
content in the cells to survive  [210]. Deep-sea fishes habituated in high salt 
concentration environment and hydrostatic pressure have known to produce significantly 
higher amounts of trimethyl amine-N-oxide (TMAO), a type of osmolyte [211]. 
Osmolyte production has shown to counteract the hydrostatic pressure, counterbalance 
the osmotic stress, and aid in metabolic functioning [212, 213]. On the other hand, 
osmolytes are also utilized in the drought conditions by plants [214]. Osmolyte 
accumulation has shown to regulate cell protein stabilization to maintain the functionality 
under abiotic stress [214].  
Different organisms have shown to produce different types of osmolytes in 
response to abiotic stress [215]. The osmolytes classes range from amino acids, amino 
acid derivatives, polyols, and amine-oxides [210]. However, the osmolytes are further 
characterized depending on the effect on proteins - protecting and denaturing. The 
osmoprotectants or protecting osmolytes such as proline, glycine, TMAO, and sorbitol, 
which are found in the organisms that survive under stress, enhance the protein stability 
[216]. Denaturing osmolytes such as urea and guanidinium hydrochloride destabilize the 
protein structures by unfolding [216].  
2.5.2 Osmolytes in biomanufacturing 
The protecting osmolytes are extensively used in the biomanufacturing due to 
their ability to promote protein stability [217, 218], and assist protein assembly to capsid 
[219]. The prominent use of protecting osmolytes has been shown in the formulation 
stage of biomanufacturing. The formulation of biopharmaceutical products involves a 
mixture of target biomolecule and compounds such as stabilizers for long term storage 
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and adjuvants [220, 221]. The osmolytes are used as stabilizers as they help protect 
proteins against unfolding [222]. Commonly used osmolytes as stabilizers are glycine, 
trehalose, sucrose, mannitol, and arginine [218]. In one study, glycine was shown to 
protect a recombinant protein-based vaccine against antigen modification upon long-term 
storage at 37 °C [223]. In the other study, the addition of a combination of the 
disaccharide, such as sucrose or trehalose, and glycine was shown to thermally stabilize 
the H1N1 influenza subunit vaccine upon freeze-drying for long-term storage and 
possibly eliminate the cold-storage [224]. Numerous such osmolytes have been used in 
the biopharmaceutical formulations and approved by the FDA [218].  
The protein structure stabilization mechanism by protecting osmolytes is still 
unclear. However, more studies are being performed both at macro and micro scale to 
understand the role of osmolytes in the protein structure fluctuations. A thermodynamic 
study suggests that the free energy of unfolded proteins increases in the presence of 
osmoprotectants, thus favoring the folded state [225]. A computational study 
demonstrated that osmoprotectant, glycine-betaine (commonly known as betaine) has a 
high affinity towards water molecules, thereby leading to preferential hydration of self-
molecules in a matrix of proteins, ions, osmolyte, and solvent [226]. The protein 
backbone has shown to exclude both osmolyte and water in the case of osmolytes 
(betaine, TMAO, and proline) or enrich with osmolyte and water (trehalose and 
sarcosine) [227]. Both the cases of exclusion and enrichment have shown to stabilize the 
proteins by compaction of the structure. 
The effect of osmolytes on viruses has been shown to differ from proteins. Viral 
surfaces are relatively hydrophobic when compared to proteins [207, 228]. The 
preferential hydration of mannitol and alanine resulted in the viral particle flocculation 
[229]. The viral flocculation was suggested to be due to hydrophobic interaction between 
the hydrophobic viral surface [198]. The promotion of hydrophobic interaction by 
osmolytes has also been demonstrated for a hydrophobic polymer, elastin [230]. Glycine 
and betaine partitioned away from the polymer-water interface, thereby promoting the 
hydrophobic interaction of the non-polar groups of elastin and causing the polymer to 
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collapse [230]. The difference in protein and virus behavior under the influence of 
osmolytes can be used in the DSP to upgrade the virus purification methods. 
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3.1 Introduction 
The large number of new vaccines and gene therapy vectors coming to market has 
spurred growth in viral particle manufacturing. Vaccine manufacturing growth is also 
shifting to India and China [1], providing an opportunity to redesign currently approved 
processes for traditional vaccines. Since industries have yet to achieve a platform virus 
particle process, as has been achieved with antibody manufacturing [2], new unit 
operations need to be considered for viral products that can provide virus stability, high 
yields, and increased purity. The ultimate goals are to increase throughput, reduce 
production cost, and to shift towards continuous processing. Two key attributes are 
hindering the manufacturing of viral particles, scale-up difficulties, and low yield. In the 
laboratory, ultracentrifugation produces high purity and high concentration viral stocks 
[3,4]. However, this extremely manual process is time consuming and expensive. In 
addition, co-precipitation has made sedimentation processes discouraging to be used for 
large-scale production of vaccines [5,6]. 
The current race to develop a robust, easy to scale up, environmentally friendly, 
and continuous process has led to tremendous research in various chromatography 
methods for viral particles. Commonly used chromatography modes for virus and viral 
vector processing include size exclusion [7–9], affinity [10,11] and ion exchange [12,13]. 
Although chromatography is a widely used method for purification of other 
biomolecules, low dynamic binding capacities of large biomolecules reduces the 
throughput and yield [14,15]. The purification of rhinovirus using anion-exchange 
chromatography (AEX) found that only a fraction of viral particles bound to the column, 
leading to a high purity but low recovery process [16]. It was also observed that two 
peaks of virus eluted from the column, suggesting either different sites on the virus 
binding to the column or different sites on the column binding with different strength to 
the virus [16]. Issues of yield need to be addressed prior to large scale manufacturing of 
these viral particles. A few studies have shown a continuous viral downstream process. 
77 
Most commonly, a continuous simulated moving bed (SMB) configuration is used 
[17,18]. Cell culture-derived influenza virus was purified with a three column SMB 
arrangement and a productivity of 3.8 times higher than batch mode was achieved [17]. 
However, the yield decreased from 80% in the batch mode to 70% in the SMB 
configuration and the purity decreased. A two column SMB chromatography system was 
used to purify adenovirus serotype 5 with size exclusion chromatography in a 
countercurrent configuration [18]. In this case, a higher yield was achieved in the SMB 
configuration (86%) as compared to batch mode (57%), with a 6-fold increase in the 
productivity. Although the integration of continuous chromatography is likely to reduce 
the overall cost and increase the productivity, the challenges pertaining to maintaining 
equipment robustness, sterility over long processing times, and real time process 
analytical technology (PAT) remain [19]. Due to these problems, the use of multiple 
columns still lack integration to the rest of the downstream processing units and is not 
currently used commercially [20]. Aqueous two-phase systems (ATPS) are potential 
candidates for 
virus purification to shorten the number of unit operations needed in the 
downstream processing train and provide simple integration into a continuous process. 
Unlike other purification methods, ATPS is robust, environmentally friendly, 
inexpensive, easy to scale up, and can be operated as a continuous process with short 
processing times [21]. ATPS involves mixing two aqueous solutions which produce two 
phases when present above a critical concentration. Water is the major constituent of each 
phase. Contrary to the high cost of chromatography resins and specialty membranes, the 
inexpensive raw materials used in ATPS, along with lower processing time and energy 
consumption, makes it a potential method to trim the cost of production for any 
biotherapuetic product [22]. A previous study of penicillin acylase purification compared 
ion exchange chromatography with ATPS, concluding that ATPS not only reduced the 
unit operation number from 7 to 4 but also lowered the gross production cost by 37%. 
The findings were obtained considering 100 times re-use of the resin [23]. ATPS 
provides a good alternative for integrating clarification and purification for a more 
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efficient downstream process. Many types of ATPS have been developed to partition 
biomolecules. 
Examples include polymer/polymer [24], polymer/salt [25,26], ionic liquid/salt 
[27,28], and quaternary ammonium salt/salt [29] systems. The polymer/polymer system, 
typically polyethylene glycol (PEG) and dextran, is the classic ATPS. However, high 
viscosities, the expense of dextran, and the difficulty in polymer recycling led to the 
development of salt-containing systems. Polymer/salt systems have been extensively 
studied for protein purification [30–33] and only a few studies have been reported on 
virus purification in ATPS. Some viruses and virus-like particles recovered by ATPS are 
shown in Table 3-1. Virus-like particles (VLPs) have been studied more often in ATPS 
to demonstrate a better downstream process for gene therapy vectors or subunit vaccines 
[25,26,34]. VLPs mimic the viral surface immunogenicity but are void of genomes [35]. 
Maintaining the infectivity of viruses is one of the major challenges in the downstream 
processes. This difference can be seen in the higher VLP recoveries as compared to the 
lower recoveries of infectious virus (Table 3-1). ATPS have been run in continuous 
mode for the processing of protein products [39–41]. The relatively low viscosities and 
interfacial tension make the PEG-salt systems the preferred ATPS for scale up and 
continuous operation. Various methods to contact the two phases, such as spray columns, 
perforated discs, pulsed cap columns, and conventional mixer-settlers have been 
suggested to perform continuous ATPS [39]. Mixer-settlers have successfully extracted 
monoclonal antibody (IgG1) [41] and an enzyme from spent yeast [40]. Some processing 
drawbacks such as flooding and backmixing have been identified [39]. But the problems 
are outweighed by the easy adaption of ATPS to continuous processes, as compared to 
chromatography. However, the complex partitioning mechanism of biomolecules has 
averted the integration of ATPS at an industrial scale. Numerous theories on the 
mechanism of partitioning of biomolecules in ATPS have been proposed. The two 
leading theories are that the partitioning is, 1) highly dependent on the excluded volume 
[30,42–44], or 2) a combination of hydrophobic and electrostatic interactions [38,45–47]. 
The excluded volume theory suggests that the random distribution of PEG molecules 
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results in a geometrically saturated solution, excluding biomolecules from the polymer-
rich phase due to a lack of space available for the biomolecule to occupy [48]. On the 
other hand, the hydrophobic and electrostatic interaction theory argues that the 
partitioning of the biomolecules results from the combined effect of the salting-out from 
the salt-rich phase and a hydrophobic driving force pulling the biomolecule into the more 
hydrophobic PEGrich phase [45]. Our data demonstrated that high MW PEG increased 
virus partitioning to the PEG-rich phase which supports the hydrophobic and electrostatic 
theory of partitioning [38]. The PEG and the salt composition and concentration control 
the hydrophobicity and electrostatics, respectively, in ATPS [49,50]. High MW PEG stay 
more globular in solution than lower MW PEG, which are more linear in solution 
[49,51]. Linear PEGs have more interaction with water and are better hydrated, whereas 
globular PEGs are less hydrated and therefore have more hydrophobic character. Unlike 
higher MW PEGs, lower MW PEGs have lower capabilities to provide multiple 
hydrophobic binding sites due to fewer of ethylene monomers [49]. For salts, the 
Hoffmeister series, which describes the hydration ability of different ions, has been used 
to describe the effect of different salts in ATPS [38,52]. A lower concentration of salt is 
required to form the twophase region when multivalent salts are used as compared to 
monovalent salts [50], demonstrating the importance of ionic strength in the system. 
However, there are still many questions as to the driving forces within the ATPS that 
govern partitioning. Without a more systematic characterization of the two-phase region, 
ATPS will continue to have too many unknown variables that make it too risky to use in 







Table 3-1. Overview of virus and virus-like particles in PEG/salt ATPS. 
*partition coefficient 
 
This study aimed to determine the effect of PEG and salt concentration on virus 
recovery. The model non-enveloped viruses used for this study were porcine parvovirus 
(PPV), a single stranded DNA virus with a diameter of 18–26 nm [53], and human 
rhinovirus (HRV), a single stranded RNA virus with a diameter of ~30nm [54]. Both 
viruses have icosahedral symmetry. Previous work had established that the PEG 12 kDa-
citrate system could recover PPV in the PEG-rich phase [38]. This particular study 
focused on tie line (TL) characterization and its effect on PPV and HRV recovery to 
create a stronger theory on the mechanism of partitioning for viral particles in ATPS. TLs 
are thermodynamic equilibrium points that form in the two-phase region. Along a TL, the 
system separates into phases that have the same concentration, but the volume ratio of the 
phases changes. This systematic evaluation of the two-phase ATPS space allowed us to 
understand the balance between the salting-out effect of the citrate-rich phase and the 
ability of the PEG-rich phase to pull the virus out of the interface and into the PEG-rich 
phase by hydrophobic interactions. It is difficult to recover biomolecules from the 
interface, so extracting as much virus into the PEG-rich phase was desired. There was a 
unique separation behavior observed at each tie line length (TLL). With a matrix 
containing TLL and TL ratios, we were able to recover the majority of the infectious PPV 
in a PEG 12 kDa-citrate system with high purity. By comparing the PPV recovery to the 
HRV recovery, we were able to add to the understanding of viral particle driving forces 
in ATPS. 
Target Biomolecule System Recovery Reference 
Rotavirus-like particles PEG 400/phosphate 90% [26] 
HIV-VLP PEG 1500/sulfate 4.4* [34] 
Bacteriophage M13 PEG 400/ phosphate 83% [36] 
Bacteriophage T4 PEG 8000/phosphate 38% [37] 
Porcine parvovirus PEG 12000/citrate 64% [38] 
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3.2 Materials & Methods 
3.2.1 Materials  
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate buffered 
saline (PBS, pH 7.2), penicillin-streptomycin (10,000 U/ml), and trypsin/EDTA for cell 
propagation were purchased from Life Technologies (Carlsbad, CA). Fetal bovine serum 
(FBS, Canada origin) was purchased from HyClone™ GE Healthcare (Pittsburg, PA). 2-
(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-dimethyl-1,3thiazole;bromide (MTT, 98%) was 
purchased from Alfa AesarTM (Haverhill, MA) and sodium dodecyl sulfate (SDS, 
BioReagent, ≥98.5%) was purchased from VWR (Radnor, PA). Polyethylene glycol with 
an average molecular weight of 12,000 (PEG 12 kDa), trisodium citrate dihydrate (ACS 
reagent grade, ≥99%), citric acid monohydrate (ACS reagent, ≥99%), and sodium 
phosphate dibasic heptahydrate (ACS reagent grade) were purchased from Sigma-Aldrich 
(St. Louis, MO). Sodium phosphate monobasic monohydrate (ACS reagent grade) was 
purchased from Fisher Scientific (Waltham, MA). All solutions were made with 
Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of ≥18 MΩ and 
filtered with a 0.2 μm Nalgene (Thermo Scientific) bottle top filter prior to use. 
 
3.2.2 Methods 
3.2.2.1 Cell maintenance and virus titration  
Porcine kidney cells (PK-13) and H1HeLa cells (HeLa), purchased from ATCC (CRL-
6489™ and CRL-1958™ respectively), were grown in EMEM supplemented with 1% 
penicillin/streptomycin. In addition, the PK-13 cell media was supplemented with 10% 
FBS and the HeLa cell media was supplemented with 5% FBS. The cells were incubated 
at 37 °C, 5% CO2, and 100% humidity. PPV strain NADL-2 was a generous gift from 
Dr. Ruben Carbonell (North Carolina State University, Raleigh, NC), and was propagated 
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in PK-13 cells, as described previously [55]. HRV-14 strain 1059 was purchased from 
ATCC (VR-284™) and propagated in HeLa cells. Briefly, HRV was infected at 0.001 
MTT50/cell after 24 h of HeLa incubation at 70–80% confluency. The infected HeLa 
cells were incubated at 35 °C for HRV propagation. The cell lysis was collected 5 days 
post-infection. 
The titer of PPV and HRV were found by the colorimetric MTT cell viability 
assay [56]. Briefly, 96-well plates were seeded with PK-13 or HeLa cells at a seeding 
density of 8×104 cells/well. The cells were infected 24 h post-incubation with PPV or 
HRV and serially diluted at a 1:5 ratio across the plate. PPV infected PK-13 cells were 
incubated at 37 °C and HRV infected HeLa cells were incubated at 35 °C. After six days, 
an MTT salt solution was added to each well and both cell lines were incubated at 37 °C. 
This was followed by addition of an acidic SDS solubilization solution. The absorbance 
was recorded with a Synergy Mx microplate reader (BioTek, Winoski, VT) after 4–12 h. 
The 50% infectious dose value of PPV and HRV was determined and reported in the 
units of MTT50/ml [55]. 
3.2.2.2 Construction of binodal curves and tie lines  
The binodal curve was generated using the turbidity method with appropriate 
stock PEG and citrate concentrations, as described earlier [38]. Briefly, systems were 
formed at high concentrations and diluted with water until the turbid systems turned 
clear. The tie lines were determined by conductivity measurements of the citrate-rich 
(bottom) phase using a VWR® sympHony™ conductivity meter (Radnor, PA), [50] and 
intrapolating the citrate compositions from a standard curve. The endpoints of the tie 
lines were determined by calculating the remaining amount of citrate in the PEG-rich 
(top) phase by completing a mass balance of the system. The tie lines were characterized 
by their tie line length (TLL), calculated as [57], 
𝑇𝑇𝑇𝑇𝑇𝑇 =  �∆𝑥𝑥𝑃𝑃𝑃𝑃𝑃𝑃2  +  ∆𝑥𝑥𝑐𝑐𝑐𝑐𝑠𝑠2       (3-1) 
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where ΔxPEG is the concentration difference of PEG in the top phase and bottom phase 
and Δxcit is the concentration difference of citrate in the top phase and bottom phase. TL 
ratios were calculated as 
𝑇𝑇𝑇𝑇 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑠𝑠 =  𝑠𝑠𝑙𝑙𝑙𝑙𝑙𝑙𝑠𝑠ℎ (𝑇𝑇𝑆𝑆
����)
𝑠𝑠𝑙𝑙𝑙𝑙𝑙𝑙𝑠𝑠ℎ (𝑆𝑆𝑆𝑆����)
                (3-2) 
where S is the system composition point, T is the top node, and B is the bottom node (see 
Fig. 1). The volume ratios were calculated as 
𝑉𝑉𝑉𝑉 =  
(𝑉𝑉𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑙𝑙)𝑠𝑠𝑡𝑡𝑝𝑝 𝑝𝑝ℎ𝑠𝑠𝑠𝑠𝑎𝑎
(𝑉𝑉𝑉𝑉𝑠𝑠𝑉𝑉𝑉𝑉𝑙𝑙)𝑏𝑏𝑡𝑡𝑠𝑠𝑠𝑠𝑡𝑡𝑏𝑏 𝑝𝑝ℎ𝑠𝑠𝑠𝑠𝑎𝑎
            (3-3) 
 After determining the tie lines, TLL 15, 25, and 36 w/w% were chosen for the 
study of virus partitioning. ATPSs were made with stock solutions of 30 w/w% citrate 
and solutions ranging from 33 to 45 w/w % of PEG. Appropriate amounts of stock 
solutions, water and 0.1 g of crude PPV were added to a microcentrifuge tube to 
complete a 1 g system. All systems were mixed with a vortex mixer and the phase 
separation was carried out in an ST16R Centrifuge (Thermo Scientific, Pittsburg, PA) at 
~12,300 xg at 21 °C for 5 min. The recovery of PPV was calculated as 
%𝑉𝑉𝑠𝑠𝑅𝑅𝑠𝑠𝑅𝑅𝑠𝑠𝑟𝑟𝑅𝑅 =  𝑉𝑉𝑃𝑃/𝐶𝐶∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖∗𝑇𝑇𝑖𝑖
∗ 100               (3-4) 
where V is the volume of the PEG-rich phase (P), the citrate-rich phase (C) or the initial 
stock (i) and T is the titer of one phase expressed as MTT50/ml [38]. The partitioning 
coefficient was calculated as 
𝐾𝐾 =  𝑉𝑉𝑃𝑃∗𝑇𝑇𝑃𝑃
𝑉𝑉𝐶𝐶∗𝑇𝑇𝐶𝐶
               (3-5) 
3.2.2.3 Physical Properties of Systems  
The refractive index of the extracted PEG-rich phases was measured with a 
Digital Brix/RI-Chek refractometer (Reichert Technologies, Depew, NY), with an 
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accuracy of±0.0002. Densities of the PEG-rich and citrate-rich phases were measured by 
weighing 1 ml of the phase using a calibrated pipette on a Mettler-Toledo analytical 
balance (Columbus, OH), with a readability up to 0.1 mg. 
3.2.2.4 SDS-PAGE  
The partitioning of the contaminant proteins in the crude lysate was measured 
using sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 4–
12% Bis-Tris NuPage gel and NuPage MOPS running buffer (Life Technologies, 
Carlsbad, CA). Benchmark™ protein ladder with a molecular weight range of 10–220 
kDa (Life Technologies) was used as the marker. Samples were reduced using 
βmercaptoethanol (Sigma-Aldrich, St. Louis, MO) at 7% concentration, and heated to 70 
°C for 10 min prior to loading onto the gel. The SDSPAGE was run for 55 min at a 
constant 200 V. The gel was loaded at a constant volume so that concentrations of 
contaminating proteins could be compared. The gel was stained with the SilverXpress™ 
staining kit (Life Technologies, Carlsbad, CA). 
3.2.2.5 DNA quantification  
DNA content in the PEG-rich phase and citrate-rich phase was measured using 
the Quant-iT™ PicoGreen® dsDNA kit (ThermoFisher Scientific, Waltham, MA). The 
PEG-rich phase and citrate-rich phase were diluted in water to have a final concentration 
of PEG and citrate as ≤1 w/w%. The host cell DNA in the crude lysate, PEG-rich and 
citraterich phase was measured, as per manufacturer's instruction. The fluorescent 
activities (excitation: 480 nm and emission: 520 nm) of the samples were measured using 
a Synergy™ Mx microplate reader. DNA recovery was calculated similar to virus 
recovery as: 
%𝐷𝐷𝐷𝐷𝐷𝐷 𝑟𝑟𝑠𝑠𝑅𝑅𝑠𝑠𝑅𝑅𝑠𝑠𝑟𝑟𝑅𝑅 =  𝐷𝐷𝐷𝐷𝐴𝐴 𝑐𝑐𝑉𝑉𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑉𝑉𝑙𝑙𝑃𝑃/𝐶𝐶∗𝑉𝑉𝑃𝑃/𝐶𝐶∗ 𝐷𝐷𝐷𝐷
𝐷𝐷𝐷𝐷𝐴𝐴 𝑐𝑐𝑉𝑉𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑉𝑉𝑙𝑙𝑖𝑖∗𝑉𝑉𝑖𝑖∗ 𝐷𝐷𝐷𝐷
∗ 100    (3-6) 
85 
where V denotes volume of the PEG-rich phase (P), citrate-rich phase (C) or initial stock 
(i) and DF denotes the respective dilution factor. 
3.2.2.6 Dynamic Light Scattering (DLS)  
Virus aggregates at varying concentrations of citrate were measured by DLS with a 
Malvern Zetasizer Nano ZS (Westborough, MA). First, virus was dialyzed in Biotech 
cellulose ester 1000 kDa dialysis tubing (Rancho Dominguez, CA) at 4 °C for two days 
with two buffer exchanges of 20mM phosphate buffer at pH 7.0 (PB). Then, the dialyzed 
virus was further purified in an Econo-Pac 10DG desalting column (Hercules, CA). The 
fraction containing the highest titer was used to mix with sodium citrate solution at pH 7 
to give different final concentrations of citrate. The hydrodynamic diameter was 
measured and the aggregate ratio (AR) was calculated as: 
𝐷𝐷𝑉𝑉 =  𝐷𝐷𝐻𝐻,18−26 𝑛𝑛𝑏𝑏
𝐷𝐷𝐻𝐻,18−26 𝑛𝑛𝑏𝑏
           (3-7) 
where DH,18-26nm is the maximum intensity of the peak at 18–26 nm (the virus 
intensity) and DH,>100nm is the maximum intensity of the aggregate peak, which 
was>100 nm and became larger as the concentration of citrate increased. 
 
3.3 Results 
3.3.1 Model Virus 
Porcine parvovirus (PPV) and human rhinovirus (HRV) were chosen as the model 
non-enveloped viruses to study the partitioning in ATPS and key properties are shown in 
Table 3-2. PPV is a ssDNA virus that is approximately 18–26 nm in diameter [53]. PPV 
is a pathogenic agent that causes reproductive failure in swine populations [58,59], and is 
a model for the human B19 parvovirus. The capsid of PPV is composed of three proteins, 
VP1, VP2, and VP3. VP2 is the major constituent (~80%) of the capsid [60]. Recently, a 
86 
comparative study using computational and experimental methods showed that PPV [61] 
and a closely related murine parvovirus, MVM [62], are more hydrophobic than a panel 
of proteins. This significant difference in the surface hydrophobicity of PPV and 
contaminant proteins is an ideal driving force to develop new purification methods for 
viral particles. HRV is a ssRNA virus that is ~30nm in diameter, composed of VP1, VP2, 
VP3, and VP4 capsid proteins [64,66]. VP1, VP2, and VP3 are surface exposed antigenic 
proteins, whereas VP4 is present in the inside of the capsid and assists in anchoring the 
RNA inside the capsid [64]. HRV is one of the agents causing common cold and 
exacerbations of asthma in humans, with three main species, namely A, B, and C, 
and>100 serotypes identified [67–71]. Despite extensive research, there is no effective 
antiviral drug treatment for HRV infections [72]. This virus was used to show the effect 
of surface hydrophobicity at net neutral surface charge on virus partitioning in ATPS. 
 
Table 3-2.A brief description and comparison of the model viruses (PPV and HRV) 
Model 





PPV ssDNA parvoviridae B19, AAV 5.0 18-26 [60, 63] 
HRV (+)ssRNA picornaviridae FMDV, Polio, Hep A 6.9 ~30 [64-66] 
PPV: porcine parvovirus; HRV: human rhinovirus; B19: B19 parvovirus; AAV: adeno 
associated virus; FMDV: foot & mouth disease virus; Polio: poliovirus; Hep A:  hepatitis 
A virus  
 
3.3.2 Binodal curves & tie lines 
The ATPS binodal phase diagram separates the homogeneous region from the 
two-phase region, as shown in Figure 3-1A. Tie lines were generated to study systems 
containing the same concentrations of each component in the PEG-rich and citrate-rich 
phases. Tie lines are thermodynamic equilibrium states in the two-phase region, 
representing a unique value of Gibb's free energy [57,73]. An increase in the TLL (Eq. 
(3-1)) increases the Gibb's free energy, which correlates to the thermodynamic driving 
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force [73] and results in higher PEG and salt concentrations in each phase. Additionally, 
an increase in TLL also provides elevated hydrophobic interaction from the PEG-rich 
phase and effective salting-out of proteins from the salt-rich phase [74]. Increasing the 
TLL is hypothesized to provide a larger hydrophobic driving force for the partitioning of 
PPV and HRV into the PEG-rich phase. Each system composition is represented by a TL 
ratio (Eq. (3-2)). The TL ratio is the ratio of a length of the segment from the system 
point to the top node divided by the length of the segment from the system point to the 
bottom node of that tie line [57]. The phase volumes change as the TL ratio changes, as 
shown in Figure 3-1A.  
 
 
Figure 3-1. Binodal curve and tie lines. (A) Schematic illustration of ATPS showing 
binodal curve separating one-phase region from the two-phase region and set of systems 
characterized by tie lines and TL ratios. (B) Experimentally determined binodal curve 
and tie lines for PEG 12kDa-citrate ATPS at pH 7. 
 
Earlier studies have shown that a PEG 12 kDa-citrate system was able to separate 
and recover 64% of infectious PPV [38]. This is a higher MW of PEG than typically 
studied in PEG-salt ATPS. Although higher MW causes an increase in viscosity and 
interfacial tension [75,76], it also elevates the hydrophobic driving force in the PEG-rich 
phase, which increased the virus recovery [38]. Hence, it was decided to study the PPV 
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purification at varying TLL in the PEG 12 kDa-citrate system to better understand the 
effect of PEG and citrate concentration on virus recovery.  
 
Table 3-3. Comparison of TL ratio (Eq. 3-2) and volume ratio (Eq. 3-3) 
System Composition 
TLL  
(w/w%) TL ratio 
Volume 








15.0 14.0 1.2 0.9 




10.3 13.2 1.0 0.5 




7.4 11.8 1.0 0.4 
4.6 13.6 2.3 0.3 
 
Several groups have generated binodal curves for polymer/salt systems [38,77–
80]. The phase diagram was experimentally determined for the PEG 12 kDa-citrate 
system and can be seen in Figure 3-1B. Refractive index and density were also used to 
confirm the tie lines (see Tables A.1-1 and A.1-2). The densities of the PEG-rich phases 
of systems did not differ much with an increasing TLL. On the other hand, the densities 
of the citrate-rich phases showed a significant increase with the TLL. Refractive index of 
the PEG-rich phases increased linearly with TLL. The binodal curve generated was 
similar to previous work [38] and the tie lines determined were parallel, as expected, and 
are also shown in Figure 3-1B. The tie lines had an average slope of −1.6 ± 0.2. The PEG 
concentrations in the PEG-rich phase was measured by generating a standard curve 
(Table A.1-3). The measured PEG concentrations showed a slight deviation from the 
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previously determined tie lines using conductivity method. However, the standard curve 
was generated without adding citrate salt, which is present when two-phase systems are 
formed. Any system composition on a given tie line separates into the same respective 
PEG and salt compositions [57], only the volume ratio changes of each system. The TL 
ratios were indirectly proportional to the volume ratios (Eq. (3-3)), as shown in Table 3-3 
thus suggesting an increase in the TL ratio will decrease the volume ratio. 
 
3.3.3 Effect of tie lines & tie line ratios 
Three TLLs and at least three TL ratios were chosen to study the recovery of PPV 
and HRV with respect to phase composition and phase volume. The system matrix also 
explored the effect of phase composition changes on the partitioning behavior of 
contaminants, in particular, host-cell proteins and DNA.  
The shortest TLL studied was 15 w/w%. TLL 15 w/w% contained the lowest 
concentration of PEG and citrate of those tested. The lower compositions have relatively 
low hydrophobic interaction from the PEG-rich phase and low salting-out effect from the 
citrate-rich phase. It was observed that PPV highly partitioned to the citrate-rich phase 
and very little PPV was recovered in the PEG-rich phase, as shown in Figure 3-2A & B. 
Recoveries in the citrate-rich phase started at 100% at TL ratio 0.1 and decreased to 20% 
at TL ratio 2.3. Irrespective of the TL ratio, the contaminant proteins partitioned to the 
citrate-rich phase, as shown in Figure 3-2C. The PPV concentration is too low to be seen 
on an SDS-PAGE. Since there was not enough preferential partitioning of the PPV 
particles to the PEG-rich phase, the lower TLL is not suitable for the purification of PPV.  
To increase the driving forces (i.e. salting-out of the citrate and hydrophobic 
interaction of the PEG) and obtain higher recovery of the viral particles in the PEG-rich 
phase, systems on TLL 25 w/w% were studied. As shown in Figure 3-2D, the PPV 
recovery in the PEG-rich phase increased almost linearly with the TL ratio. A maximum 
of 52% PPV was recovered in the PEG-rich phase at TL ratio 2.3. This corresponded to a 
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decrease in recovery in the citrate-rich phase as the TL ratio increased (Figure 3-2E). 
However, the recoveries in the citrate-rich phase remained low at<30%. The remainder of 
the viral particles are likely aggregated at the interface or have been rendered 
noninfectious by the system and are not recoverable, as stated previously [38]. It is most 
likely that the virus has been trapped at the interface, since we do obtain high recoveries 
at TLLs with both increased and decreased concentrations of PEG and citrate. 
Most of the contaminant proteins partitioned to the citrate-rich phase, as shown in 
Figure 3-2F. One contaminant protein partitioned along with PPV in the PEG-rich phase 
for TLL 25 w/w%, as seen by the band between 50 and 60 kDa. The decreasing band 
intensity with an increase in the TL ratio was observed in the citrate-rich phase, the cause 
of which might be the decreasing concentration of the proteins with an increasing volume 
of the citrate-rich phase, i.e. the citrate is diluting the protein. TLL 25 w/w% provided a 
better driving force for the preferential partitioning of PPV to the PEG-rich phase than 




Figure 3-2. PPV recovery in the PEG-rich phase (A, D, and G) and the citrate-rich phase 
(B, E, and H) at different TLL. SDS-PAGE of marker (M), starting PPV (S) and the 
PEG-rich phase (P) and the citrate-rich phase (C) at different TLL and TL ratios. The 
starting titer was log10 6.5 MTT50/ml. Experiments were done in triplicates and the error 
bars represent the standard deviation.  
 
 
Similar studies were performed with HRV to determine the effect of viral surface 
charge on the partitioning and recovery of the virus. The recovery of HRV in the PEG-
rich phase on TLL 15 w/w% remained low, almost 0% (Figure 3-3A). This low recovery 
was similar to PPV for TLL 15 w/w%. At the increased TLL of 25 w/w%, the HRV 
recovery increased to between 11 and 21%, depending on the TL ratio. Furthermore, TLL 
36 w/w% provided an even stronger driving force where the recovery of HRV increased 
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to 36% at TL ratio 0.3 (Figure 3-3A). The recovery of the HRV in the PEG-rich phase 
showed an opposite trend on TLL 25 w/w% and 36 w/w%. This trend was similar to the 
PPV behavior at the same TLLs, as shown in Figure 3-2D & G. Also, the HRV titers 
were almost identical to the PPV titers in the PEG-rich phase for all the systems studied 
(Table A.1-4) suggesting that the highly hydrated citrate ions dehydrate the HRV surface 




Figure 3-3. HRV recovery in the PEG-rich phase (A) and the citrate-rich phase (B) at 
different TLL. SDS-PAGE of marker (M), starting HRV (S), PEG-rich phase (P) and the 
citrate-rich phase (C) at TLL 15, 25, and 36w/w%. %. The starting titer was log10 6.5 
MTT50/ml. Experiments were done in triplicates, and the error bars represent the standard 
deviation. 
 
The citrate-rich phase titers were strongly affected by the presence of citrate in the 
samples. This is clearly seen in the citrate-rich phase recoveries, where the recoveries at 
TLL 15 w/w% and 25 w/w% were>150% at TL ratios>1. These high titers, which then 
resulted in high recoveries in the citrate-rich phase, were likely due to the interaction of 
the cells with the citrate. Some groups have shown that citrate reduces cell viability [82] 
and is cytotoxic to cancer cells [83] at certain concentrations. Reduction of the cell 
viability increases the titer in the MTT assay as the virus quantification is based on the 
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cell viability. An increase in the titer increases the recovery. The mass balance of viral 
particles held true only at TLL 36 w/w% with a total mass balance ranging between 77 
and 102%. Overall, the HRV recovery followed the same trends as PPV. At low TLL, the 
virus remained in the citrate-rich phase and transitioned to the PEG-rich phase at the 
highest TLL studied. 
Similar to PPV, the contaminant proteins present in the HRV solution were found 
mainly in the citrate rich phase (Figure 3-3C). The bands of the PEG-rich phase and 
citrate-rich phase corresponding to all the systems studied were identical. Hence, only 
one representative gel comprising of TLL 15, 25, and 36 w/w% at TL ratio 1.2 is shown 
(Figure 3-3C). The purity of the PEG-rich phase was similar to PPV. HRV partitioning 
demonstrated a high purity but low recovery as compared to the high purity and high 
recovery found with PPV. 
3.3.4 Effect of increased PPV load 
To understand the effect of loading, the initial PPV load was increased from 6.5 
log10(MTT50/ml), used in Figure 3-2, to 8 log10(MTT50/ ml). The loading effect was only 
performed with PPV as the highest titer of the HRV stock achieved was only 7 log10 
MTT50/ml. The PPV partitioning coefficient, K (Eq. (5)), on all three TLLs showed 
similar trends for both loadings, as shown in Figure 3-4A & B. TLL 15 and 25 w/w% 
showed increasing K values with respect to an increasing TL ratio and exhibited 
decreasing K values for TLL 36 w/w%. It was noted that the partitioning coefficient 
values are similar or lower for the higher load on all the TLLs. However, the virus titer 
increased in the PEG-rich phase by increasing the initial load for all the systems studied 
(Table A.1-5). But a respective increase of virus titer in the citrate-rich phase suggested 
that a considerable number of viral particles still remained in the citrate-rich phase. This 
suggests that all the systems with an initial PPV load of 8 log10(MTT50/ml) have higher 
ability than systems with an initial PPV load of 6.5 log10(MTT50/ml) to drive viral 
particles in the PEG-rich phase, but the distribution of the viral particles is maintained to 
balance the free energy between the two-phases. In the previous studies, the free energy 
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has been correlated to the partition coefficient suggesting that for a given system 
composition the partition coefficient should remain the same [31,84]. 
 
 
Figure 3-4. Comparison of PPV partitioning at two different loads along (A) TLL 15 
w/w%, (B) TLL 25 w/w%, and (C) TLL 36 w/w%. Experiments were repeated in 





This study examined the partitioning of PPV and HRV in an ATPS of PEG 12 
kDa-citrate. The goal was to determine the influential driving forces in ATPS partitioning 
at pH 7. There are two main theories that explain the partitioning of biomolecules in 
ATPS, 1) the excluded volume effect [30,42–44] and 2) hydrophobic and electrostatic 
interactions [45–47,74]. A previous study conducted for PPV ATPS partitioning using 
various molecular weights of PEG, salt types and pHs supported the concept of viral 
surface and phase hydrophobicity as the main driving forces [38]. This work supports two 
main conclusions, 1) increasing the PEG and citrate concentration, and therefore 
increasing the phase hydrophobicity and salting-out effect, increases the PPV and HRV 
recovery in the PEG-rich phase at a constant pH and 2) the influence of the electrostatic 
interaction is vital in achieving the high recovery of viruses in the PEG-rich phase. 
Therefore, the data supports that in a PEG 12 kDa-citrate system, electrostatics and 
hydrophobic interactions are the dominant forces. 
The current theory for the partitioning of virus in ATPS involve the electrostatic 
interaction of the virus with the salt-rich phase and the hydrophobic interaction of the 
virus with the water-reduced PEG-rich phase. The first interaction appears to be the 
salting-out of the virus from the citrate-rich phase. This is due to the charge repulsion of 
the citrate with the virus. PPV is negatively charged at pH 7, and when the salt 
concentration is raised from TLL 15 w/w% to TLL 25 w/w%, all of the PPV is salted-out 
of the salt-rich phase and is likely at the interface. When the PEG-rich phase 
concentration is increased to TLL 36 w/w%, there is enough hydrophobic interaction 
driving force from the PEGrich phase to extract the virus from the interface and have it 
recovered in the PEG-rich phase. This is illustrated by the recovery map shown in Figure 
3-5. This theory is also supported by the data from HRV. HRV is neutrally charged at pH 
7, and therefore does not experience the same amount of charge repulsion from the 
citrate-rich phase. Since the virus is not driven to the interface, it is not extracted from the 
interface by the PEG-rich phase. Therefore, our current hypothesis is that first the virus 
must be salted-out by charge repulsion from the salt-rich phase to the interface. Then the 
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PEG-rich phase needs to be strong enough to extract the virus from the interface into the 
PEG-rich phase. The experiments described here never reached a citrate concentration 
that salted-out the contaminating proteins so that they could be extracted into the PEG-
rich phase. This is preferred because it provides a difference in driving force needed to 
purify the viral particles. 
 
 
Figure 3-5. Schematic PPV recovery map in the two-phase region for (A) PEG-rich 
phase and (B) citrate-rich phase. 
 
The salting-out phenomena is the interaction of salt ions (electrolyte), 
biomolecules (non-electrolyte) and solvent. At lower salt concentrations, the salt ions 
interact with the biomolecules by forming a layer of counter ions around the charged 
biomolecule. The counter ion layer increases the water structure stability and decreases 
the free energy, therefore promoting biomolecule solubility. An increase in the salt 
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concentration, above a critical concentration, causes a high repulsion force to develop 
from the development of an electronic double layer and the close proximity of liked 
charged ions near the surface of the biomolecule [85]. This high repulsion force increases 
the free energy of the biomolecule surface, thereby making the surface 
thermodynamically unstable [86]. 
To test the effect of citrate concentration on the aggregation of PPV, DLS was 
measured for PPV in different citrate concentrations. Due to aggregates that were present 
in the starting material, an aggregation ratio was used to compare the intensity of the PPV 
peak and the aggregate peak. The full calculation is described in Eq. (3-7). PPV particles 
started to aggregate at 15 w/w% citrate, with extensive aggregation occurring at 20 w/w% 
and above (Figure A.1-1). 20 w/w% citrate and above are close to the citrate-rich phase 
compositions of the TLLs, 25 and 36 w/w%, studied (see Figure A.1-1). These results 
support the hypothesis that PPV is salted-out at high citrate concentration. Without the 
PEG-rich phase present (i.e. citrate only, as was conducted in the DLS experiments), PPV 
aggregated. In the presence of the PEG-rich phase, the PPV particles can reduce their free 
energy by migrating to the PEG-rich phase. Aggregation was not measured for HRV due 
to the low HRV titer available which was not detectable by DLS measurements. 
The proposed theory of hydrophobicity as the main driving force in ATPS was 
based on recent studies that have shown viral particles to be relatively more hydrophobic 
than proteins [61,87]. The PPV surface was shown to be more hydrophobic than the 
model proteins BSA, lysozyme, bovine fibrinogen, and human IgG by studying reverse 
phase chromatography and ANS fluorescence, and the results were compared with 
computationally determined solvent exposed surface area [61]. Another team performed 
hydrophobic interaction chromatography (HIC) studies on a variety of enveloped and 
non-enveloped mammalian viruses and protein models, where viruses eluted at lower 
citrate concentrations as compared to the model proteins, suggesting the relatively 
hydrophobic nature of the viruses studied [87]. One of the viruses studied was MVM. 
MVM and PPV are both parvoviruses, therefore complementing the idea that PPV is 
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hydrophobic. Similarly, the ATPS described here was designed to utilize the hydrophobic 
property of PPV to induce preferential partitioning of the virions to the PEG-rich phase. 
A few studies have been reported to measure the hydrophobicity or predict the 
partitioning behavior based on hydrophobicity of proteins [45], or peptides [47] in ATPS. 
The hydrophobic interaction in ATPS is driven by the PEG molecular weight and 
concentration. This growing evidence of the hydrophobic interaction as a vital driving 
force in ATPS could be reasoned by the molecular composition of PEG. The increase in 
the PEG molecular weight and/or concentration increases the number of ethyl groups in 
the polymer chain. Ethyl groups are hydrophobic and optimum number of monomers 
provide the necessary hydrophobic interaction binding sites to attract proteins or viruses 
[49]. The minimization of free energy increase of the biomolecules, from the salting-out 
effect, is compensated by the availability of the free energy provided by the amount of –
CH2-CH2– groups in the PEG-rich phase. The high recoveries of virus in PEG-citrate 
ATPS is possible by the right balance of salting-out and hydrophobic interaction. 
3.5 Conclusion 
This study reported the recoveries of PPV and HRV in a PEG 12 kDa-citrate 
system at pH 7. The PPV and HRV titers in the PEG-rich phase increased with an 
increase in TLL. Most of the viral particles were recovered in the citrate-rich phase at 
TLL 15 w/w%, the lowest TLL studied. The PPV and HRV recovery in the PEG-rich 
phase increased at TLL 25 w/w%. Across this tie line, the PPV and HRV recovery 
increased in the PEG-rich phase as the TL ratio increased. TLL 36 w/w% showed the 
opposite trend; the recovery decreased as the TL ratio increased. The highest PPV 
recovery of 79% and HRV recovery of 36% was found on TLL 36 w/w% and the lowest 
TL ratio studied. An increase in the PPV titer yielded higher titers in the PEG-rich phase. 
Overall, this work supported the hypothesis that the main driving forces in viral particle 
ATPS are the salting-out from the citrate-rich phase followed by the hydrophobic 
interaction of the PEG-rich phase. Therefore, a higher TLL, leading to higher 
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concentrations of salt and PEG, is needed for a high virus recovery in the PEG-rich 
phase. 
The framework in this study achieves high virus recovery in a PEG-citrate system 
using known surface properties of the virus. The model viruses used, demonstrated a 
need to understand the virus properties to improve virus recovery. By systematically 
studying the partitioning and recovery of negatively charged PPV and neutral HRV 
across tie lines, it was determined that the surface hydrophobicity and the charge at a 
given pH of the virus were key in the selective partitioning of the virus to the more 
hydrophobic PEG-rich phase. By combining the study of virus particle surfaces and the 
experimental ATPS design space, future correlations can be determined that will reduce 
the number of ATPS experiments needed to find an optimal system. 
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4.1 Introduction 
Downstream purification of viral vaccines needs to address the challenges of 
yield, purity, scale-up, and robust processing. In addition, continuous processing is also a 
future target. To accomplish these goals, we are studying the use of aqueous two-phase 
systems (ATPSs) to purify viral particles. The biphasic systems are formed by mixing 
two aqueous solutions above certain critical compositions with different phase-forming 
components. Typical phase-forming components are polymer-polymer and polymer-salt, 
due to their superior biocompatibility and mild, water-based environment. ATPSs have 
been mostly studied for therapeutic proteins [1-3] and plasmid DNA [4, 5] purification in 
the biotherapeutic area over the decades, with a limited focus on viruses. Viral 
purification using ATPS has only recently gained attention, as the onset of new vaccines 
and gene therapy modalities create a need to increase capacity and throughput for viral 
processing methods. However, this technique still requires extensive study to understand 
viral behavior in these types of biphasic systems. Traditionally, viral partitioning has 
been studied in a polyethylene glycol (PEG)-dextran system [6-8] and more recent 
studies have focused on PEG-salt systems [9-12]. This study explores a PEG-salt system 
and ways to enhance virus partitioning to the PEG-rich phase and contaminant retention 
in the salt-rich phase by addition of a third component.   
Numerous studies have tried to understand the characteristics of ATPSs that lead 
to biomolecule partitioning. A comprehensive review suggests that the partitioning of 
biomolecules is synergistically influenced by the excluded volume theory, electrostatic 
interaction, and hydrophobic interaction [13]. However, recent reports have demonstrated 
critical contributions from the electrostatic and hydrophobic interactions in a PEG-salt 
system for virus purification [12, 14], with a contradictory contribution of the excluded 
volume theory. The virus prefers the PEG-rich phase once it is salted out of the salt-rich 
phase. This is accomplished by employing a stronger kosmotropic salt, such as citrate, for 
salting out, and a higher molecular weight PEG to provide hydrophobic interaction. One 
could also operate the ATPS at higher system compositions, which will create a higher 
ionic strength of the salt-rich phase and an increase in relative hydrophobicity of the 
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PEG-rich phase, thus promoting virus separation [12]. However, the hydrophobic 
interactions are relatively weak in a PEG-salt system as compared to a conventional 
hydrophobic interaction chromatography using phenyl-based resins. Due to this, a higher 
ionic strength might be detrimental to the virus structure and functional stability. On the 
other hand, higher compositions of the PEG-rich phase, needed to achieve high 
recoveries, generate a viscous solution which pose a processing challenge. Moreover, 
with an increasing array of viruses used in biotherapeutics that have a wide variety of 
surface characteristics and stability, there is a need to look for driving force enhancers 
that will preferentially increase the virus partitioning at milder system compositions.     
Osmolytes are a class of molecules that occur naturally and are used by cells to 
compensate for changes in osmotic stress [15, 16]. Osmolytes have been divided into two 
groups based on the nature of their interaction with the protein backbone; 1) 
osmoprotectants or protecting osmolytes and 2) denaturing osmolytes. Osmoprotectants, 
such as betaine and trimethylamine N-oxide (TMAO), help in stabilizing protein 
structures [17]. Denaturing osmolytes, such as urea and guanidinium chloride, have been 
shown to unfold and destabilize protein structures [18, 19]. Numerous applications of 
osmoprotectants have been reported in the life sciences and biomanufacturing. Osmolytes 
function as water structure modulators, either to maintain osmotic balance [20, 21] or 
induce intramolecular or intermolecular interactions that stabilize proteins during osmotic 
stress [22]. Osmoprotectants have been utilized to induce intramolecular interactions to 
stabilize biologics in the formulation of biomolecules [23, 24]. Conversely, osmolytes 
have been shown to induce intermolecular interactions to flocculate viruses [25], which 
aided in the development of filtration-based method for virus purification. The exact 
mechanism of osmolyte function in protein stabilization or viral flocculation, however, is 
not clearly understood.  
A few studies have used osmolytes as additives in ATPS. However, most of them 
have reported the effects in polymer-polymer systems on small organic molecules or 
protein partitioning (Ferreira, Fan [26], [27, 28]). This study explores the effect of 
osmolytes on two virus models in a PEG 12kDa-citrate system. Our previous study 
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showed that negatively charged non-enveloped viral particles partition to the PEG-rich 
phase only at higher system compositions [14]. It was hypothesized that a high salt 
concentration was needed to salt-out the virus to the interface. Then a high PEG 
concentration was needed to draw the virus out of the interface and into the more 
hydrophobic PEG-phase. To decrease the concentration of salt and PEG needed in the 
system, we added osmolytes and explored the partitioning of two viruses. The use of 
additives demonstrated preferential enhancement of partitioning at lower system 
compositions. This was likely by improving the hydrophobic interaction of virus and 
VLP with the PEG-rich phase.  Moreover, the efficiency of osmolyte type to improve 
virus recover in the hydrophobic PEG-rich phase has led to theories on the mechanism of 
osmolyte action. Understanding the mechanism driving partitioning has direct correlation 
not only in the viral purification, but also in understanding the differential action of 
osmolyte towards biomolecules. 
4.2 Materials and Methods 
4.2.1 Materials  
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate 
buffered saline (PBS, pH 7.2), penicillin-streptomycin (pen-strep) (10,000 U/ml), fetal 
bovine serum (FBS, USDA approved) and trypsin/EDTA for cell propagation were 
purchased from Life Technologies (Carlsbad, CA). 2-(3,5-diphenyltetrazol-2-ium-2-yl)-
4,5-dimethyl-1,3thiazole;bromide (MTT, 98%) was purchased from Alfa AesarTM 
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased 
from Sigma Aldrich (Radnor, PA). Polyethylene glycol with an average molecular weight 
of 12,000 Da (PEG 12 kDa), trisodium citrate dihydrate (ACS reagent grade, ≥99%), 
citric acid monohydrate (ACS reagent, ≥99%) were a generous gift from MilliporeSigma 
(Burlington, MA). Osmolytes glycine (BioUltra, ≥99.0%), betaine (BioUltra, ≥99.0%), 
trimethylamine N-oxide (TMAO) dihydrate, D-mannitol, and urea were purchased from 
Sigma-Aldrich (St. Louis, MO). Stable isotopes glycine (1-13C, 99%), betaine (D-11, 
98%), TMAO (D9, 98%), and D-mannitol (U-13C6, 99%) were purchased from 
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Cambridge Isotope Laboratory (Tewksbury, MA). All solutions were made with 
Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of ≥18 MΩ and 
filtered with a 0.2 μm Nalgene (Thermo Scientific) bottle top filter or 0.22 µm cellulose 
acetate syringe filters (VWR, Radnor, PA) prior to use. 
HIV-VLP crude stock was a generous gift from Esperovax (Plymouth, MI). HIV-
VLP with genetically infused green fluorescent protein (GFP) were expressed in 
Saccharomyces cerevisiae with a proprietary method. 
4.2.2 Methods 
4.2.2.1 Cell maintenance, virus propagation and virus titration 
 Porcine kidney cells (PK-13, CRL-6489TM) purchased from ATCC were cultured 
in EMEM pH 7.1 supplemented with 10 v/v% FBS and 1 v/v% pen-strep. The cell 
cultures were grown by incubating at 37°C, 5% CO2, and 100% humidity. Porcine 
parvovirus (PPV) strain NADL-2, gifted by Dr. Ruben Carbonell (North Carolina State 
University, Raleigh, NC), was propagated in PK-13 cells as described previously [29]. 
PPV titration was performed by a colorimetric cell viability assay using MTT salt as 
described previously [14]. 
4.2.2.2 Generation of binodal curve and tie lines 
  Binodal curves were generated using the turbidity method [12] with 50 w/w% 
PEG and 35 w/w% citrate, and 0.5 M osmolyte stocks. Titration was done using 0.5 M 
osmolyte solutions to maintain the osmolyte concentration in the systems until the 
systems turned clear.  
The tie lines were determined using the conductivity measurements of the citrate-
rich phases as described previously [14]. The conductivity contribution of osmolytes was 
measured and determined to be negligible as compared to the conductivity of citrate. The 
osmolyte concentration was disregarded in the calculation of the citrate concentrations in 
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the citrate-rich phase. The tie line length (TLL) and tie line ratios (TLR) were calculated 
as mentioned previously [14]. 
4.2.2.3 Osmolyte detection and quantification 
 Osmolyte in the citrate-rich phases were quantified using LC-MS. A Thermo 
ScientificTM UltiMateTM 3000 HPLC (Thermo Fisher Scientific, Waltham, MA) was 
coupled with an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific) with an 
electrospray ionization capability. Separate LC-MS/MS methods were developed for 
detection and quantification of glycine, betaine, TMAO, and urea. For each method, a 
corresponding isotope was added to all the calibration solutions and samples at the same 
concentration as the internal standard were used to compensate for instrument 
fluctuations. The analytical column used was an Ascentis Express HILIC 15 cm x 2.1 
mm, 2.7 micron (Sigma Aldrich). Eluent A was acetonitrile (HPLC grade, Fisher 
Scientific) and eluent B was 0.1 v/v% formic acid (98-100%, Sigma Aldrich) in HPLC 
grade H2O (Fisher Scientific). The LC-MS/MS conditions used for each osmolyte are 
listed in the Table A.2-1 in the appendix. For quantifications, standard curves were 
generated by with the measuring the elution curve area of osmolyte and corresponding 
internal standard at different concentrations detected by the mass spectrometry. For mass 
spectrometry, selected ion monitoring (SIM) of the parent ion [M+H]+, or the selected 
reaction monitoring (SRM) of the suitable fragmentation ion were used. For SRM, the 
transitions used for parent ion and fragment ion used for each osmolyte are reported in 
the Table A.2-1.  
4.2.2.4 Virus and virus-like particle partitioning 
Two phase systems were prepared with 50 w/w% PEG and 35 w/w% citrate. 
Appropriate stock concentration of each osmolyte was used to maintain a concentration 
of 0.5 M in the total system. Appropriate amounts of stocks with 0.1 g crude virus were 
added to a microcentrifuge tube to total 1g systems. The rest of the procedure was similar 
to our study reported earlier [14]. The virus and VLP recoveries and partition coefficient 
(K) were calculated using equations 4-1 and 4-2, respectively. 
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% 𝑉𝑉𝑠𝑠𝑅𝑅𝑠𝑠𝑅𝑅𝑠𝑠𝑟𝑟𝑅𝑅 = 𝑉𝑉𝑃𝑃/𝐶𝐶∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖∗𝑇𝑇𝑖𝑖
∗ 100                                                  (4-1) 
𝐾𝐾 = 𝑉𝑉𝑃𝑃∗𝑇𝑇𝑃𝑃
𝑉𝑉𝐶𝐶∗𝑇𝑇𝐶𝐶
                                                                    (4-2) 
 where V refers to the volume of either PEG-rich phase (P), citrate-rich phase (C), or 
initial stock (i) and T refers to the titer of the virus or virus-like particle in either phases 
or initial stock. PPV titer was expressed as MTT50/mL. HIV-VLP titers were expressed as 
relative fluorescent unit (RFU)/0.1 mL, as measured with a Synergy Mx microplate 
reader (BioTek, Winoski, VT) at an excitation wavelength of 485 ± 9 nm and emission 
wavelength 509 ± 9 nm with 80% sensitivity and 10 mm probe offset in black 96-well 
plates (VWR). 
4.2.2.5 SDS-PAGE for protein detection 
The contaminant protein partitioning was detected using sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) with a 4–12% Bis-Tris NuPage gel and 
NuPage MOPS running buffer (Life Technologies, Carlsbad, CA). SeeBlue Plus2 pre-
stained protein ladder (molecular weight range: 14–191 kDa, Life Technologies) was 
used as the marker. Samples were reduced using 7 v/v% βmercaptoethanol (Sigma-
Aldrich, St. Louis, MO) and heated to 90 °C for 10 minutes prior to loading onto the gel. 
The SDS-PAGE was run for 55 min at a constant 200 V. The gel was loaded with a same 
volume of the samples. The gel was stained with the SimplyBlue Safe stain (Life 
Technologies, Carlsbad, CA) as per the manufacturer’s protocol. 
4.2.2.6 DNA Quantification 
Host cell dsDNA content was measured using the Quant-iT™ PicoGreen® 
dsDNA kit (ThermoFisher Scientific, Waltham, MA) as per the manufacturer’s protocol. 
The PEG-rich phase and citrate-rich phase were diluted in water to a final concentration 
of PEG and citrate ≤1 w/w% to reduce the interference with the assay. The fluorescence 
(excitation: 480 nm and emission: 520 nm) of the samples were measured using a 
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Synergy™ Mx microplate reader. A DNA partition coefficient was calculated similar to 
virus partitioning using equation 4-3 
𝐾𝐾 = 𝑉𝑉𝑃𝑃 ∗ 𝐷𝐷𝐷𝐷𝐴𝐴 𝑐𝑐𝑉𝑉𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑉𝑉𝑙𝑙𝑃𝑃 ∗ 𝐷𝐷𝐷𝐷 
𝑉𝑉𝐶𝐶 ∗ 𝐷𝐷𝐷𝐷𝐴𝐴 𝑐𝑐𝑉𝑉𝑙𝑙𝑐𝑐𝑙𝑙𝑙𝑙𝑠𝑠𝑐𝑐𝑠𝑠𝑠𝑠𝑐𝑐𝑉𝑉𝑙𝑙𝐶𝐶 ∗ 𝐷𝐷𝐷𝐷
       (4-3) 
where V denotes volume of respective phases and DF denotes respective dilution factor.  
4.3 Results  
4.3.1  Effect of osmolytes on two-phase behavior 
In this study, both protecting and denaturing osmolytes were used to study the 
partitioning of viruses in ATPS. Protecting osmolytes modulate the water structure in the 
solution due to their strong solvation ability, denoted by the hydration number. The 
classification and characteristic hydration number of osmolytes in the concentration range 
used in this study is listed in Table 4-1.  The osmolytes affected the two-phase systems 
by changing the threshold compositions of immiscibility and/or altering the equilibrium 
phase compositions.  
 
Table 4-1. Osmolytes and their characteristics 





Glycine Amino acid 75..07 7 [28, 30] 
Betaine Modified amino acid 117.15 31 (0.1 - 1) [31] 
Mannitol Sugar alcohol 182.17 NA  
TMAO Amine oxide 75.11 22.6 - 23 (0.9 - 0.46) [27, 32] 
Urea Carbamide 60.06 ~1 - 1.8 (0.5 - 1) [33] 
*Values in the parenthesis denote the range of concentrations for which the hydration 
numbers were determined 
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Binodal curves generated with the addition of 0.5 M osmolyte in the PEG-citrate 
system changed the two-phase formation. Osmoprotectants demonstrated a shift of the 
two-phase region (Figure 4-1A), whereas the denaturant urea did not show considerable 
change in the separation between the homogeneous and heterogeneous region. The 
addition of osmoprotectants shifted the binodal curve towards the citrate axis, indicating 
an increase in the salting-out behavior of the citrate-rich phase. The incompatibility of the 
phases is driven by the salting-out ability of salt-rich phase towards the ethylene oxide 
groups in the PEG chains [34]. On the other hand, the system formed with urea did not 
demonstrate a significant shift in the binodal curve as compared to the osmolyte-free 
binodal curve. It is likely that a high concentration of urea is required to make significant 
change in the phase behavior as studied previously [35]. 
 
 
Figure 4-1. (A) Binodal curves and (B, C, D) tie lines for PEG 12kDa – citrate systems 
in presence of various 0.5 M osmolytes. Denaturing osmolyte – (B) urea and protecting 
osmolytes – (C) mannitol, TMAO, (D) betaine, and glycine. 
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 The other important characteristic of two-phase systems are tie-lines, 
representing the set of systems at thermodynamic equilibrium with identical final phase 
compositions. The slope of a tie-line determines the equilibrium system compositions. 
The change in the TL slopes due to addition of osmolytes is compared to the osmolyte-
free system in Table 4-2 and shown in Figures 4-1(B-D). Osmoprotectants betaine, 
TMAO, and mannitol showed a negative change in the TL slope (in that order) as 
compared to the osmolyte-free system, thus showing an increase in the PEG 
concentration and a decrease in citrate concentration as compared to a common point on 
that TL for the no osmolyte control. Glycine did not significantly change the slope. The 
denaturant urea demonstrated a positive change in the slope. If the altered equilibrium 
compositions generate an optimum balance between the hydrophobic and electrostatic 
interaction for the preferential partitioning of biomolecules, higher recovery and yield 
could be achieved. In this regard, mannitol, a polyol, demonstrated the largest increase in 
the PEG-rich phase composition and the largest decrease in the citrate-rich phase 
composition followed by TMAO (see Figure 4-1 and Table 4-2).    
 
Table 4-2. Changes in the TLL and TL slope with addition of osmolytes 
Osmolyte Δ TLL Average TL Slope Δ TL Slope t-test values of Δ TL Slope  
 (w/w%) Deg (rad) Deg (rad) P  
-  -1.48 ± 0.05   
Glycine 10.4 -1.54 ± 0.12  -0.06 0.4688 
Betaine 9.5 -1.95 ± 0.18  -0.47 0.0121 
TMAO 7.8 -2.23 ± 0.11 -0.75 0.0004 
Mannitol 13.8 -3.33 ± 0.11 -1.85 0.0001 
Urea 2.3 -1.33 ± 0.07 +0.16 0.0392 
Note: Mannitol was not used to generate TL at high TLL 
Δ = control - osmolyte 
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The osmolytes affected the interactions by variably partitioning between the two 
phases. Osmoprotectants preferred the citrate-rich phase, whereas the urea highly 
partitioned to the PEG-rich phase (Figure 4-2A). Almost 100% of the glycine was 
recovered in the citrate-rich phase at all TLL. Glycine partitioning to the citrate-rich 
phase shifted the binodal curve towards the citrate axis and increased the length of tie-
lines, without affecting the tie-line slope, as compared to the osmolyte-free system. 
Betaine, TMAO, and mannitol demonstrated similar partitioning behavior. 60% recovery 
was observed for these osmolytes in the citrate-rich phase at the lowest TLL and 
increased up to 80% recovery at the higher TLLs (Figure 4-2B). Only 40% of urea was 
recovered in the citrate-rich phase at all TLL. Overall, the degree of osmolyte partitioning 
to the citrate-rich corresponded to the shift of binodal curve away from the osmolyte-free 
system.     
  
 
Figure 4-2. Partitioning of the osmolytes at common compositions of ATPS with 
increasing TLL represented as (A) ln (K) and (B) % recovery in the corresponding 
citrate-rich phases. 
 
4.3.2 Model viruses 
Two virus models - porcine parvovirus (PPV) and human immunodeficiency virus-group 
specific antigens virus-like particles (HIV-gag VLP) were used to determine the effect of 
osmolytes on the partitioning within an aqueous two-phase system. The structural and 
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physiochemical characteristics of PPV and HIV-gag VLPs are compiled in Table 4-3. 
Essentially, PPV used in this study is a non-enveloped infectious virus and comprises of 
three capsomeres VP1, VP2, and VP3, assembled in an icosahedral geometry [36]. HIV-
gag VLP is an enveloped, non-infectious, virus-like particle comprised of Gag 
polyproteins self-assembled in spherical particles and enclosed in the envelope derived 
from S. cerevisiae cell membrane [37] These two models were used to determine the 
osmolyte action to modulate the partitioning of both non-enveloped and enveloped 
virus/VLP in the PEG-citrate system.   
 
Table 4-3. Biophysical and biochemical characteristics of model virus/VLP 
Model family Cell origin pI Size (nm) genome Structure Ref 







Yeast ? 80-120 - Enveloped proprietary 
PPV: porcine parvovirus; HIV-gag-VLP: human immunodeficiency virus-group specific 
antigen-virus like particle 
 
4.3.3 Influence of osmolyte class on virus partitioning  
Initially, three global compositions having similar osmolyte concentrations were 
studied to understand the efficacy of different osmolyte classes to modulate virus 
partitioning in the PEG-citrate system at pH 7. Previous studies have shown that the 
negatively charged PPV partitions to the PEG-rich phase only at high system 
compositions. This is hypothesized to be due to the need to salt-out the virus from the 
citrate-rich phase to the interface. Then, the virus is pulled from the interface at high PEG 
concentrations due to the hydrophobic interaction between the amphiphilic PEG [14]. 
Here, the objective is to determine the additive that could enhance the purification at 





Figure 4-3. Effect of different osmolytes on (A) PPV and (B) HIV-gag VLP partitioning. 
Biomolecule portioning upon addition of 0.5 M protecting (glycine, betaine, and TMAO) 
and non-protecting (urea) osmolytes are compared to osmolyte-free (control) system. 
Experiments were performed in triplicates and the error bars represent standard deviation. 
 
The zwitterionic osmolytes glycine and betaine had most significantly altered the 
binodal curve as compared to the other osmolytes used (Figure 4-1A), indicating 
elevated driving forces for phase separation. A similar effect was observed for the viral 
partitioning, whereas addition of glycine and betaine significantly improved the PPV and 
HIV-VLP partitioning to the PEG-rich phase (Figure 4-3). Glycine-containing systems 
were able to enhance the partitioning of PPV at the lowest composition studied, yielding 
about 95% PPV recovery in the PEG-rich phase as compared to ~0% with the osmolyte-
free systems (Figure A.2-11A in Appendix). The other two higher systems compositions 
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both yielded ~100 % recovery of PPV when glycine was added. Betaine improved the 
PPV partitioning slightly at the lowest composition studied, whereas TMAO did not 
change the partitioning behavior as compared to osmolyte-free system. However, most of 
the viral particles still partitioned to the citrate-rich phase in both betaine and TMAO-
containing systems, exhibiting a lack of salting-out (Figure 4-3). Interestingly, urea-
containing systems demonstrated a similar effect on the partitioning behavior of PPV as 
TMAO. It should be noted here that most of urea partitioned to the PEG-rich phase as 
compared to the citrate-rich phase partitioning of TMAO (Figure 4-2).  
A similar study was performed to determine the effect of osmolytes on the 
enveloped HIV-VLP. At the lowest system composition, the glycine-containing system 
demonstrated an insignificant increase in the partition coefficient and betaine and TMAO 
reduced the partitioning of the VLP in the PEG-rich phase, as compared to the control 
(Figure 4-3B). The partition coefficient elevated significantly at the mid-system 
composition containing glycine, betaine, and TMAO, yielding 92% VLP recovery in the 
PEG-rich phase (Figure 4-3B and Figure A.2-11C). The highest system composition 
containing glycine demonstrated an increase in the partition coefficient as compared to 
the osmolyte-free system but yielded 83% recovery (Figure 4-3B and Figure A.2-11C). 
On the other hand, betaine and TMAO-containing systems did not show any significant 
differences in the partition coefficients (Figure 4-3B).  
In both model viruses, osmolyte systems with betaine and TMAO recovered a 
lower number of viral particles in the PEG-rich phase when compared to glycine-
containing systems of the same composition. This difference is likely due to the osmolyte 
partition in the citrate-rich phase, where glycine is recovered at >80%, and 
betaine/TMAO are recovered at ~60% (Figure 4-2). Although the hydration number of 
glycine is almost three-fold lower than betaine and TMAO (see Table 4-2), it is likely 
that the higher concentration of glycine in the citrate-rich phase compensates for the 
lower hydration number. It has been also shown that glycine is more kosmotropic as 
compared to betaine and TMAO [39]. Now, the same study suggested that betaine is less 
kosmotropic than TMAO which also correlated with the change in the TL slopes in our 
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study (Table 4-2). However, this kosmotropic difference was not translated to the virus 
partitioning, which showed similar salting-out effect by betaine and TMAO, but higher 
hydrophobic interaction to draw the virus into the PEG-rich phase by betaine than TMAO 
(Figure A.2-11A & B). Secondly, as the TLL increases with osmolyte-containing 
systems, the recovery is lower at low TLL compared to higher TLL. However, at the mid-
TLL, the system reaches a maximum PEG-rich phase virus recovery meaning the 
addition of more osmolyte no longer increases virus recovery. This is hypothesized to be 
due to the salting-out effect of the citrate itself being the dominant driving force to salt-
out virus from the citrate-rich phase, regardless of osmolyte concentration. A common 
trend of driving force enhancement for non-enveloped PPV and enveloped HIV-VLP 
recovery appears to follow the order glycine > betaine > TMAO > Urea ~ osmolyte-free.  
4.3.4 Influence of osmolyte class on protein and HC-DNA partitioning 
Depending on the class, the osmolytes in the previous section demonstrated an 
elevated partitioning of virus and VLP. It is essential to see if a similar effect is observed 
on the proteins which would lower the purity of the virus recovered PEG-rich phase.  
As glycine and betaine had demonstrated the most improvement in the virus 
partitioning, host cell proteins (HCP) and host cell DNA (HC-DNA) were tracked only in 
these systems. The HCP were only detected in the citrate-rich phase, except at the highest 
TLL in which one band at 51 kDa appeared in the PEG-rich phase (Figure 4A & B). 
Also, all the contaminant proteins from HIV-VLP crude partitioned to the citrate-rich 
phase (data not shown). It is noted that the lower TLLs were of primary interest, as the 
glycine and betaine additions were able to recover most of the viral particles in the PEG-
rich phase (Figure A.2-11). The partitioning of proteins in the citrate-rich phase is likely 
because the osmolytes stabilize the protein structure. Stabilization causes intraparticle 
interactions [22, 25] and likely does not induce interaction between the proteins and the 
PEG-rich phase. These results correlate with the previous studies that have shown 
osmolytes to induce only structural changes in the flexible proteins, whereas the 
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comparatively rigid viral particles experience interparticle interactions or flocculation in a 
single-phase solution [25, 40]. 
The HC-DNA partitioned to the citrate-rich phase at the lower TLLs of both the 
glycine and betaine-added systems (Figure 4-4C& D). At the highest TLL, glycine, but 
not betaine, enhanced the HC-DNA partitioning to the PEG-rich phase. This indicates 
that either glycine enhances the hydrophobic interaction of DNA with the PEG-rich phase 
or induces interaction between viral particles and DNA causing DNA to attach to the 
viral particles and co-partition in the PEG-rich phase. Overall, the lower TLLs with lower 
PEG and citrate compositions achieved a very high yield and purification of the viruses in 
the PEG-rich phases when glycine or betaine were used as additives. 
 
Figure 4-4. Contaminant protein (A & B) and HC-DNA (C & D) partitioning at varying 
TLL in presence of 0.5 M glycine or betaine. Contaminant protein partitioning were 
visualized on Coomassie stained SDS-PAGE and HC-DNA were quantified using Quant-
iTTM PicoGreen® dsDNA assay. The error bars in the DNA partitioning figures represent 
standard deviations from the experiments done in triplicates. 
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4.3.5 Effect of tie-line framework on virus partitioning     
Tie-lines guide the volume ratio of the phases, providing opportunity to recover 
viral particles in the PEG-rich phase having low volume. However, the system 
characteristic changes at the phase inversion point where the dispersed phase changes 
from the citrate-rich phase to PEG-rich phase as the TL ratio increases [41]. The phase 
inversion dictates if the viral particles directly partition to the bulk PEG-rich phase or 
accumulates at the interface of the dispersed PEG-rich phase to coalesce. This study was 
performed only with PPV to evaluate the phase inversion effects. The partition 
coefficient of PPV increased with the increasing TL ratio at lower TLLs and remained 
constant at the highest TLL (Figure 4-5A). This indicates that at the lower TL ratio, 
where the citrate-rich phase is the dispersed phase, there is no salting out of the viral 
particles. The increase in the TL ratio, where the PEG-rich phase is the dispersed phase, 
resulted in a slightly higher partition coefficient. PPV still partitioned to the citrate-rich 
phase at the lower TLL. However, more PPV was in the PEG-rich phase than the citrate-
rich phase at the mid-TLL which indicates that the salting-out effect caused the viral 
particles to partition at the interface and coalition of the PEG-rich phase droplets 
collected the viral particles from the interface. At the highest TLL studied, PPV clearly 
exhibited hydrophobic interaction with the PEG-rich phase as the partitioning trend 
flattened. The PPV partitioning not only demonstrated a flat trendline in the systems 
containing glycine but also demonstrated that most of the viral particles partitioned to the 
PEG-rich phase at all TLLs (Figure 4-5B). This trend was observed at the mid and 
highest-TLL in the systems containing betaine or TMAO (Figure 4-5C&E). 
Interestingly, urea containing systems demonstrated similar trend as osmoprotectants 
(Figure 4-5D). However, the partition coefficients were lower than glycine and close to 
betaine and TMAO (Figure 4-5B-E). The systems containing mannitol demonstrated a 
reverse trendline as compared to the osmolyte-free system where the partitioning 
coefficient decreased with the TL ratios (Figure 4-5F). The overall trend of PPV 
partition coefficients implies that the osmolytes, except mannitol, provide consistent 
partitioning of viral particles across the tie line on contrary to the osmolyte-free systems.  
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Figure 4-5. Partition coefficient of PPV in the systems (A) without osmolyte and systems 
enhanced with 0.5 M protecting osmolytes (B) glycine (C) betaine (D) TMAO (E) 
mannitol. Experiments were done in triplicates and the error bars represent the standard 
deviation. 
 
The effect of osmolytes on the interaction of PPV and either phases is too 
complex to just be explained by the partition coefficients. Glycine containing systems 
yielded high PPV titers in the PEG-rich phase at all the TLL and TL ratio (Table A.2-2). 
However, the titers dropped with the increasing TLL in the citrate-rich phase. Similar 
trend was observed for betaine-containing systems, except the PPV titers in the PEG-rich 
phase were slightly lower than glycine. On the other hand, both TMAO and urea-
containing systems demonstrated an increasing PPV titer with increasing TLLs, but the 
actual titers were much lower than glycine and betaine. The significantly different titers 
in the PEG-rich phase followed a decreasing order as glycine > betaine > TMAO > urea.    
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4.3.6 Effect of pH on virus partitioning   
Surface charge of the viruses plays a vital role in the paritioning between the PEG-
rich and citrate-rich phases. Negatively charged viruses experience repulsion effects by 
citrate ions, causing the salting-out effect. The repulsion effect decreases at the isoelectric 
point of the virus, causing the majority of viruses to partition to the citrate-rich phase [14, 
38]. PPV has a pI near 5, thus it has a net neutral charge at that pH [38]. The systems 
containing the osmolytes glycine, betaine, or TMAO at pH 5 seem to have no effect on 
the interaction between PPV and the PEG-rich phase, as the systems infused with either 
of these osmolytes resulted in similar partitioning (Figure 4-6). However, an increase in 
the TLL increased the partitioning of the PPV, which is likely due to an increase in the 
ionic strength of the citrate-rich phase. This is a preliminary, yet significant observation, 
and more studies need to be performed to fully understand the effect of osmolytes on 




Figure 4-6. PPV partitioning at varying TLL in presence of (A) 0.5 M glycine, (B) 0.5 M 
betaine, and (C) 0.5 M TMAO maintained at pH 5 and 7. The error bars represents 
standard deviation of experiments done in triplicates. 
 
4.4 Discussion 
The partitioning of biomolecules in the PEG-salt systems is suggested to be 
highly affected by the balance of electrostatic and/or hydrophobic interactions [42]. The 
goal of this study was to improve the virus recovery in the PEG-rich phase at lower TLL 
where high recoveries were not achieved without additives. Osmolytes are known to 
modulate solvent properties and induce hydrophobic interactions in aqueous solutions 
[43, 44]. Changes in electrostatic and hydrophobic interactions can result in either 
intraparticle or interparticle interactions. The flexible smaller proteins are known to 
undergo conformational changes (intraparticle interactions) in the presence of 
127 
osmoprotectants [17, 18] and comparatively rigid viruses have been shown to flocculate 
(interparticle interactions) [25] in the presence of similar osmolytes. In this study, the 
osmolytes induced interfacial interactions between virus particles and the PEG-rich phase 
to improve virus recovery. This is an interesting observation in that the addition of 
protecting osmolytes yielded a high selectivity, as there was no interaction between the 
contaminant proteins and PEG-rich phase. It is likely that the osmolytes only affected the 
conformation of proteins.  
The mechanism of protecting osmolytes glycine, betaine, and TMAO to stabilize 
the proteins structures and flocculate viruses is still unclear. In one study, the stabilizing 
effect of glycine and betaine disrupted the hydrogen bond network of elastin-like 
polypeptide with water [39]. The changes in the water structure was caused by osmolytes 
partitioning away from the polypeptide. On the other hand, TMAO was observed to 
favorably interact with the backbone of a collapsed protein and a hydrophobic 
homopolymer [39, 45]. Among the three osmolytes, TMAO was least recovered in the 
citrate-rich phase and this might indicate an interaction with the globular PEG molecules 
in the PEG-rich phase. Moreover, in this study, glycine and betaine (in that order) 
induced hydrophobic interactions between the virus models and PEG-rich phase to 
improve the partition coefficient (Figure 4-3). TMAO did not seem to improve the 
hydrophobic interaction, as previously shown [46] and shown here.  
The enhancement of the driving forces at lower TLL also signifies comparatively 
easier processability of the phases, as the high recovery of biomolecules are obtained at 
lower phase compositions. The concentrated PEG-rich phase is viscous, which might 
pose challenges towards phase handling. The osmolytes recovered viruses at lower 
compositions that have lower viscosities of the PEG-rich phase as compared to osmolyte-
free systems (Table A.2-3). Also, lower ATPS concentrations have a lower ionic 
strength. A lower ionic strength is highly preferred to maintain the stability of the viral 




This study reports the use of osmolytes to modify the partitioning behavior of 
PPV and HIV-gag-VLP. Glycine followed by betaine, among the zwitterionic osmolytes, 
demonstrated an increase in the salting-out ability of the citrate-rich phase and an 
increase in the phase hydrophobicity of the PEG-rich phase. The elevated driving forces 
improved the recoveries of viruses at lower TLLs, where the systems without osmolytes 
are insufficient to induce the needed electrostatic and hydrophobic interactions to cause 
preferential virus partitioning. TMAO increased the ability of two-phase formation at 
lower system compositions, but it did not increase the hydrophobic interaction of viruses 
with the PEG-rich phase at lower TLL. ~100% of PPV and 90% of HIV-gag-VLP were 
recovered using glycine at the lowest TLL studies. The order of efficiency of osmolytes 
to enhance the driving forces was determined to be glycine > betaine > TMAO > urea. 
High recovery and purity of viral modalities in the PEG-rich phase implied that 
osmolyte addition enhances the interfacial interactions for comparatively hydrophobic 
and rigid viruses as compared to the intramolecular interactions for flexible proteins. The 
HC-DNA partitioned to the citrate-rich phase at low TLL but increased towards the PEG-
rich at higher TLL in presence of glycine and betaine. This study provides evidence that 
osmolyte addition not only improves the recovery, but also alleviate the challenges of 
high concentration ATPS processing. Moreover, this study showed that the effect of 
osmolytes on virus is drastically different than a protein, which is essential to develop a 
robust and versatile downstream process for viral particle manufacturing.   
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5.1 Introduction 
Aqueous two-phase systems (ATPS) formed by partially miscible aqueous 
solutions (polyethylene glycol-salt) have shown a great potential to be used in the 
downstream processing of viral vaccines and biotherapeutics [1-3]. However, our 
previous studies have shown that higher viral recoveries are obtained in the systems that 
have higher PEG-rich phase volume [4]. When the PEG-rich phase volumes are higher 
than the salt-rich phase volume, the PEG-rich phase acts as a continuous phase with the 
dispersed salt-rich phase [5]. The PEG-rich phase being viscous, the processing of ATPS 
becomes difficult. Moreover, the separation of viral particles from the PEG-rich phase is 
challenging. The possible strategy to reduce the processing burden is to operate the two-
phase systems with the compositions that yield continuous salt-rich phase and dispersed 
PEG-rich phase is limited by the virus partitioning at the interface [4, 6]. This problem of 
lower virus recovery with lower PEG-rich phase volumes needs to be to addressed by 
developing novel systems that improve the affinity of the PEG-rich phase to allow higher 
virus partitioning. 
  ATPS composed of different phase forming components such as polymer-
polymer (polyethylene glycol-dextran) and polymer-salt (polyethylene glycol-
sulfate/citrate/phosphate) have found numerous applications in bioprocessing and 
biotechnology. The common application of ATPS in biotherapeutic field has been in the 
recovery and purification of cells [7-9], antibodies [10, 11], viruses [12-14], and nucleic 
acids [15, 16]. The advantages of ATPS as a potential alternative to the conventional 
downstream processing unit operations are high target biomolecule yield, inexpensive, 
easy-to-scale up, and continuously processable unit operation. However, in the early 
days, the unambiguity in understanding the partitioning behavior of biomolecules 
between the two phases hindered the potential use of the mild biphasic systems. Various 
studies point to the following factors affecting the partitioning behavior: hydrophobicity, 
electrostatics, and volume-exclusion [17, 18]. These interactive forces are influenced by 
the phase-forming component and biomolecule structural and physicochemical 
properties. The insight into the driving forces has been used to investigate ATPS as a tool 
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in the surface physicochemical characterization of biomolecules [19, 20], developing 
assays for molecular recognition [21-23], and producing microspheres for protein and 
drug encapsulation [24, 25].   
There has been a significant advancement in designing and synthesizing 
molecules to enhance the affinity for biomolecules. The affinity ligands are made from 
peptides [26, 27], aptamers [28, 29], proteins [30], and polysaccharides [31]. These 
ligands have been utilized in the affinity and multimodal chromatography for purification 
of a target biomolecule. Protein A, used for the affinity purification of immunoglobulin G 
(IgG), is expensive, labile, and requires harsh elution conditions. One way to alleviate the 
disadvantages of Protein A is to design short peptides to mimic the protein A binding to 
IgG [32, 33]. A hybrid ligand composed of a trimeric peptide FYE conjugated with a 
hydrophobic charge-induction group provided a comparable purity and recovery of IgG 
with a milder elution condition than protein A [34]. The design of appropriate ligands to 
alleviate harsh processing conditions has helped to improve the downstream processing 
of biologics [35, 36]. 
While similar strategies have been used to select ligands with a high affinity 
towards viral particles, the diversity in the viral surface composition and physicochemical 
characteristics makes the use of appropriate ligands difficult. Ligands for viral processing 
has come in the form of antibodies [37, 38], protein-based lectin [36, 39], metal ions [40, 
41], and polysaccharide-based heparin and heparan sulfate [42, 43]. A more robust 
method suggests the use of multimodal ligands that use a combination of electrostatic 
interaction, hydrophobic interaction, and hydrogen bonding mechanisms [44, 45]. 
Synthetic peptide libraries are also being explored as the potential sources of multimodal 
ligands. Zheng and coworkers (2017) demonstrated that the peptide motif 
YHDCFSAGFCIG presented a high affinity with a dissociation constant of 98 nM 
towards porcine circovirus type 2 Cap protein [46]. The other study found that the 
peptide sequence CAAALAKPHTENHLLT, selected by phage-display, was able to bind 
to retrovirus virus-like particle expressing Ampho4070A protein and recovered 90% viral 
particles with a mild elution condition [47]. However, such peptides not only depend on 
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the amino acid sequence to harness the molecular interactions but also on the spatial 
orientation of the peptide to dock in a targeted pocket of the viral proteins [48]. The 
peptide ligands could also be designed to preferentially interact with viral proteins based 
only on the molecular interactions without requiring a constrained structural 
conformation of amino acid residues. This was achieved previously by limiting the 
number of residues where trimeric peptides were found to bind porcine parvovirus and 
the binding was not improved by adding more amino acids, which likely resulted in 
secondary structure of the ligand [49].  
Affinity ligands have also been used in ATPS to improve the specificity and 
processing abilities for biomolecule partitioning. The affinity ligands are generally 
conjugated with the polymer and attract the target biomolecule to the polymer-rich phase. 
Polyethylene glycol has been modified to present electrophilic, nucleophilic, or 
hydrophobic end groups [50]. Ligands were either small organic molecules, such as 
benzoyl or dinitrophenyl, or biospecific proteins or enzymes such as avidin or antibody-
horse radish peroxidase. However, there have been hardly any studies performed with the 
inclusion of small peptide ligands in affinity ATPS. The challenge of using a PEGylated 
ligand is the long PEG tail may hinder the accessibility of the active site of the ligand 
[51]. The conjugation of a small antimicrobial peptide with PEG inhibited the 
antimicrobial activity and was hypothesized that the PEG chain interfered with the 
functioning of the active sites [52]. The presence of PEG functionalized with the cell 
adhesion domain (RGD) did not induce cell adhesion as the peptide was surrounded by a 
PEG shell [53]. However, the masking of the active domains by PEG chain could be 
averted by utilizing an optimum molecular weight of PEG that increases the flexibility of 
the polymer and provides steric hindrance for nonspecific interactions [54].  
In this study, a non-enveloped porcine parvovirus (PPV) partitioning behavior 
was studied in the PEG-citrate system in the presence of peptides conjugated to PEG 
10kDa. A trimeric multimodal affinity region WRW was chosen due to its high affinity 
towards PPV [55]. With the growing interest of determining if the active sites of ligands 
are accessible upon conjugation, the target peptide with the WRW region was 
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characterized using the fluorescence quenching method. High solvent accessibility of the 
target multimodal region favored the PPV partitioning into the PEG-rich phase. The 
improved PPV partitioning was suggested to be the result of either direct binding with the 
PPV capsids or enhancing the hydrophobicity and electrostatic potential of the PEG-rich 
phase. The use of multimodal peptide ligand demonstrated that the virus partitioning 
could be enhanced at lower phase composition and lower volumes of the PEG-rich phase.  
5.2 Materials & Methods 
5.2.1 Materials 
Eagle's minimum essential media (EMEM), sodium bicarbonate, phosphate buffer 
saline (PBS, pH 7.2), penicillin-streptomycin (pen-strep) (10,000 U/ml), fetal bovine 
serum (FBS, USDA approved) and trypsin/EDTA for cell propagation were purchased 
from Life Technologies (Carlsbad, CA). 2-(3,5-diphenyltetrazol-2-ium-2-yl)-4,5-
dimethyl-1,3thiazole;bromide (MTT, 98%) was purchased from Alfa AesarTM 
(Haverhill, MA) and sodium dodecyl sulfate (SDS, BioReagent, ≥98.5%) was purchased 
from Sigma Aldrich (Radnor, PA). Polyethylene glycol with an average molecular weight 
of 12,000 Da (PEG 12 kDa), trisodium citrate dihydrate (ACS reagent grade, ≥99%), and 
citric acid monohydrate (ACS reagent, ≥99%) were a generous gift by Millipore Sigma 
(Burlington, MA). Monofunctional methoxy-polyethylene glycol-vinyl sulfone (mPEG-
VS) (PEG molecular weight: 10000 Da) was purchased from Creative PEGworks 
(Chapel Hill, NC). Peptide ligands GRCDGGWRW, GRCDGGGGG, and 
GRCDGGAAA (98% purity) were purchased from Peptide 2.0 Inc. (Chantilly, VA). 
Acrylamide solution (40% w/v) was purchased from Bio-Rad Laboratories (Hercules, 
CA). Triethanolamine (TEA) was purchased from Thermo Fisher Scientific (St. Louis, 
MO). Phosphate buffer saline (PBS) was obtained from HyClone Laboratories (South 
Logan, UT). Dialysis tubing (MW cutoff 3.5 kDa) and black-walled, glass-bottom 96-
well plates were purchased from Thermo Fisher Scientific (Waltham, MA). Solutions 
were prepared with Nanopure water (Thermo Scientific, Waltham, MA) at a resistance of 
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≥18 MΩ and filtered with either a 0.2 μm Nalgene (Thermo Scientific) bottle top filter or 
0.22 µm cellulose acetate syringe filters (VWR, Radnor, PA) before use. 
 
5.2.2 Methods 
5.2.2.1 Cell culture, virus propagation, and titration 
Porcine kidney cells (PK-13, CRL-6489) purchased from ATCC (Manassas, VA) 
were maintained in EMEM pH 7.1 mixed with 10 v/v% FBS and 1 v/v% pen-strep as 
described previously [4]. Porcine parvovirus strain NADL-2 (PPV) was a generous gift 
from Dr. Ruben Carbonell (North Carolina State University, Raleigh, NC) and was 
propagated in PK-13 cells, as described previously [56]. PPV was quantified by titration 
using MTT salt-based colorimetric cell viability assay [4]. 
5.2.2.2 Functionalized PEG conjugation and purification 
The functionalization of PEG with peptide ligands was carried out by reacting 
vinyl sulfone on mPEG(10 kDa)-VS with the thiol group of cysteine on the peptide 
sequence GRCDGGXXX, where XXX represents GGG, AAA, or WRW (Figure 5-1). 
Each peptide (WRW, GGG or AAA at 12 mM) was reacted via Michael-type addition 
with mPEG-VS (10 mM) in 0.3 M triethanolamine (TEA) pH 7.4 at a molar ratio of 1.2 
peptide:1 PEG in an incubator at 37 °C for 30 minutes. The solution was removed from 
the incubator and dialyzed in dialysis tubing of molecular weight cut-off 3.5 kDa in 
deionized water with convective mixing at 200 RPM. The water was replaced 3 times in 
the first hour and once a day for two more days. The solution was then aliquoted, frozen 
at −80 °C for ~1 hour and lyophilized overnight. The resulting functionalized mPEGVS-
peptide was stored in a desiccated container at −20 °C until use. The average product 
yield was ~90% and the average derivatization was >95% as confirmed by proton nuclear 
magnetic resonance (1H NMR): the product was dissolved in deuterated chloroform 





Figure 5-1. Synthesis flow diagram of functionalized PEG-peptide conjugates. A linear 
PEG-vinyl sulfone is covalently functionalized with a cysteine terminated peptide. 
 
5.2.2.3 Steady-state fluorescence quenching 
To determine whether derivatization with PEG ‘buried’ the peptide, GRCDWRW 
peptide and mPEGVS-WRW were dissolved in PBS at a final concentration of 1200 nM. 
Acrylamide solutions of 0.8 M, 0.6 M, 0.4 M, and 0.2 M were prepared in PBS by serial 
dilution. Next, 50 µL of GRCDWRW or mPEGVS-WRW solutions were added in 
triplicate to a black-walled, glass-bottom 96-well plate and 50 µL of acrylamide solution 
was added to each well for a total of 100 µL volume per well. Fluorescence of the 
tryptophan amino acid (W; excitation at 280 nm/emission at 350 nm) was then recorded 
using a spectrophotometer (SpectraMax i3, Molecular Devices, Sunnyvale, CA). 
Fluorescence quenching experiments were performed by measuring the fluorescence 
intensity loss of the free GRCDWRW peptide or conjugated mPEGVS-WRW as a 
function of acrylamide concentration. Acrylamide quenches the fluorescence of W, where 
quenching kinetics depends on W accessibility. Fluorescence quenching data were fitted 
to the Stern-Volmer equation [57]:  
𝐹𝐹0 𝐹𝐹⁄ = 1 + 𝐾𝐾𝑆𝑆𝑉𝑉[𝑄𝑄]     (5-1) 
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where 𝐹𝐹0 and 𝐹𝐹 are the fluorescence intensities in the absence and presence of the 
quencher, 𝑄𝑄, and 𝐾𝐾𝑆𝑆𝑉𝑉 is the Stern-Volmer quenching constant. 
5.2.2.4 Virus Partitioning and Recovery 
1 g two-phase systems were prepared by mixing appropriate amounts of 45 w/w% 
PEG and 35 w/w% citrate stocks along with 0.1 g crude PPV stock to a non-stick 1.5 mL 
microcentrifuge tube (VWR, Radnor, PA) for systems without affinity ligands [4]. The 
systems with affinity ligands were prepared by maintaining a 7:3 mass ratio of PEG to 
PEG-peptide, and the rest of the components remaining identical to the ligand-free 
systems. A 7:3 mass ratio of unfunctionalized and functionalized PEG was maintained by 
an appropriate amount of 45 w/w% PEG-peptide stock. The virus partitioning procedure 
was similar to the previously described study [4]. The PPV partitioning (K) and recovery 
were calculated using equations 2 and 3, respectively. 
𝐾𝐾 = 𝑉𝑉𝑃𝑃∗𝑇𝑇𝑃𝑃
𝑉𝑉𝐶𝐶∗𝑇𝑇𝐶𝐶
                                                  (5-2) 
% 𝑉𝑉𝑠𝑠𝑅𝑅𝑠𝑠𝑅𝑅𝑠𝑠𝑟𝑟𝑅𝑅 = 𝑉𝑉𝑃𝑃/𝐶𝐶∗𝑇𝑇𝑃𝑃/𝐶𝐶
𝑉𝑉𝑖𝑖∗𝑇𝑇𝑖𝑖
∗ 100                                                        (5-3) 
where V and T are the volume and PPV titers of the PEG-rich phase (P), citrate-rich 
phase (C), or initial stock virus (i). PPV titers are expressed as MTT50/mL 
 
5.3 Results 
5.3.1 Virus partitioning in the presence of affinity ligand 
Aqueous two-phase systems are defined by a binodal curve and tie lines (see 
Figure 5-2A). The binodal curve defines the two-phase region and tie lines represent the 
thermodynamic equilibrium of the system, where any system on a tie line will separate 
into two phases containing the concentrations found by the intersection of the tie line and 
the binodal curve. Previous work has shown that high PEG and salt concentrations (i.e. 
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longer tie line lengths) are needed to partition viral particles to the PEG-rich phase [3, 4]. 
Also, virus partitioning increases with higher volume ratios or lower tie-line ratios (TLR) 
[4]. Since partitioning is an equilibrium process, virus titers in each phase were similar at 
different volume ratios, but when taking volume into account, yield was higher in the 
PEG-rich phase when there was more PEG-rich phase volume (i.e. lower TLR). A non-
enveloped porcine parvovirus (PPV) comprised of capsid proteins VP1, VP2, and VP3 is 
used as a model virus in this study [58].  A multimodal peptide-based affinity ligand was 
used in this study to enhance the PPV partitioning at lower volume ratios in the PEG 
12kda-citrate systems at pH 7.  
 Two TLR at three different tie-line lengths were selected (Figure 5-2A) such that 
the volume ratios of the equilibrium PEG-rich phase to the citrate-rich phase volumes 
were < 1 (Table A.3-1). These represent cases where there is low virus partitioning to the 
PEG-rich phase without affinity ligands present. WRW peptide has been shown to 
display high affinity towards PPV with a combined hydrophobic and electrostatic 
interaction of WRW with the PPV capsids [49]. Thus, this peptide was used as the 
primary affinity ligand in this study. As controls to the multimodal WRW ligand, GGG 
and AAA were used to evaluate the specificity of the virus partitioning. The effect of a 30 
w/w% replacement of PEG with functionalized PEG can be found in Figure 5-2B & C. 
At the TLR of 1 (Figure 5-2C), PEG-WRW increased the PPV partitioning to the PEG-
rich phase significantly at all tie-line lengths, as compared to the unmodified systems 
(ligand-free systems). However, most of the PPV particles still partitioned to the citrate-
rich phase at the tie-line length 15 w/w%, and the significant increase by was observed at 
the tie-line length 36 w/w%. On the other hand, control ligands demonstrated the 
opposite trend. The PPV partitioning was not significantly affected by GGG and AAA at 
the tie-line lengths 15 and 36 w/w%. The PPV partitioning was pushed to the citrate-rich 
phase at tie length 25 w/w%. The WRW ligand is likely attracting viral particles to the 
PEG-rich phase if the viral particles are at the interface, and the control ligands seem to 
push the viruses away from the interface to the citrate-rich. An increase in the TLR to 2.3 
only increased the partition coefficient at the tie-line length 15 w/w% of the PEG-WRW 
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containing systems, whereas, the other two tie-line lengths did not show any significant 
change in the virus partitioning (Figure 2C). Even though the equilibrium PEG-rich 
phase composition remains the same for each tie line length, a lower number of affinity 
ligands were added to the system due to the overall lower PEG mass in the system. On 
the other hand, the control ligands (GGG and AAA) had no significant effect on the virus 
partitioning at the tie-line length 15 w/w%. However, the control ligands reduced the 
virus partitioning at tie-line length 25 and 36 w/w% even more than the addition of PEG-
WRW. It is likely that PEG-WRW makes the PEG-rich phase more hydrophobic and 
positively charged than the unmodified systems, thereby elevating the negatively charged 
virus partitioning towards the PEG-rich phase. The control polymers PEG-GGG and 
PEG-AAA may make the PEG-rich phase more hydrophilic, thereby suppressing the 





Figure 5-2. Effect of TLL and TL ratios on PPV partitioning with an inclusion of affinity 
ligand mPEGVS-WRW. (A) Six systems were selected on three different tie-lines and 
two TLR. The partitioning coefficients in the presence of 30% PEG-peptide doping are 
demonstrated at (B) TLR:1 and (C) TLR:2.3 on all the three TLL along with systems 
without the affinity ligand doping.  Experiments were conducted in triplicates and the 
error bar represents standard deviation. *p-value < 0.05 using Student’s t-test as 
compared to the ligand-free system. 
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Another way to assess the effect of viral behavior at the interface and determine 
the ligand efficiency is to explore the recoveries of the viral particles in each equilibrium 
phase. The viral transport through the interface was traced by determining the viral 
recovery (Figure 5-3A and B) in the PEG-rich and citrate-rich phases of the systems 
studied in Figure 5-2. The PPV recovery in the PEG-rich phase was higher at the TLR 
2.3 as compared to the TLR 1 with the inclusion of PEG-WRW (Figure 5-3C and D). It 
is likely that the increased volume of the citrate-rich phase was able to induce an 
interaction of additional number of the viral particles with the PEG-rich phase, as a lower 
PPV recovery was observed in the citrate-rich phase of the TLR 2.3 compared to the TLR 
1 (see Figure 5-3E and F). The PEG-WRW containing system at the TLR 2.3 was able 
to recover the virus at the interface in the PEG-rich phase due to the high affinity towards 
PPV. The ligand-free system was incapable of transporting a similar number of salted-out 
PPV to the PEG-rich phase. The system at TLR 1 was able to recover only 10% of PPV 
as most of the viral particles were not salted-out (Figure 5-3C and F). However, this 
effect is more prominently observed at the tie-line length 15 w/w% because the citrate-
rich phase composition is insufficient for the driving force to act upon all the viral 
particles. The tie line lengths 25 and 36 w/w% demonstrated that most of the viral 
particles salted-out of the citrate-rich phase at both the TLRs. The PPV recoveries in the 
citrate-rich phases ranged between 0-5% in the unmodified and PEG-WRW systems (See 
Figure 5-3E and F). A similar effect was observed in the PEG-rich phase at the tie line 
length 25 w/w% where the system at TLR 2.3 was able to recover more PPV as 
compared to the TLR 1 (Figure 5-3C and D). The control ligands GGG and AAA 
demonstrated a similar high PPV recovery of 80-90% in the citrate-rich phase at TLR 1 
of the tie line length 15 w/w% as compared to the ligand-free system (Figure 5-3E). 
However, similar viral particles were still recovered in the citrate-rich phase as compared 
to a relatively lower recovery in the ligand-free and PEG-WRW systems at the TLR 2.3. 
On the other hand, the PPV recoveries in the PEG-rich phases were minimal, indicating 
that the viruses do interact with the PEG-rich phases. The increased concentration of 
control ligands in the systems at tie-line length 25 w/w% showed a comparatively higher 
PPV recovery in the citrate-rich phase at TLR 1 and a similar recovery at TLR 2.3 as the 
145 
ligand-free systems (Figure 5-3E and F). A slight increase in the PPV recovery was seen 
at the TLR 2.3 than the TLR 1, but most of the PPV appears to be stuck at the interface 
(Figure 5-3C and D). The tie line length 36 w/w% demonstrated a similar low PPV 
recovery in both the citrate-rich phase and PEG-rich phase as the ligand-free system 
indicating that the viruses partitioning to the interface. In general, PEG-WRW enhanced 
the virus recovery at TLR 2.3 on all the tie lengths and likely improved the virus 
partitioning by directly attaching to PPV capsids or increasing the affinity of the PEG-
rich phase for PPV partitioning. 
 
 
Figure 5-3. PPV recovery comparison at (A&B) the three TLL and two TLRs in the 
(C&D) PEG-rich phase and (E&F) citrate-rich phase. Three separate ligands (AAA, 
GGG, and WRW) were added individually in each system at a 7:3 ratio of PEG 12 kDa to 
PEG-peptide conjugate and compared with the ligand-free control systems. The error bars 
represent the standard deviations from three individual experiments.  
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5.3.2  Efficiency and characterization of PEG-peptide conjugation 
The conjugation of PEG-peptide was confirmed using the 1H NMR spectra of the 
polymers. The disappearance of the peaks at 6, 6.5, and 7 ppm (orange box) after 
functionalization of mPEG-VS indicates that functionalization had successfully occurred 
(Figure 5-5A-D). This absence of peaks, which corresponded to the unreacted VS group, 
indicated a successful conjugation of PEGVS and peptide at the thiol group of the cystine 
terminal [59]. The conjugation of PEG-WRW was further confirmed as PEG-peptide and 
free WRW peptide demonstrated a similar fluorescence profile with a peak at 310 nm 
(Figure A.3-1A). Lastly, a high absorbance of PEG-WRW between 210-280 nm as 
compared to a no absorbance of unfunctionalized PEGVS further confirmed successful 
conjugation (Figure A.3-1B). 
 
Figure 5-4. Conjugation confirmation of mPEGVS and peptides represented as 1H NMR 
spectra of (A) mPEGVS, (B) mPEGVS-AAA, (C) mPEGVS-GGG, and (D) mPEGVS-
WRW. The orange box at 6, 6.5, and 7 ppm indicates the vinyl sulfone peaks, whose 




The affinity of WRW towards PPV was possible only if the target peptide was 
accessible in the aqueous solution. It was possible that the WRW peptide would be buried 
by the PEG polymer. However, WRW was found to be accessible as acrylamide highly 
quenched the fluorescence intensity of PEG-WRW as compared to the unconjugated 
WRW peptide (Figure 5-6). The Stokes-Volmer coefficient (KSV) was found to be 13.5 
for PEG-WRW as compared to only 5.1 for the free WRW. This indicated that the PEG 




Figure 5-5. Acrylamide quenching of free WRW peptide and mPEGVS-WRW 
fluorescence. Fitting of data points to the Stern-Volmer equation yields KSV values of 
5.1 ± 0.8 and 13.5 ± 1.1 M-1 for free WRW and mPEGVS-WRW, respectively. 




Aqueous two-phase systems have been widely utilized for developing an 
alternative to the conventional downstream processing unit operations. The new 


















drug encapsulation, delivery, and model bio-compartmentalization [24, 60, 61]. These 
applications have recognized the potential of affinity ligands to improve the specificity 
and partitioning of target biomolecules [50, 61, 62]. In this study, PEG conjugated with 
the multimodal affinity ligand WRW demonstrated an enhancement in the virus 
partitioning, which provides an opportunity for various applications stated above. 
However, the changes to virus partitioning depended on the bioavailability of the peptide 
upon conjugation. The PEGylation of peptides has shown to alter the peptide 
conformations depending on the physicochemical characteristics of the peptide and the 
PEG chain length [63, 64]. A molecular simulation study showed that the cationic 
residues of the peptides interacted favorably with the PEG oxygen atoms and the 
hydrophobic residues interacted with non-polar ethyl regions of the PEG subunits [64]. 
The favorable interactions of the peptide residues with the PEG chain led to a shielding 
effect by PEG, thereby reducing the solvent-accessible surface area of α-helical peptides. 
A similar study showed that charged and polar smaller peptides had higher solvent-
exposed structures than hydrophobic peptides [63]. The same study demonstrated that 
PEG has an insignificant effect on the conformation of neutral peptides. In another study, 
a specific PEG chain length has shown to display a shielding effect for peptides with a 
specific amino acid number [65]. Specifically, PEG 10kDa has shown to have the 
shielding of the electrostatic potential of the peptide with a maximum of eight amino acid 
residues. In this study, the biologically active region WRW of the nine amino acids 
peptide, with both hydrophobic and positively charge amino acids at physiological pH 
(Table 5-1), was found to be solvent accessible upon conjugation (Figure 5-6). It is 
highly possible that the tendency of hydrophobic residues to avoid exposure to the polar 
solvent was comprised of the highly charged peptide or the hydrophilic PEG chain length 
resisted the structural change of small peptide due to the hydrophilic and neutral spacer 
region (GRCDGG). It has been shown previously that the preferential partitioning of 
PPV to the PEG-rich phase in a PEG-salt system is driven by electrostatic and 
hydrophobic interactions [3, 4]. The accessible bioactive region WRW likely improved 
the virus partitioning through the charge and hydrophobic interactions with the PPV 
capsid. It is also possible that the WRW increased the biospecific affinity of the PEG-rich 
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phase towards negatively charged PPV by increasing the positive charge density of the 
phase as the neutrally charged slightly hydrophobic ligand AAA did not improve the 
virus partitioning (Figure 5-2).  
Previous studies have shown that the high virus partitioning is achieved at lower 
TLR where the PEG-rich phase volumes are higher than the salt-rich phase volumes [4, 
6]. The addition of hydrophobic and positively charged peptide containing WRW 
residues improved the virus recovery in the PEG-rich phase at the higher TLR with lower 
volumes of the PEG-rich phases. The enhanced recovery at higher TLR is beneficial for 
the downstream processing of biomolecules. The high TLR systems fall in the regime of 
continuous citrate-rich phases, which have higher settling kinetics, lower dependence of 
viscosity, and low volume of target biomolecule containing PEG-rich phase [5]. Further, 
the high partitioning of the viruses in low PEG-rich phase volumes may be desired to 
generate droplet hydrogels or microgels for drug encapsulation and compartmentalization 
studies. Overall, the two-phase system designs with conjugated multimodal affinity 
peptides, having balanced physicochemical characteristics to preserve the accessibility 





























































The pI and hydrophobicity measures were determined using the peptide analyzer tool 
from ThermoFisher Scientific [66]. 
 
5.5 Conclusions 
This study demonstrates the potential use of peptides as multimodal affinity 
ligands in the PEG-salt system for virus purification. The partitioning behavior of PPV 
significantly improved in the presence of the multimodal ligand GRCDGGWRW. The 
affinity ligand-induced biospecific affinity through hydrophobic interaction and charge to 
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drive the PPV particles to the PEG-rich phase at lower TLR generating lower PEG-rich 
phase volumes than the citrate-rich phases. The control hydrophobic peptide containing 
AAA residues with a neutral charge did not improve the virus partitioning, confirming 
that the multimodal effects of WRW were influential in the virus partitioning. The 
inclusion of affinity ligand did not seem to affect the salting-out ability but only the 
ability to extract the viral particles residing at the interface into the PEG-rich phase. This 
suggests that the multimodal ligand only changes the physicochemical environment of 
the PEG-rich phase.  
The conjugation of peptides with PEG generally affects the bioactivity of the 
peptides by either increasing or decreasing the accessibility of the biologically active 
domain [67]. Through fluorescence quenching, we demonstrated that the accessibility of 
the WRW domain was retained upon the conjugation to PEG. This unique combination of 
ligand accessibility and high virus partitioning improve the downstream processing of the 
viral vaccines and biotherapeutics. 
 
5.6 References 
1. Ladd Effio, C., et al., Downstream processing of virus-like particles: single-stage 
and multi-stage aqueous two-phase extraction. J Chromatogr A, 2015. 1383: p. 
35-46. 
2. Jacinto, M.J., et al., Optimization and miniaturization of aqueous two phase 
systems for the purification of recombinant human immunodeficiency virus-like 
particles from a CHO cell supernatant. Separation and Purification Technology, 
2015. 154: p. 27-35. 
3. Vijayaragavan, K.S., et al., Separation of porcine parvovirus from bovine serum 
albumin using PEG-salt aqueous two-phase system. J Chromatogr B Analyt 
Technol Biomed Life Sci, 2014. 967: p. 118-26. 
4. Joshi, P.U., et al., Tie line framework to optimize non-enveloped virus recovery in 
aqueous two-phase systems. J Chromatogr B Analyt Technol Biomed Life Sci, 
2019. 1126-1127: p. 121744. 
152 
5. Asenjo, J.A. and B.A. Andrews, Aqueous two-phase systems for protein 
separation: phase separation and applications. J Chromatogr A, 2012. 1238: p. 1-
10. 
6. Benavides, J., et al., Rotavirus-like particles primary recovery from insect cells in 
aqueous two-phase systems. J Chromatogr B Analyt Technol Biomed Life Sci, 
2006. 842(1): p. 48-57. 
7. Albertsson, P.-A., Partition of cell particles and macromolecules in polymer two 
phase systems. Advances in protein chemistry, 1970. 24: p. 309-341. 
8. Yamada, M., et al., Continuous cell partitioning using an aqueous two-phase flow 
system in microfluidic devices. Biotechnol Bioeng, 2004. 88(4): p. 489-94. 
9. Gonzalez-Gonzalez, M., M. Rito-Palomares, and O. Mendez Quintero, Partition 
behavior of CD133(+) stem cells from human umbilical cord blood in aqueous 
two-phase systems: In route to establish novel stem cell primary recovery 
strategies. Biotechnol Prog, 2014. 30(3): p. 700-7. 
10. Azevedo, A.M., et al., Partitioning of human antibodies in polyethylene glycol–
sodium citrate aqueous two-phase systems. Separation and Purification 
Technology, 2009. 65(1): p. 14-21. 
11. Rosa, P.A., A.M. Azevedo, and M.R. Aires-Barros, Application of central 
composite design to the optimisation of aqueous two-phase extraction of human 
antibodies. J Chromatogr A, 2007. 1141(1): p. 50-60. 
12. Schloer, G.M. and S.S. Breese Jr, Purification of African malignant catarrhal 
fever virus using a two-phase aqueous polymer system. Journal of General 
Virology, 1982. 59(1): p. 101-110. 
13. Philipson, L., P.Å. Albertsson, and G. Frick, The purification and concentration 
of viruses by aqueous polymer phase systems. Virology, 1960. 11(3): p. 553-571. 
14. González-Mora, A., et al., Recovery and primary purification of bacteriophage 
M13 using aqueous two-phase systems. Journal of Chemical Technology & 
Biotechnology, 2017. 92(11): p. 2808-2816. 
15. Gomes, G.A., et al., Purification of plasmid DNA with aqueous two phase systems 
of PEG 600 and sodium citrate/ammonium sulfate. Separation and Purification 
Technology, 2009. 65(1): p. 22-30. 
16. Johansson, H.O., et al., Plasmid DNA partitioning and separation using 
poly(ethylene glycol)/poly(acrylate)/salt aqueous two-phase systems. J 
Chromatogr A, 2012. 1233: p. 30-5. 
153 
17. Grilo, A.L., M. Raquel Aires-Barros, and A.M. Azevedo, Partitioning in Aqueous 
Two-Phase Systems: Fundamentals, Applications and Trends. Separation & 
Purification Reviews, 2014. 45(1): p. 68-80. 
18. Albertsson, P.-Å., Aqueous Biphasic Systems. Properties and Applications in 
Bioseparation, in Aqueous Biphasic Separations: Biomolecules to Metal Ions, 
R.D. Rogers and M.A. Eiteman, Editors. 1995, Springer US: Boston, MA. p. 21-
30. 
19. Mi, X., et al., Virus Isoelectric Point Determination Using Single-Particle 
Chemical Force Microscopy. Langmuir, 2020. 36(1): p. 370-378. 
20. Umakoshi, H., R. Kuboi, and I. Komasawa, Control of partitioning of bacterial 
cells and characterization of their surface properties in aqueous two-phase 
systems. Journal of fermentation and bioengineering, 1997. 84(6): p. 572-578. 
21. Jue, E., et al., Using an aqueous two-phase polymer-salt system to rapidly 
concentrate viruses for improving the detection limit of the lateral-flow 
immunoassay. Biotechnol Bioeng, 2014. 111(12): p. 2499-507. 
22. Mashayekhi, F., et al., Enhancing the lateral-flow immunoassay for viral 
detection using an aqueous two-phase micellar system. Anal Bioanal Chem, 2010. 
398(7-8): p. 2955-61. 
23. Frampton, J.P., et al., Aqueous two-phase system patterning of detection antibody 
solutions for cross-reaction-free multiplex ELISA. Sci Rep, 2014. 4: p. 4878. 
24. Mytnyk, S., et al., Compartmentalizing Supramolecular Hydrogels Using 
Aqueous Multi-phase Systems. Angew Chem Int Ed Engl, 2017. 56(47): p. 14923-
14927. 
25. Watanabe, T., I. Motohiro, and T. Ono, Microfluidic Formation of Hydrogel 
Microcapsules with a Single Aqueous Core by Spontaneous Cross-Linking in 
Aqueous Two-Phase System Droplets. Langmuir, 2019. 35(6): p. 2358-2367. 
26. Ho, K.L., et al., Selection of high affinity ligands to hepatitis B core antigen from 
a phage-displayed cyclic peptide library. J Med Virol, 2003. 69(1): p. 27-32. 
27. Trasatti, J.P., et al., Rational design of peptide affinity ligands for the purification 
of therapeutic enzymes. Biotechnol Prog, 2018. 34(4): p. 987-998. 
28. Perret, G. and E. Boschetti, Aptamer affinity ligands in protein chromatography. 
Biochimie, 2018. 145: p. 98-112. 
29. Percze, K., et al., Aptamers for respiratory syncytial virus detection. Sci Rep, 
2017. 7: p. 42794. 
154 
30. Reyes-del Valle, J. and R.M. del Angel, Isolation of putative dengue virus 
receptor molecules by affinity chromatography using a recombinant E protein 
ligand. J Virol Methods, 2004. 116(1): p. 95-102. 
31. Mejía-Manzano, L.A., et al., Optimized purification of mono-PEGylated lysozyme 
by heparin affinity chromatography using response surface methodology. Journal 
of Chemical Technology & Biotechnology, 2017. 92(10): p. 2554-2562. 
32. Kruljec, N. and T. Bratkovic, Alternative Affinity Ligands for Immunoglobulins. 
Bioconjug Chem, 2017. 28(8): p. 2009-2030. 
33. Fassina, G., et al., Protein a mimetic peptide ligand for affinity purification of 
antibodies. Journal of Molecular Recognition, 1996. 9(5‐6): p. 564-569. 
34. Zou, X., et al., Development of a hybrid biomimetic ligand with high selectivity 
and mild elution for antibody purification. Chemical Engineering Journal, 2019. 
368: p. 678-686. 
35. Fang, Y.M., D.Q. Lin, and S.J. Yao, Review on biomimetic affinity 
chromatography with short peptide ligands and its application to protein 
purification. J Chromatogr A, 2018. 1571: p. 1-15. 
36. Opitz, L., et al., Lectin-affinity chromatography for downstream processing of 
MDCK cell culture derived human influenza A viruses. Vaccine, 2007. 25(5): p. 
939-47. 
37. Brgles, M., et al., Nonspecific native elution of proteins and mumps virus in 
immunoaffinity chromatography. Journal of Chromatography A, 2016. 1447: p. 
107-114. 
38. Elkana, Y., A. Thornton, and A.J. Zuckerman, Purification of hepatitis A virus by 
affinity chromatography. Journal of immunological methods, 1979. 25(2): p. 185-
187. 
39. Olofsson, S., S. Jeansson, and E. Lycke, Unusual lectin-binding properties of a 
herpes simplex virus type 1-specific glycoprotein. Journal of virology, 1981. 
38(2): p. 564-570. 
40. Opitz, L., et al., Purification of cell culture-derived influenza virus A/Puerto 
Rico/8/34 by membrane-based immobilized metal affinity chromatography. J 
Virol Methods, 2009. 161(2): p. 312-6. 
41. Jiang, C., et al., Immobilized cobalt affinity chromatography provides a novel, 
efficient method for herpes simplex virus type 1 gene vector purification. J Virol, 
2004. 78(17): p. 8994-9006. 
155 
42. del Cañizo, A.A.N., et al., Foot and mouth disease virus concentration and 
purification by affinity chromatography. Applied biochemistry and 
biotechnology, 1997. 61(3): p. 399-409. 
43. Du, P., et al., Purification of foot-and-mouth disease virus by heparin as ligand 
for certain strains. J Chromatogr B Analyt Technol Biomed Life Sci, 2017. 1049-
1050: p. 16-23. 
44. Nestola, P., et al., Improved virus purification processes for vaccines and gene 
therapy. Biotechnol Bioeng, 2015. 112(5): p. 843-57. 
45. Kallberg, K., H.O. Johansson, and L. Bulow, Multimodal chromatography: an 
efficient tool in downstream processing of proteins. Biotechnology journal, 2012. 
7(12): p. 1485-1495. 
46. Zheng, G., et al., Selection of affinity peptides for the purification potential of 
porcine circovirus type 2 (PCV2) Cap virus-like particles (VLPs). RSC Advances, 
2017. 7(62): p. 38911-38914. 
47. Fernandes, C.S., et al., Retroviral particles are effectively purified on an affinity 
matrix containing peptides selected by phage-display. Biotechnol J, 2016. 11(12): 
p. 1513-1524. 
48. Menegatti, S., A.D. Naik, and R.G. Carbonell, The hidden potential of small 
synthetic molecules and peptides as affinity ligands for bioseparations. 
Pharmaceutical Bioprocessing, 2013. 1(5): p. 467-485. 
49. Heldt, C.L., et al., Porcine parvovirus removal using trimer and biased hexamer 
peptides. Biotechnol J, 2012. 7(4): p. 558-65. 
50. Ruiz-Ruiz, F., et al., Aqueous two-phase affinity partitioning systems: current 
applications and trends. J Chromatogr A, 2012. 1244: p. 1-13. 
51. Veronese, F.M., Peptide and protein PEGylation: a review of problems and 
solutions. Biomaterials, 2001. 22(5): p. 405-417. 
52. Guiotto, A., et al., PEGylation of the antimicrobial peptide nisin A: problems and 
perspectives. Il Farmaco, 2003. 58(1): p. 45-50. 
53. Castelletto, V., et al., Self-assembly and bioactivity of a polymer/peptide 
conjugate containing the RGD cell adhesion motif and PEG. European Polymer 
Journal, 2013. 49(10): p. 2961-2967. 
54. Chiu, K., et al., Effects of Polymer Molecular Weight on the Size, Activity, and 
Stability of PEG-Functionalized Trypsin. Biomacromolecules, 2010. 11(12): p. 
3688-3692. 
156 
55. Heldt, C.L., et al., Identification of Trimeric Peptides That Bind Porcine 
Parvovirus from Mixtures. Biotechnology Progress, 2008. 24(3): p. 554-560. 
56. Heldt, C.L., et al., A colorimetric assay for viral agents that produce cytopathic 
effects. J Virol Methods, 2006. 135(1): p. 56-65. 
57. Lakowicz, J.R., et al., Measurement of subnanosecond anisotropy decays of 
protein fluorescence using frequency-domain fluorometry. Journal of Biological 
Chemistry, 1986. 261(5): p. 2240-2245. 
58. Simpson, A.A., et al., The structure of porcine parvovirus: comparison with 
related viruses. J Mol Biol, 2002. 315(5): p. 1189-98. 
59. Zustiak, S.P., R. Durbal, and J.B. Leach, Influence of cell-adhesive peptide 
ligands on poly(ethylene glycol) hydrogel physical, mechanical and transport 
properties. Acta Biomater, 2010. 6(9): p. 3404-14. 
60. Pereira, J.F.B., M.G. Freire, and J.A.P. Coutinho, Aqueous two-phase systems: 
Towards novel and more disruptive applications. Fluid Phase Equilibria, 2020. 
505. 
61. Ma, Q., et al., Affinity Partitioning-Induced Self-Assembly in Aqueous Two-Phase 
Systems: Templating for Polyelectrolyte Microcapsules. ACS Macro Letters, 
2016. 5(6): p. 666-670. 
62. Lin, C.C. and K.S. Anseth, Controlling Affinity Binding with Peptide-
Functionalized Poly(ethylene glycol) Hydrogels. Adv Funct Mater, 2009. 19(14): 
p. 2325. 
63. Xue, Y., et al., Effect of poly(ethylene glycol) (PEG) spacers on the 
conformational properties of small peptides: a molecular dynamics study. 
Langmuir, 2011. 27(1): p. 296-303. 
64. Hamed, E., T. Xu, and S. Keten, Poly(ethylene glycol) conjugation stabilizes the 
secondary structure of alpha-helices by reducing peptide solvent accessible 
surface area. Biomacromolecules, 2013. 14(11): p. 4053-60. 
65. Thi Nguyen, N.T., et al., Shielding effect of a PEG molecule of a mono-
PEGylated peptide varies with PEG chain length. Prep Biochem Biotechnol, 
2018. 48(6): p. 522-527. 
66. Mishra, R., D. Sjolander, and P. Hammarstrom, Spectroscopic characterization of 
diverse amyloid fibrils in vitro by the fluorescent dye Nile red. Molecular 
Biosystems, 2011. 7(4): p. 1232-1240. 
157 
67. Veronese, F.M. and A. Mero, The impact of PEGylation on biological therapies. 









Aqueous two-phase systems (ATPS) have emerged as potential alternatives for 
the purification of biomolecules that is easy-to-scale-up and can be run continuously. A 
few studies performed on the separation of viruses using ATPS have shown discrepancies 
in the proposed partitioning mechanism. Some argue that the main driving force is 
volume exclusion [1-3], while others interpret the mechanism to be a mixture of 
intermolecular interactions based on hydrophobicity and electrostatics [4]. The lack of 
understanding of the viral behavior and interactions with the phases have led to a large 
experimental design to optimize the virus purification. The tie-line framework (chapter 3) 
presented in this dissertation supported the intermolecular interaction theory. The 
combination of high PEG-rich phase hydrophobicity combined with the salting-out 
ability of the salt-rich phase could achieve the high virus recoveries. However, the tie line 
framework demonstrated the desired virus recovery in the higher system compositions 
that are not optimal for processing. The motivation to reduce the system concentrations 
led to the use of osmolytes in the systems (chapter 4). The osmolytes enhanced the 
driving forces to achieve higher virus recoveries at lower system compositions. Along 
with the osmolytes, multimodal peptides were explored as the alternatives to improve the 
specificity and affinity of the PEG-rich phase to viruses (chapter 5). The affinity peptide 
demonstrated the potential to recover viruses at lower system compositions having lower 
PEG-rich phase volumes.    
The optimization of virus recoveries was performed in the PEG 12kDa-citrate 
system using a tie-line framework. Non-enveloped porcine parvovirus (PPV) and human 
rhinovirus 14 (HRV) were used as model viruses. The framework comprising of three tie-
line lengths (TLL) and tie-line ratios (TLR) were used to study the viral partitioning 
behavior. The negatively charged PPV (pI ~5) at pH 7 demonstrated that the virus 
partitioning shifts from the citrate-rich phase to the PEG-rich phase with an increasing 
TLL. The PPV partitioning at the highest TLL demonstrated similar virus titers in the 
PEG-rich phase irrespective of the TLR leading to lower recoveries in the PEG-rich 
phase with the increasing TLR. Overall, 80% PPV recovery and high purity were 
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achieved at the lower TLR. An increased PPV load demonstrated a similar pattern of 
virus partitioning along the TLL and across TLR. However, a lower recovery of ~40% 
was achieved in the system that yielded a high recovery with a lower load. The PPV 
partitioning behavior strongly supported the intermolecular interactions (hydrophobicity 
and charge) to be the dominant forces in the virus partitioning. The neutrally charged 
HRV (pI~6.9-7) in the systems operated at pH 7 demonstrated a high recovery in the 
citrate-rich phase leading to a low recovery in the PEG-rich phase at all the TLL. Overall, 
36% HRV recovery was achieved in the PEG-rich phase in the system that yielded a high 
PPV recovery. The HRV behavior suggested inefficiency of the citrate-rich phase in 
salting-out and inducing hydrophobic interaction with the PEG-rich phase for viruses 
with a net neutral charge. Overall, the framework aids in the high-throughput 
optimization of virus recovery.  
Naturally occurring osmolytes were used as the additives in the PEG 12kDa-
citrate systems to enhance the driving forces for virus partitioning. The objective was to 
improve the virus recovery at higher virus loadings, and system compositions that yield 
lower PEG-rich phase compositions and volume. PPV and human immunodeficiency 
virus-group specific antigen virus-like particles (HIV-gag-VLP) were used as the model 
viruses. Different osmolytes, glycine, betaine, TMAO, mannitol, and urea were added to 
the system components. The effect of each osmolyte on the system characteristics was 
analyzed by the changes in the phase diagrams comprising of the binodal curve and tie 
lines. The effect of osmolytes on the binodal shift away from the control system was 
observed in the order of glycine > betaine > mannitol > TMAO > urea. A similar effect 
on the virus partitioning was observed. The highest recoveries of PPV and HIV-gag-VLP 
were observed in the systems-containing glycine and betaine. ~ 100% PPV and 80% 
HIV-gag-VLP recoveries were obtained in the PEG-rich phase with glycine and betaine 
containing-systems. The high recoveries were obtained in the lower system compositions 
that yield a lower PEG-rich phase composition and viscosity. The contaminant 
partitioning was unaffected upon the addition of osmolytes. Overall, the use of osmolytes 
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not only enhances the virus recovery but also will reduce the processing challenges in 
scaled-up manufacturing.  
The affinity of the PEG-rich phase towards viruses was enhanced using a 
multimodal peptide ligand. The goal was to improve virus recovery in the PEG-rich 
phase of the systems at lower volume ratios of the PEG-rich phase to citrate-rich phase. 
Systems were chosen that would have virus partition to the interface or citrate-rich phase 
when the affinity peptide was not present. The multimodal affinity peptide WRW was 
used in conjugation with PEG 10kDa to drive PPV to the PEG-rich phase. A 30% 
replacement of the unfunctionalized PEG with PEG-WRW showed a significant increase 
in the PPV recovery in the PEG-rich phase at higher TLR. The control hydrophobic 
trimer AAA did not show improvement in the PPV partitioning; instead, it decreased the 
partitioning. The multimodal nature of WRW displaying hydrophobic and positive charge 
characteristics was regarded as the driving force to capture hydrophobic and negatively 
charged viral particles in the PEG-rich phase. Moreover, the citrate-rich phase being the 
continuous phase at the higher TLR provides an ATPS that is easier to process as the 
system viscosity decreases as compared to the lower TLR with continuous PEG-rich 
phase. The PEG-conjugate structure analyzed by acrylamide quenching demonstrated the 
accessibility of WRW, supporting the enhanced specificity of the PEG-rich phase 
towards PPV. Overall, this was the first study reported in the ATPS literature to utilize 
affinity peptides to enhance virus partitioning. 
 The framework demonstrated in this dissertation allows for the rapid 
optimization of viral product purification. The reduced experimental framework will aid 
in faster process development of vaccines and viral biotherapeutic. Moreover, the high-
throughput recovery of ATPS will help in producing higher number of vaccine doses 
required for global outreach. The rationale of selecting the phase parameters and the use 
of specific enhancers will help platform the ATPS as the unit operation for viral 
processing in the near future. 
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6.2     Future work 
6.2.1 Viral behavior at interface and mathematical model validation 
The partitioning of viruses to the PEG-rich phase from the citrate-rich phase 
depends on the viral ability to crossover the interface. Very few studies have been 
reported characterizing the biomolecule behavior at the interface [5, 6]. The transition of 
biomolecules from the interface to the PEG-rich phase has been shown to be related to 
the surface energy of the biomolecules [6]. The surface energy of the viral particles can 
be determined through a single particle measurement technique using atomic force 
spectroscopy (AFM) [7]. The AFM setup could include a two-phase droplet system, and 
the force measured to pull or push the virus through the interface could be translated to 
the free energy transfer of viral particle across the interface. 
A bulk method using a microfluidic device can be used to determine the diffusion 
coefficient of viral particles across the interface [8]. Relating the equilibrium phase 
properties such as viscosity, electrochemical potential difference, and interfacial tension 
with the diffusion coefficient will yield a better understanding of the local effects of the 
interface as compared to the bulk phases. Moreover, previous studies have proposed 
empirical models to predict protein and peptide partitioning by relating biomolecule 
surface properties and phase properties [9-11]. The ability to measure single particle and 
bulk surface characteristics of viruses could be potentially used to validate the models for 
prediction of the partitioning.  
6.2.2 Expanding the viral database 
The current work showed a proof-of-concept for the optimization of viral 
recovery in the PEG-salt system. A database of model viruses with different viral surface 
characteristics and their partitioning behavior needs to be studied. The enveloped viruses 
are comparatively more prone to aggregation and inactivation than non-enveloped viruses 
due to high ionic strength of citrate-rich phase and osmotic pressure of the PEG-rich 
phase. Different enveloped viruses such as herpes simplex virus (HSV), bovine viral 
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diarrhea virus (BVDV), and influenza B virus need to be evaluated for the deviation in 
the partitioning behavior and stability to design appropriate systems. Novel ATPS needs 
to be developed with lower phase compositions and higher driving forces, as shown with 
the osmolyte addition (chapter 4). The diversity in viral surfaces has been characterized 
based on morphology [12], hydrophobicity [13], and charge [14]. The relation between 
viral surface and phase characteristics will help generate a hierarchical model that will 
help in generalizing the systems for a group of virus models. Neither a single 
combination of the system parameter nor the extensive variation in the optimized systems 
is the solutions for platforming ATPS in biotherapeutic manufacturing. The database 
generated might be used to predict and narrow the search for the virus recovery 
optimization.    
6.2.3 Back-extraction of viral product 
The inclusion of ATPS in the DSP train would require a follow-up back 
extraction stage to separate viral products from the PEG-rich phase. Various methods to 
extract viral particles from the PEG-rich phase needs to be evaluated for their 
applicability in the high-throughput production and continuous operation strategy. Some 
of the methods considered for this process are ultrafiltration, ATPS re-extraction, and 
steric exclusion chromatography. Ultrafiltration with a membrane pore size ranging from 
50 kDa to 500 kDa MWCO needs to be evaluated to retain the viral product and allowing 
PEG chains in the permeate. The tie-line framework showed that the viral particles 
partition to the citrate-rich phase at lower TLL (chapter 3). This information can be used 
to develop a system by mixing a fresh citrate stock with the virus-containing PEG-rich 
phase to shift from the high TLL to low TLL, which will promote virus partition to the 
citrate-rich phase. A novel chromatography method using the steric exclusion principle 
can be used by loading the column at high PEG concentration (PEG-rich phase) and 
eluting at low PEG concentration [15].  
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6.2.4 Scale-up and sustainability analysis of ATPS 
The implementation of ATPS at an industrial scale needs extensive expertise in 
the hydrodynamic behavior of the phases [16], and their effects on viral partitioning. We 
are currently exploring the challenges of the ATPS scale-up and its implementation of the 
continuous operation for viral processing. The shear effects of mixing hydrodynamics on 
viral stability need to be evaluated. The viral partitioning effects on the phase separation 
kinetics need to be assessed.  
There is a green manufacturing initiative call for the biomanufacturing industry to 
prevent environmental risk posed by a high process mass intensity (PMI) [17]. PMI is the 
mass ratio of consumables to active pharmaceutical ingredient. A previous study has 
shown that increasing the number of chromatography steps increases the PMI, mainly 
due to the high consumption of water. PMI needs to be assessed for the proposed DSP 
train with the inclusion of ATPS and back extraction. The relative intensity index could 
be assessed by comparing an industry-standard DSP train with the optimized ATPS-
included DSP train on a case-by-case basis. The evaluation will guide the industrial 
implementation of ATPS in the viral vaccine and biotherapeutic manufacturing.       
 
6.3 Dissertation Summary 
The work presented in this dissertation helped gain crucial insights into the viral 
partitioning behavior in the PEG-salt ATPS. The framework to narrow down the 
experimental space for optimization, and enhancers to aid in the higher throughput of 
viral particles suggested a promising future of ATPS to improve viral based vaccines and 
biotherapeutic manufacturing. However, additional knowledge is still needed before 
commercial implementation. Partitioning behavior of an extensive virus library, 
interaction of viruses with the phase components at molecular level, and hydrodynamic 
behavior of phases at large scales are some of the missing pieces to the puzzle. The 
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deeper understanding of these pieces would elevate the confidence in implementing the 
ATPS in the industrial processes.  
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A Supplementary information 
A.1 Tie-line framework for virus optimization 
 
Table A.1-1. Physical Properties (density and refractive index) of the systems at TLL 15, 












  Average Std Dev Average Std Dev Average Std Dev 
15 
0.3 1.0675 0.0080 1.0889 0.0142 1.3690 0.0030 
1.2 1.0627 0.0051 1.0895 0.0040 1.3709 0.0029 
2.3 1.0667 0.0125 1.0939 0.0092 1.3731 0.0008 
25 
0.3 1.0685 0.0044 1.1071 0.0056 1.3755 0.0017 
1.2 1.0630 0.0131 1.1115 0.0033 1.3799 0.0020 
2.3 1.0741 0.0055 1.1248 0.0120 1.3828 0.0012 
36 
0.1 1.0646 0.0099 1.1456 0.0140 1.3902 0.0058 
0.3 1.0671 0.0066 1.1413 0.0129 1.3897 0.0048 
0.6 1.0755 0.0091 1.1507 0.0096 1.3879 0.0049 
1.2 1.0700 0.0182 1.1459 0.0148 1.3889 0.0034 
2.3 1.0513 0.0361 1.1366 0.0114 1.3886 0.0024 
Experiments were conducted in triplicate and the standard deviations were calculated for 














(RI) PEG concentration 
(w/w%) Average Std Dev 
36 1.3891 0.0009 36 
25 1.3784 0.0037 30 
15 1.3710 0.0020 26 
PEG concentrations in the PEG-rich phase were calculated from known PEG 
concentrations found in Table S3. Experiments were conducted in triplicate and the 


















 Average Std Dev Average 
Std 
Dev  Average 
Std 
Dev 
0 1.3330 0.0017 0.9933 0.0036    
5 1.3386 0.0055 1.0144 0.0088 5 1.0255 0.0014 
10 1.3456 0.0009 1.0189 0.0104 10 1.0417 0.0151 
15 1.3517 0.0012 1.0166 0.0120 15 1.0876 0.0169 
20 1.3585 0.0028 1.0398 0.0155 20 1.1132 0.0077 
25 1.3662 0.0023 1.0152 0.0113 25 1.1467 0.0010 
30 1.3735 0.0028 1.0410 0.0142 30 1.1817 0.0043 
50 1.4159 0.0006 1.0785 0.0136    
Experiments were conducted in triplicate and the standard deviations were calculated for 
those three trials 
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Table A.1-4. HRV titer in the PEG-rich phase and citrate-rich phase as a function of TLL 
and TL ratio 
 Initial Titer 6.7 ± 0.4 log10 MTT50/mL 
TLL 






0.3 3.4 ± 0.4 6.4 ± 0.4 
1.2 3.3 ± 0.5 6.4 ± 0.4 
2.3 3.7 ± 0.9 6.2 ± 0.3 
25 
0.1 4.4 ± 0.5 6.2 ± 0.0 
1.2 4.9 ± 0.8 6.2 ± 0.2 
2.3 5.2 ± 1.3 6.0 ± 0.4 
36 
0.3 5.4 ± 0.4 5.8 ± 0.5 
1.2 5.3 ± 0.6 5.8 ± 0.3 
2.3 5.1 ± 0.6 5.7 ± 0.2 















Table A.1-5. PPV titer in the PEG-rich phase and citrate-rich phase as a function of TLL 
and TL ratio 
  PEG-rich phase titer Citrate-rich phase titer 
TLL 
(w/w%) 
      Initial Titers 
 
TL ratio 
6.4 ± 0.2 8.3 ± 0.2 6.4 ± 0.2 8.3 ± 0.2 
15 
0.3 3.1 ± 0.9 4.8 ± 0.4 5.7 ± 0.4 7.7 ± 0.3 
1 3.7 ± 1.1 5.1 ± 0.3 5.4 ± 0.1 7.4 ± 0.2 
2.3 4.4 ± 0.4 6.1 ± 0.9 5.1 ± 0.3 7.2 ± 0.1 
25 
0.1 4.1 ± 0.8 5.2 ± 0.3 5.3 ± 1.0 6.5 ± 0.3 
1 5.2 ± 0.6 6.7 ± 0.3 3.9 ± 1.0 5.4 ± 0.9 
2.3 5.9 ± 0.1 7.4 ± 0.6 3.4 ± 0.8 5.9 ± 0.8 
36 
0.3 5.2 ± 0.2 7.1 ± 0.7 *2.8 ± 0.1 5.7 ± 0.2 
1.2 5.2 ± 0.3 7.0 ± 0.5 *2.7 ± 0.0 5.9 ± 0.3 
2.3 5.3 ± 0.2 7.5 ± 0.1 *2.6 ± 0.1 4.8 ± 0.6 
*limit of detection. All the titers are expressed log10 (MTT50/mL) 
Data is the average of experiments performed in triplicates and the error represents the 




Figure A.1-1. Aggregate ratio of 8 log10 MTT50/ml PPV at varying citrate 
concentration. Aggregation ratio compares the intensity of the PPV peak to the intensity 
of the aggregate peak in DLS and can be found in Eq. 3-7. The open bars represent the 
lack of a PPV peak. Experiments were conducted in triplicate and the error bars represent 
the standard deviation. 
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A.2 Osmolyte-containing aqueous two-phase systems 
 
Table A.2-1. Description of the LC-MS method development parameters for osmolyte 
detection and quantification. Corresponding stable isotopes of each osmolyte was used as 




LC Gradient MS polarity Quantification Ion 
Glycine 85/15 to 50/50 A/B in 6 
min at 0.4 mL/min 
positive SIM of m/z 76 
Glycine-C13 positive SIM of m/z 77 
Betaine 85/15 to 50/50 A/B in 6 
min at 0.4 mL/min 
positive SRM of m/z 118 --> 59 
Betaine-D11 positive SRM of m/z 129 --> 68 
TMAO 85/15 to 50/50 A/B in 6 
min at 0.6 mL/min 
positive SRM of m/z 76 --> 59 
TMAO-D9 positive SRM of m/z 85 --> 68 
Mannitol 85/15 to 60/40 A/B in 4 
min at 0.4 mL/min 
negative SRM of m/z 181 --> 101 
Mannitol-U-13C6 negative SRM of m/z 187 --> 105 
Urea 85/15 to 70/30 A/B in 5 
min at 0.2 mL/min 
positive SIM of m/z 61 
Urea-C13-2N15 positive SIM of m/z 64 














Figure A.2-1. LC-MS profile of glycine. (A) The area under the elution curve of 
showing(A) was used in relation to the elution area of glycine-C13 internal standard 
(Figure A.2-2) to form a standard curve and (B) MS peak used to detect glycine, operated 





Figure A.2-2. LC-MS profile of glycine-C13, used as the internal standard for glycine. 
(A) The area under the elution curve of  glycine-C13 was used in relation to the elution 
area of glycine (Figure A.2-1) to form a standard curve and (B) MS peak used to detect 





Figure A.2-3. LC-MS profile of betaine. (A) The area under the elution curve of  betaine 
was used in relation to the elution area of betaine-D11 (Figure A.2-4) to form a standard 







Figure A.2-4. LC-MS profile of betaine-D11 used as the internal standard for betaine. 
(A) The area under the elution curve of  betaine-D11 was used in relation to the elution 
area of betaine (Figure A.2-3) to form a standard curve and (B) MS peak used to detect 





Figure A.2-5. LC-MS profile of TMAO. (A) Area under the elution curve of  TMAO 
was used in relation to the elution area of TMAO-D9 (Figure A.2-6) to form a standard 





Figure A.2-6. LC-MS profile of TMAO-D9 used as internal standard for TMAO. (A) 
Area under the elution curve of  TMAO -D9 was used in relation to the elution area of 
TMAO (Figure A.2-5) to form a standard curve and (B) MS peak used to detect TMAO-






Figure A.2-7. LC-MS profile of mannitol. (A) Area under the elution curve of  mannitol 
was used in relation to the elution area of mannitol-U-13C6 (Figure A.2-8) to form a 
standard curve and (B) MS peak used to detect mannitol, operated with conditions shown 





Figure A.2-8. LC-MS profile of mannitol-U-13C6, used as the internal standard for 
mannitol. (A) Area under the elution curve of  mannitol-U-13C6 was used in relation to 
the elution area of mannitol (Figure A.2-7) to form a standard curve and (B) MS peak 






Figure A.2-9. LC-MS profile of urea. (A) Area under the elution curve of urea was used 
in relation to the elution area of Urea-C13-2N15 (Figure A.2-9) to form a standard curve 





Figure A.2-10. LC-MS profile of urea-C13-2N15, used as the internal standard for urea. 
(A) Area under the elution curve of urea-C13-2N15 was used in relation to the elution 
area of urea (Figure A.2-9) to form a standard curve and (B) MS peak used to detect 










Table A.2-2. Average of PPV titers across TL ratio and TLL in osmolyte-containing 
ATPS. 
Glycine 
TLL Avg.  Top Titer Avg.  Bottom Titer Avg. Top Titer 
Low 7.7 ± 0.5 6.7 ± 0.4 
7.9 ± 0.4 Mid 8.0 ± 0.3 5.8 ± 0.6 
High 8.1 ± 0.2 4.3 ± 0.9 
    
Betaine 
TLL Avg.  Top Titer Avg.  Bottom Titer Avg.  Top Titer 
Low 7.1 ± 0.5 7.8 ± 0.4 
7.5 ± 0.4 Mid 7.7 ± 0.3 5.7 ± 0.5 
High 7.6 ± 0.2 4.8 ± 0.3 
    
TMAO 
TLL Avg.  Top Titer Avg.  Bottom Titer Avg.  Top Titer 
Low 5.0 ± 0.4 7.4 ± 0.2 
6.3 ± 0.9 Mid 6.8 ± 0.4 5.6 ± 0.5 
High 6.9 ± 0.3 4.9 ± 0.3 
    
Urea 
TLL Avg.  Top Titer Avg.  Bottom Titer Avg.  Top Titer 
Low 5.4 ± 0.9 7.3 ± 0.5 
6.1 ± 0.9 Mid 6.3 ± 0.7 5.1 ± 0.5 
High 6.6 ± 0.4 3.5 ± 0.9 






Figure A.2-11. PPV and HIV-gag VLP recoveries in (A & C) PEG-rich and (B & D) 
citrate-rich phases, at three common global compositions in presence of different 
osmolytes. The open columns indicate 100% recovery in the represented phase. The error bars 
represent standard deviation of experiments done in triplicates. The high error bars are because of 





Table A.2-3. Viscosities of the PEG-rich phase with and without addition of osmolytes 
of systems at different TLL 
Osmolyte TLL Viscosity (mPa-s) 
None 
Low 31 ± 6 
Mid 122 ± 41 
High 221 ± 7.8 
Glycine 
Low 97 ± 21  
Mid 265 ± 87 
Betaine 
Low 73 ± 17 
Mid 239 ± 76 
TMAO 
Low 71 ± 17 
Mid 221 ± 79 
Mannitol 
Low 94 ± 25 
Mid 279 ± 85 
Urea 
Low 27.2 ± 5 
Mid 110 ± 34 
Low: system composition of 10 w/w% PEG and 10 w/w% citrate 
Mid: system composition of 10.3 w/w% PEG and 13.2 w/w% citrate 












A.3 Multimodal affinity ligand based aqueous two-phase 
system for virus purification 
 
Table A.3-1. Correlation of tie-line ratio and volume ratios of the selected systems on 
different tie-line lengths 












Figure A.3-1. Conjugation confirmation of mPEG-VS and GRCD-WRW by (A) relative 
fluorescence spectra comparison of free WRW peptide and PEGVS-WRW and (B) 
absorbance spectra comparison of free mPEGVS and mPEGVS-WRW in 1x PBS, pH 
7.4. The presence of fluorescence at 310 nm and a high relatively absorbance between 
210-280 nm confirms the successful attachment of PEGVS to the peptide with the target 
sequence of WRW   
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B Enveloped virus partitioning in ATPS  
 
Aqueous two-phase system (ATPS) has been identified as a potential candidate 
for virus purification in the downstream processing of viral products. However, the lack 
of partitioning mechanisms and experience with the viral behavior in ATPS leads to a 
large experimental space to optimize the recovery process. The viral partitioning studies 
must be expanded to familiarize the influence of viral structural characteristics on the 
partitioning. A systematic study that involves the viral partition behavior in a pre-defined 
standard system needs to be conducted to develop empirical prediction models. The 
standard system can be defined with a set polyethylene glycol (PEG) molecular weight 
and salt type operated under similar process conditions such as pH and temperature. A 
database of the relationship between the viral partitioning deviations from a model virus 
behavior and differences in the structural and physicochemical characteristics could yield 
a better design for the high-throughput screening of the optimal system.  
The standard system determined from the tie-line framework proposed in Chapter 
3 can be used to understand viral partitioning behavior of other viruses. Our previous 
work developed a tie-line framework to study the partitioning behavior of porcine 
parvovirus (PPV) in a PEG 12 kDa-citrate system at pH 7 (refer to Chapter 3 for details). 
PPV was a non-enveloped virus model sized 18-26 nm in diameter with a pI ~5. In the 
framework, most of PPV was recovered in the citrate-rich phase at the lowest tie-line 
length (TLL). PPV salted-out from the citrate-rich phase with an increasing TLL. 
However, the viral particles accumulated at the interface due to the lack of driving force 
to cross the interface. It was at the highest TLL studied where the salted-out PPV 
partitioned to the PEG-rich phase. This partitioning behavior of PPV can be compared to 
more virus models with varied structural features to get a better understanding of the 
partitioning mechanism.   
 The previously developed tie-line framework was extended to an enveloped virus 
model, herpes simplex virus -1 (HSV) to add to the partitioning behavioral database. 
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HSV is a dsDNA virus, 200-250 nm in diameter, with a pI ~5. The envelope presence 
makes a virus more fragile and susceptible to structural disintegration under 
environmental stress as compared to a non-enveloped virus. The partitioning behavior of 
infectious HSV was studied in the pre-defined PEG-citrate system.  
 
 
Figure B-1. HSV-1 partitioning behavior studied with the tie-line framework. (A) 
Partitioning coefficient of HSV at increasing TLL and TLR. Recovery of HSV-1 in (B) 
PEG-rich phase and (C) citrate-rich phase. The experiments were performed in 
triplicates, and the error bars represent standard deviation. 
 
An overall increase in the HSV partition coefficient trend was observed with an 
increasing TLL (Figure B-1A). However, the partitioning coefficients were < 1, 
indicating lower partitioning to the PEG-rich phase. HSV was salted-out of the citrate-
rich phase with the increasing TLL, as demonstrated by the lower recoveries in the 
citrate-rich phase, but not recovered in the PEG-rich phase (Figure B-1B and C). The 
lower recoveries of salted-out HSV in the PEG-rich phase likely signifies two 
possibilities. First, HSV partitioned to the PEG-rich phase but was rendered non-
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infectious. Second, HSV partitioned to the interface due to ineffective driving forces. 
Additional non-infectivity assays, such as ELISA, or DLS, are required to evaluate the 
possibilities of the presence of the inactivated virus or aggregated viral particles.   
 
 
Figure B-2. Effect of osmolytes on the partitioning coefficient of HSV in PEG 12kDa-
citrate pH 7 systems. The experiments were performed in triplicates. The error bars 
represent the standard deviation. 
 
To evaluate the possibility of ineffective driving forces, previously used 
protecting osmolytes, glycine, betaine, and TMAO were added to the system (see 
Chapter 4 for details on PPV). The osmolyte addition increased the overall HSV partition 
coefficients in the order of glycine > betaine > TMAO as compared to the osmolyte-free 
systems (Figure B-2). The most substantial increase in the partition coefficient by 
glycine did not yield a higher HSV recovery in the PEG-rich phase (Figure B-3A). 
Addition of glycine increased the salting-out ability of the glycine-containing citrate-rich 
phase (Figure B-3B). The other osmolytes showed a similar enhanced salting-out ability 
in the order mentioned above without increasing the HSV recovery in the PEG-rich 
phase. On the other hand, the same osmolytes used in this study increased the recovery of 
the enveloped HIV-VLPs (see Chapter 5 for details). All three virus models, PPV, HSV, 
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and HIV-VLP were negatively charged, which enabled a better salting-out ability of the 
citrate-rich phase. However, the interface and PEG-rich phase interaction with the viruses 
differed. Thus, additional work needs to be performed to understand the enveloped virus-
PEG interaction and virus-interface interaction.   
 
 
Figure B-3. Effect of osmolytes on HSV recovery in (A) PEG-rich phase and (B) citrate-
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Figure 2, The experimental binodal curves of PEG 4000 
DPT water [32] compared to PEG 1500 DPT water, and 
PEG 6000 DPT water at pH 7.74 at 298.15 K. The solid 
line calculated from equations (3), (4). 
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Figure 4.(b) Elution salt concentration and relative 
hydrophobicity to the Phenyl as compared to RNase, 
calculated using the fraction containing the highest titer. 
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